SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS

Abstract: The invention provides a method of treating of inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof which comprises administering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof and further provides a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules and promoting microtubule polymerization which comprises administering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof.

Description: SUBSTITUTED-TRIAZOLOPYR1MIDINES AS ANTICANCER AGENTS Background of the Invention Field of the Invention The present invention relates to a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal by administering an effective amount of a substituted-triazolopyrimidine derivative and pharmaceutically acceptable salts thereof. Further, the present invention relates to a method for the treatment or prevention of (MDR) multiple drug resistance in a mammal in need thereof which method comprises adminstering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal by interacting with tubulin and microtubules and promotion of microtubule polymerization which comprises administering to said mammal an effective amount of a substituted-triazolopyrimidine derivative and pharmaceutically acceptable salts thereof. b) Description of the Prior Art Most of the cytostatics in use today either inhibit the formation of essential precursors for biosynthesis of DNA or block DNA polymerases or interfere with the template function of DNA because DNA was the primary target for developing therapeutic drugs for chemotherapy. Unfortunately, inhibition of the formation of essential precursors for biosynthesis of DNA or blocking DNA polymerases or interference with the template function of DNA also affects normal tissues. Microtubules are among the cellular structures necessary for cell growth. Tubulin is the biochemical target for several anticancer drugs, which include the vinca alkaloids vincristine and vinblastine. The interaction of vincristine and vinblastine by binding to the alpha and beta-tubulin subunits interfere with the growing and shortening of the microtubules and prevents the formation of microtubules necessary for ceil functions. While these compounds have efficacy in cancer chemotherapy, they also have a destabilizing effect on the microtubules which also affects rapidly proliferating normal tissues and leads to toxicity. Paclitaxel and its semisynthetic derivative docetaxel (Taxotere®) also interfere with microtubule formation and stabilise microtubules. Paclitaxel (Taxol®),is a diterpene isolated from the bark of the Western (Pacific) yew, Taxus brevifolia and is representative of a new class of therapeutic agent having a taxane ring system. It was additionally found in other members of the Taxacae family including the yew of Canada (Taxus canadensis) found in Gaspesia, eastern Canada and Taxus baccata found in Europe whose needles contain paclitaxel and analogs and hence provide a renewable source of paclitaxel and derivatives. The crude extract was tested for the first time during the 1960s and its active principle was isolated in 1971 and the chemical structure identified (M.C. Wani et al, J.Am.Chem.Soα, 93, 2325 (1971)). Further, a wide range of activity over melanoma cells, leukemia, various carcinomas, sarcomas and non-Hodgkin lymphomas as well as a number of solid tumors in animals was shown through additional testing. Paclitaxel and its analogs have been produced by partial synthesis from 10- deacetylbaccatin III, a precursor obtained from yew needles and twigs, and by total synthesis (Holton, et al., J. Am. Chem. Soc. 116:1597-1601 (1994) and Nicolaou, et al., Nature 367:630-634 (1994)). Paclitaxel has been demonstrated to possess antineoplastic activity. More recently, it was shown that the antitumor activity of paclitaxel is due to a promotion of microtubule polymerization (Kumar, N., J. Biol. Chem. 256:10435-10441 (1981); Rowinsky, et al., J. Natl.Cancer Inst, 82:1247-1259 (1990); and Schiff, et al., Nature, 277:665-667 (1979)). Paclitaxel has now demonstrated efficacy in several human tumors in clinical trials (McGuire, et al., Ann. Int. Med., 111 :273-279 (1989); Holmes, et al., J. Natl. Cancer Inst., 83:1797-1805 (1991 ); Kohn et al., J. Natl. Cancer Inst, 86:18-24 (1994); and A. Bicker et al., Anti-Cancer Drugs, 4,141-148 (1993) Paclitaxel is a microtubule blocker, inhibiting mitosis by interaction with microtubules. Paclitaxel does not prevent tubulin assembly but rather accelerates tubulin polymerization and stabilizes the assembled microtubules. Paclitaxel acts in a unique way which consists in binding to microtubules, preventing their depolymerization under conditions where usually depolymerization occurred(dilution, calcium, cold and microtubules disrupting drugs). Paclitaxel blocks the cell cycle at prophase which results in an accumulation of cells in G2+M. Accordingly, there is still a need in the art for cytotoxic agents for use in cancer therapy. In particular, there is a need for drugs which inhibit or treat the growth of tumors which have an effect similar to paclitaxel and interfere with the process of microtubule formation. Additionally, there is a need in the art for agents which accelerate tubulin polymerization and stabilize the assembled microtubules. Accordingly, it would be advantageous to provide a method of treating or inhibiting cell proliferation, neopiastic growth and malignant tumor growth in mammals by administering compounds which have paclitaxel like anticancer activity. Additionally, it would be advantageous to provide a method for treating or inhibiting multiple drug resistance (MDR). Substituted triazolopyrimidine compounds of this invention are known to the art and have found use in agriculture as fungicides. The preparation of compounds of this invention and methods of preparation are disclosed in the following United States Patent Numbers: 5,593,996; 5,756,509;5,948,783; 5,981 ,534; 5,612,345; 5,994,360; 6,020,338; 5,985,883; 5,854,252; 5,808,066; 5,817,663; 5,955,252; 5,965,561 ; 5,986,135 ; and 5,750,766. Compounds of this invention are also prepared according to procedures described in the following International Publication Numbers: WO98/46607; WO98/46608; WO99/48893; WO99/41255; EPO 834513A2; EPO 782997A2; EPO 550113B1 ; EPO 613900B1 ; FR2784381A1 ; EPO 989130A1 ; WO98/41496; WO94/20501 ; EPO 945453A1 ; EPO 562615A1 and EPO 562615B1. Summary of the Invention A first object of the present invention is to provide a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal by administering an effective amount of a substituted- triazolopyrimidine derivative and pharmaceutically acceptable salts thereof. A second object of the present invention is to provide a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of a substituted- triazolopyrimidine derivative and pharmaceutically acceptable salts thereof. A third object of the present invention is to provide a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof by administering to said mammal an effective amount of a compound of Formula (I): (I) wherein: R 1 is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyi of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-cycioalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b ; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms.optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyi, -S-alkenyl, -S0 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl, -SO 2 alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may optionally be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R 2 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen; R 3 is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, araikyloxy, haioalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or. -N 3 ; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or alkyl of 1 to 12 carbon atoms; R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF 3 ; provided that when: a) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4- methoxyphenyl; b) R 1 is diethylamino, R 3 is bromo, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl; c) R 1 is isopropylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-benzyloxyphenyl or 3,4,5-trimethoxyphenyl; d) R 1 is cyclopentylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,5-trimethoxyphenyl, 2-napthyl or 2-stilbene; e) R 1 is 2-amino- bicyclo(2.2.1.)heptyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,5- trimethoxyphenyl and f) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl and g) R 1 is 1 ,1 ,1 -trifluoroethoxy, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6-fluorophenyl h) R 1 is -SO 2 ethyl or -SO 2 cyclopentyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6- fluorophenyl; i) R is hydrogen, R 2 is 2-chloro-6-fluorophenyl, R 1 and R 3 are not 1 ,2,4-triazole; j) R 1 is cyclohexyl, R 4 is hydrogen, R 2 is 2,4,6- trifluorophenyl, and R 3 is not -OCH 2 0 2 C(CH 3 ) 3 ; k) R 1 is 2-thienyl, R 4 is ethyl, R 3 is hydrogen and R 2 is not 2-methoxyphenyl, 4-methoxyphenyl, and 4-trifluorophenyl; I) R 2 is phenyl, R 3 is chloro, R 4 is hydrogen, R 1 is not (2E)-,7-dimethyl-2,6-octadienyl or a pharmaceutically acceptable salt thereof. A fourth object of the present invention is to provide a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of a compound of Formula (I): (I) wherein: R 1 is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryi of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b ; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms.optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl, -S-alkenyi, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl, -SO 2 alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may optionally be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R 2 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen; R 3 is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, araikyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 ; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 ' carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or alky! of 1 to 12 carbon atoms; R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF 3 ; t provided that when: a) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4- methoxyphenyl; b) R 1 is diethylamino, R 3 is bromo, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl; c) R 1 is isopropylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-benzyloxyphenyl or 3,4,5-trimethoxyphenyl; d) R 1 is cyclopentylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,5- trimethoxyphenyl, 2-napthyl or 2-stilbene; e) R 1 is 2-amino- bicyclo(2.2.1.)heptyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,5- trimethoxyphenyl and f) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl and g) R 1 is 1 ,1 ,1 -trifluoroethoxy, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6-fluorophenyl h) R 1 is -S0 2 ethyl or -S0 2 cyclopentyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6- fluorophenyl; i) R 4 is hydrogen, R is 2-chloro-6-fluorophenyl, R 1 and R 3 are not 1 ,2,4-triazole; j) R 1 is cyclohexyl, R 4 is hydrogen, R 2 is 2,4,6- trifluorophenyl, and R 3 is not -OCH 2 0 2 C(CH 3 ) 3 ; k) R 1 is 2-thienyl, R 4 is ethyl, R 3 is hydrogen and R 2 is not 2-methoxyphenyl, 4-methoxyphenyl, and 4-trifluorophenyl; I) R 2 is phenyl, R 3 is chloro, R 4 is hydrogen R 1 is not (2E)-,7-dimethyl-2,6-octadienyl or a pharmaceutically acceptable salt thereof. A fifth object of the present invention is to provide a method for the treatment or prevention of multiple drug resistance (MDR) in a mammal in need thereof which method comprises administering to said mamma! an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof. In particular the multiple drug resistance (MDR) is mediated by p-g!ycoprotein or MXR. A sixth object of the present invention is to provide a method for the treatment or prevention of multiple drug reistance (MDR) in a mammal in need thereof by administering to said mammal an effective amount of a compound of Formula (I): 0) wherein: R 1 is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiόphene, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyi of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -S0 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -S0 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b ; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms.optionally substituted alkadienyl of 4 to 12 carbon « atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl, -S-alkenyl, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl, -SO 2 alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may optionally be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R 2 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen; R 3 is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 ; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or alkyl of 1 to 12 carbon atoms; R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF 3 ; provided that when: a) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4- methoxyphenyl; b) R 1 is diethylamino, R 3 is bromo, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl; c) R 1 is isopropylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-benzyloxyphenyl or 3,4,5-trimethoxyphenyl; d) R 1 is cyclopentylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,5-trimethoxyphenyl, 2-napthyl or 2-stilbene; e) R 1 is 2-amino- bicyclo(2.2.1.)heptyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,5- trimethoxyphenyl and f) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl and g) R 1 is 1 ,1 ,1 -trifluoroethoxy, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6-fluorophenyl h) R 1 is -SO 2 ethyl or -SO 2 cyclopentyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6- fluorophenyl; i) R 4 is hydrogen, R 2 is 2-chloro-6-fluorophenyl, R 1 and R 3 are not 1 ,2,4-triazole; j) R 1 is cyclohexyl, R 4 is hydrogen, R 2 is 2,4,6- trifluorophenyl, and R 3 is not -OCH 2 O 2 C(CH 3 ) 3 ; k) R 1 is 2-thienyi, R 4 is ethyl, R 3 is hydrogen and R 2 is not 2-methoxyphenyl, 4-methoxyphenyl, and 4-trifluorophenyl; I) R 2 is phenyl, R 3 is chloro, R 4 is hydrogen, R 1 is not (2E)-,7-dimethyl-2,6-octadienyl or a pharmaceutically acceptable salt thereof. Among the preferred groups of compounds of Formula (I) including pharmaceutically acceptable salts thereof useful for the methods of this invention are those in the subgroups below wherein the other variables of Formula (I) in the subgroups are as defined above wherein: a) R 1 . is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by-O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -S0 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b ; b) R a and R each independently represent the moiety -C*H(R e )(R ) where R 6 and R f independently represent an optionally halo-substituted alkyl group of 1 to 12 carbon atoms where C * represents the (R) or (S) isomer; c) R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms, aryloxy, thienyl, benzyloxy, heterocyclyl or halogen; d) R 3 is halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, hydroxy, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 ; e) R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF 3 ; Among the additionally preferred groups of compounds of this invention according to general Formula (I) including pharmaceutically acceptable salts thereof useful for the methods of this invention are those in the subgroups below, wherein the other variables of Formula (I) in the subgroups are as defined above wherein: a) R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -S0 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; b) R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms or heterocyclyl; c) R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 ; d) R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF 3 ; Among the more preferred groups of compounds of Formula (I) including pharmaceutically acceptable salts thereof useful for the methods of this invention are those in the subgroups below including the pharmaceutically acceptable salts thereof wherein the other variables of Formula (I) in the subgroups are as defined above wherein: a) R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 5 to 10 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; b) R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms; c) R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; d) R 4 is H; Among the most preferred groups of compounds of Formula (I) including pharmaceutically acceptable salts thereof useful for the methods of this invention are those in the subgroups below including the pharmaceutically acceptable salts thereof wherein the other variables of Formula (I) in the subgroups are as defined above wherein: a)R 1 is selected from the group consisting of an optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H; b) R 1 is the moiety -NR a R wherein R a R are optionally taken together with the nitrogen to which each is attached; R • > 2 . is optionally substituted phenyl; R is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H; c) R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 toδ carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may also be replaced by -0-, -S-, or-NR where R is H or an alkyl group of 2 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or alkyl of 2 to 20 carbon atoms; d) R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is selected from R is halogen, alkoxy, -NR ,Cr R,d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to12 carbon atoms, cyano, or -N 3 ; R 4 is H; e) R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached and wherein R 1 : is. selected from -N(C 2 H 5 ) 2 -N(CH 3 ) 2 -NHC 2 H 5 R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H; f) R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached and wherein R 1 is selected from -N(C 2 H 5 ) 2 , -N(CH 3 ) 2 -NHC 2 H 5 R is optionally substituted thienyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H; Also, among the most particularly preferred compounds for the methods of this invention according to Formula (I) are the following compounds or a pharmaceutically acceptable salt thereof: 7-(1-azepanyl)-5-chloro-6-phenyl[1 ,2,4]triazolo[1,5-a]pyrimidine; 5-chloro-6-(2,6-difluorophenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(4-methoxyphenyl)-7-(1-piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methyi-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 7-(1 -azepanyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-thiomorpholinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; methyl [[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- yl](methyl)amino]acetate; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 ,1 ,3,3- tetramethylbutyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 7-(1-azepanyl)-5-chloro-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 7-(1-azepanyl)-6-(4-bromophenyl)-5-chloro[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-chloro-7-(1 -piperidinyI)-6-[2-(trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,5- ajpyrimidine; 6-(4-tert-butylphenyl)-5-chloro-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(4-methoxyphenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(4-methoxyphenyl)-7-(3-methyl-1 -piperidinyl)[1 ,2,4]triazoio[1 ,5- ajpyrimidine; 6-(4-bromophenyl)-5-chloro-7-(3-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(3,4-difluorophenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2,6-dichlorophenyl)-7-(2-methyl-1-pyrrolidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chlorophenyl)-7-(2-methyl-1-pyrrolidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 7-(1 -azepanyl)-5-chloro-6-(3-chloro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(2-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 6-(4-tert-butylphenyl)-5-chloro-7-(2-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-7-(2-methyl-1-piperidinyl)-6-[3- (trifluoromethyl)phenyl][1 ,2,4jtriazolo[1 ,5-ajpyrimidine; Diethyl 2-[6-(2,6-difluorophenyl)-5-ethoxy[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7- yljmalonate; 7-(azepanyl)-5-chloro-6-{2-chloro-6-nitrophenyl}[1 ,2,4}triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2- trifluoroethyl)[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-[(2,2-dichlorocyclopropy!)methyij-N- methyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 1 -[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-ylj-3- piperidinol; N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(3-chloro-4- methoxyphenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2,5-difluorophenyl)-N-dodecyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7- amine; 5-chloro-7-(4-methyl-1-piperidinyl)-6-(2,3,6- trifluorophenyi)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; N-[5-chloro-6-(2,3,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-yl]-N- isopropylamine; 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,3,6- trifluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; N-allyI-5-chloro-6-(2-chioro-6-fluorophenyl)-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(3-chloro-4-methoxyphenyl)-N-cycloheptyl[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(3,3-dimethyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-N-(3-chloropropyl)-N-methyl-6-(2,3,6- trifiuorophenyi)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 7-(1 -azocany!)-5-chloro-6-(2,3,6-trifluorophenyi)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2,6-difluorophenyl)-7-(3,6-dihydro-1 (2H)- pyridinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 7-(1-azocanyl)-5-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-methoxy-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; [5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4jtriazolo[1 ,5-a]pyrimidin-7- yljmethanol; 1-[5-chloro-6-(2,6-difluorophenyl)[1,2,4Jtriazolo[1 ,5-ajpyrimidin-7-ylj-4- piperidinol; 5-chloro-7-(4-chloro-1-piperidinyl)-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-7-(4-thiomorpholinyl)-6-(2,3,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2,6-difluorophenyl)-7-(2,4-dimethyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 7-(4-methyl-1-piperidinyl)-5-amino-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2,6-difluorophenyi)-7-(2,5-dihydro-1 H-pyrrol-1 - yl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2,5-dimethyl-2,5-dihydro-1 H-pyrrol-1 - yl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-ethyl-1 H-imidazol-1- yl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 7-(4-bromo-1-piperidinyl)-5-chloro-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-methylphenyl)-7-(4-thiomorpholinyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 6-(2-bromophenyl)-N-(sec-butyl)-5-chIoro[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- amine; 5-chloro-N-ethyl-6-(4-methoxyphenyl)-N-(2-methyl-2- propenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-6-(4-methoxyphenyl)-7-(4-thiomorpholinyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-7-(4-chloro-1 -piperidinyl)-6-[2- (trifluoromethyl)phenyl][1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(trifluoromethyl)-1- piperidinylj[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 7-(4-bromo-1 -piperidinyl)-5-chloro-6-(2,6-difluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 7-(4-bromo-1 -piperidinyl)-5-chloro-6-(2-chlorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-N-ethyl-N-(2-methyl-2-propenyI)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-N-isopropyl-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7- amine; 5-chloro-7-(4-thiomorpholinyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; 7-(1-azepanyl)-5-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1-pyrrolidinyl)-1-cyclopenten-1- ylj[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-7-(4-isopropyl-1 -piperidinyl)-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-7-(2,4-dimethy!-1 -piperidinyl)-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-7-[ethyl(2-methyl-2-propenyl)amino]-6-{4- nitrophenyl}[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 7-(1 -azepany!)-5-chloro-6-{4-nitrophenyl}[1 ,2,4]triazolo[1 ,5-ajpyrimidine; N-bicyclo[2.2.1jhept-2-yl-5-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoroethyl)[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoroethyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorobenzyl)-7-tetrahydro-2-furanyl[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 7-(allylsulfanyl)-5-chloro-6-(2-chioro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-N-ethyl-6-mesityl-N-(2-methyl-2-propenyl)[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-N-ethyl-6-(2-methoxyphenyl)-N-(2-methyl-2- ι propenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; , 5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7- amine; 5-chloro-7-(4-methyl-1 -piperidinyl)-6-[4- (methylsulfanyl)phenyl][1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-[4- (methylsulfanyl)phenyl][1 ,2,4Jtriazolo[1 ,5-a]pyrimidin-7-amine; N-(sec-butyl)-5-chloro-6-[4-(methylsulfanyl)phenylj[1 ,2,4jtriazolo[1,5- ajpyrimidin-7-amine; 5-chloro-6-[4-(methyisulfanyl)phenylj-7-(4-thiomorpholinyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 7-(1-azepanyl)-5-chloro-6-[2,6-dichloro-4- (trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2,2,2- trifluoroethyl)sulfanyl][1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-dimethyl-1 - piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-7-(4- thiomorpholinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(3,5-difluorophenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-tetrahydro-2-furanyl[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 4-[5-chloro-7-(4-methyl-1 -piperidinyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-6-yl]aniiine; N-{4-[5-chloro-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-6- yl]phenyl}acetamide; [5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-yl]methyl acetate; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(chloromethyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; diethyl 2-[6-(2-chIoro-6-fluorophenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-5-yl]malonate; 7-(1 -azepanylmethyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; N-allyl-5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-7-(4-methyl-1-piperidinyl)-6-[4- (trifluoromethoxy)phenylj[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-7-(4-methyl-1 -piperidinyl)-6-(4-phenoxyphenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(cyclopropylmethyl)-N- propyl[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-7-(2-methyl-1 -piperidinyl)-6-(4-phenoxyphenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-{2-chloro-4-nitrophenyl}-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(4-chloro-2,3,5,6-tetrafluorophenyl)-N- cyclopentyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 4-[5-chloro-2-methyl-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin- 6-yl]-N,N-dimethylaniline; 6-(2-chloro-6-fluorophenyl)-5-methyl-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1 -pyrrolidinyl)-1 -cyclohexen-1 - yl][1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(methoxymethyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-{2-chloro-4-nitrophenyl}-7-[ethyl(2-methyl-2- propenyl)aminoj[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-bromo-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-N-cyclopentyl-6-(4-ethoxy-2,3,5,6- tetrafluorophenyl)[1 ,2,4Jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-N-methyl-N-(2-methyl-2-propenyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 4-bromo-1 -[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin- 7-yl]butyl acetate; diethyl 2-allyl-2-{[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-yl]oxy}malonate; 6-(2-chloro-6-fluorophenyl)-N-ethyl-5-methyl[1 ,2,4]triazolo[1 ,5-ajpyrimidin- 7- amine; N-butyl-5-chloro-N-ethyl-6-(2,3,4,5,6-pentafluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 6-(2-chloro-6-fluorophenyl)-5-(difluoromethoxy)-7-(4-methyl-1 - piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(4- chlorophenyl)sulfanyl][1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2- methoxyphenyl)sulfanylj[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2,3,4,5,6-pentafluorophenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4jtriazoIo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2,4,6-trifluorophenyi)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-6-(4-fluorophenyl)-N-(1 ,2,2- trimethylpropy!)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5,7-bis(4-methyl-1 -piperidinyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-methylphenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2,4,5-trifluorophenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 6-(2-bromophenyl)-5-chloro-N-(1 ,2,2-trimethylpropyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-N-isobuty]-N-(2,2,2-trifluoroethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-N-isobutyl-6-(2-methylphenyl)-N-(2,2,2- trifluoroethyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4Jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chioro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-N-(2,2,2-trifluoro-1 -methyiethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4jtriazolo[ ,5-ajpyrimidin-7-amine; N-allyl-5-chloro-N-isobutyl-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-N-(1 ,2-dimethylpropyI)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-N-isopropyl-N-methyl-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-N-isopropyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 7-butyl-5-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-N-(1 -phenylethyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoro-1-methylethyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-N-ethyl-N-isobutyl-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-hexyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-methylphenyl)-N,N-bis(2,2,2-trifluoroethyl)[1 ,2,4jtriazolo[1 J 5- ajpyrimidin-7-amine; 5-chloro-N-cyclopentyl-N-methyl-6-(2,3,4,5,6- pentafluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 7-butyl-5-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-N-(1 ,2-dimethylpropyI)-N-methyl-6-(2,3,4,5,6- pentafluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-phenyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methylpropanyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-pentyl[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-N-(1 ,2-dimethyipropyl)-N-methyl-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-bromo-5-chlorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(3,3,3-trifluoropropyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(3-methylphenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; [5-chloro-6-(2,4,6-trifluorophenyl)-[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-ylj-(1-p- tolyl-ethyl)-amine; 5-chloro-6-(2,4,6-trifluoro-phenyl)-7-cyclohexyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-7-cyclohexyl-6-(2,3,4,5,6-pentafluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-difluoro-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 7-(bicyclo[2.2.1Jhept-2-ylamino)-5-chloro-6-{2-fluoro-4- nitrophenyl}[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-{2-fluoro-4-nitrophenyl}-7-(4-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-(methylsulfanyl)-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4]triazolo[1 ,5- ajpyrimidine; [5-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-ylj (2,2,2- trifluoro-1 -phenylethyl)-amine; 5-chloro-N-[1-(trifluoromethyl)propyl]-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-bromo-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1,2,4jtriazolo[1 ,5- ajpyrimidine; 6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-5- amine; [5-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazoio[1,5-ajpyrimidin-7-y!j-(2- methyl-1 -trifluoromethyl-propyl)amine; 5-chloro-7-(3-cyclohexen-1 -yl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-7-(1 -cyclohexen-1 -yl)-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-N-[(1 R)-2,2,2-trifluoro-1-methylethylj-6-(2,4,6- trifluorophenyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-N-[(1 R)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6- trifluorbphenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 6-(2,4-difluorophenyl)-5-chloro-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-[(1S)-2,2,2-trifluoro-1- methylethyl][1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 7-cyclohexyi-6-(2,6-difluoro-4-methoxyphenyl)-5-methoxy[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-7-(4-fluorocyciohexyl)-6-(2,4,6-trifluorophenyl)[1,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2,6-dich!oro-4-fluorophenyl)-7-(3,3,3- trifluoropropyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; N-(sec-butyl)-5-chioro-6-(2,6-dichloro-4-fluorophenyl)[1 ,2,4jtriazolo[1,5- ajpyrimidin-7-amine; 4-{5-chloro-7-[(2,2,2-trifluoro-1 -methylethyl)aminoj[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-6-yl}-3,6-difluorophenol; 5-chloro-7-(3-cyclohexen-1-yl)-6-(2,6-difluoro-4- methoxyphenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyi)f1,2,4jtriazolo[1,5-a]pyrimidin-7- amine; 5-chloro-N-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)[1,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3,6-dihydro-1(2H)- pyridinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)~7-(4- thiomorpholinyl)[1 ,2,4Jtriazolo[1 ,5-ajpyrimidine; 7-(1 -azepany!)-5-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4- fluorocyclohexyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 6-(4-{5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)aminoj[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-6-yl}-3,5-difluorophenoxy)hexanoic acid; 2,6-difluoro-4-(2-fluoroethoxy)phenylj-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-N-isopropyl-6-{2-[(trifluoromethyl)sulfanyljphenyl}[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-N-[4-(trifluoromethyl)phenyl]-6-(2,4,6- trif!uorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-N-(4,4,4-trifluoro-2-methylbutyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3-methyl-3- butenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-isobutyl[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 7-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)-5-methoxy[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-thienyl)-N-[(1 R)-2,2,2-trifluoro-1-methylethyl[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 4-(5-chloro-7-(2,2,2-trifluoro-1 -methyl-ethylamino)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-6-ylj-3,5-difluoro-phenol; {5-chloro-6-[2,6-difluoro-4-(2,2,2-trifluoro-ethoxy)-phenylj-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-yl}-(2,2,2~trifluoro-1 -methyl-ethyl)amine; 5-chloro-6-{2,6-difluoro-4-(methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; (5-chloro-6-{4-[2-(2-ethoxyethoxy]-ethoxyJ-2,6-difluoro- phenyl}[1 ,2,4Jtriazoio[ ,5-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1 - methylethyl)amine; (5-chloro-6-{2,6-difluoro-4-[2-(2-methoxy-ethoxy)ethoxy]-phenyl}- [1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-yl-)-(2,2,2-trifluoro-1 -methylethyl)amine; 5-chloro-6-[2,6-difluoro-4-(3-furan-3-yimethoxy)phenyl[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-yl}-N-(2,2,2-trifluoro-1-methylethyl)amine; 5-chloro-6-(2,5-difluoro-4-methoxyphenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 7-cyclohexy!-6-[2,6-difluoro-4-(2-methoxyethoxy)phenylj-5- methoxy[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-fluoro-4-methoxy-6-chlorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-[2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 2-[2-(4-{5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)aminoj[1 ,2,4]triazolo[1 ,5- a]pyrimidin-6-yl}-3,5-difluorophenoxy)ethoxyjethanol; 5-chloro-6-(2,3-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-{4-(2-fluoroethoxy)-2,6-difluorphenyl}-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-N-(4-chlorobenzyl)-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazoio[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-pyridinyl)-1- piperazinyl][1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 -ethylpentyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-chlorophenyl)-1- piperazinyl][1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(4-methoxyphenyl)-3-methyl-1- piperazinylj[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-N-cyclopentyl-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-7-phenoxy-6-(4-methoxy-phenyl)[1,2,4jtriazoIo[1 ,5-ajpyrimidine; 5-chloro-N-cyclopentyl-6-(4-methylphenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- amine; 5,7-diphenoxy-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-N-cyclopentyl-6-(2-chlorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- amine; 5-chloro-N,N-diethyl-6-[4-methoxyphenylj[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- amine; amine; N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(2,4-dichlorophenyl)[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(1 ,4-dioxa-8-azaspiro[4.5]dec-8- yl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-cyano-7-(4-methyl-1-piperidinyl)-6-(2-chloro-5- fluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-(methylsuIfanyl)-7-(4-methyl-1-piperidinyl)-6-(2-chloro-6- fluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-(methylsulfanyl)-7-(4-methyI-1-piperidinyl)-6-(2-chloro-5- (methylsulfanyl)phenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-7-(1 ,4-dioxa-8-azaspiro[4,5jdec-8-yl)-6-(4- methoxyphenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4- (methylsulfanyl)phenyl)[1 ,2,4]triazoIo[1 ,5-ajpyrimidin-7-amine; 2-methyl-6,7-di-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 2-methyl-6-phenyl-7-(4-chlorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 2-trifluoromethyl-6-phenyl-7-(4-methoxyphenyl)[1 ,2,4Jtriazolo[1 ,5-ajpyrimidine; 5,7-diphenoxy-6-(2-methylpropyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(3,4-difluorophenyl)-N-(isopropyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7- amine; 5-bromo-6-(4-bromophenyl)-7-dimethylamino[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-bromo-6-(4-trifluoromethylphenyl)-7-dimethylamino[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; 5-chioro-6-(3,4-difiuorophenyl)-7-dimethylamino[1 ,2,4jtriazoio[1 ,5- ajpyrimidine; 5-chloro-6-(4-trifluoromethylphenyl)-N-(ethyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7- amine; 7-(1 -azepanyl)-5-chloro-6-(4-tert-butylphenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; ethyl {[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- yl]amino}acetate; diethyl 5-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7- malonate; i 5-chloro-6-(2,5-difluorophenyl)-N-(3-methyl-2-butenyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; [5-chloro-6-(2-chloro-6-fluorophenyl)-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-yl]acetic acid methyl ester; , 5-chloro-6-(2,6-difluorophenyl)-7-(2-ethyl-1 H-imidazol-1-yl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-N,N-diethyl-6-[4-(methylsulfanyl)phenyl][1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; ethyl [6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1 -piperidinyl)- [1 ,2,4jtriazolo[1 ,5- ajpyrimidin-5-yl]acetate; 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4- phenoxyphenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; dimethyl 2-[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin- 7-yl]malonate; diethyl 2-{[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7- yi]oxy}-2-isobutylmalonate; 2-[5-chloro-6-(2-ch!oro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-yl]-1 ,3- cyclohexanedione; 2-[5-chloro-6-(2-chioro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7- yljcyclohexanone; 5-chloro-7-(3-nitro-4-methylanilino)-6-(2, 4, 6-trifluorophenyl) [1 ,2,4]triazolo[1 ,5-ajpyrimidine; 7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenylj5-(2- methoxyethoxy)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 7-(3-bromophenyl)-2-ethyl-6-(4-methoxyphenyl)[1,2,4jtriazolo[1 ,5- ajpyrimidine; 7-(3-bromophenyl)-6-(3-chlorophenyl)-2-ethyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 7-(4-bromophenyl)-2-ethyl-6-[4-(trifluoromethyl)phenylj[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(3,4,5- trimethoxybenzyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 7-(2-benzyl-4,5-dihydro-1H-imidazol-1-yl)-5-chloro-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; N-4-[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-yl- N,N-1-diethyl-1 ,4-pentanediamine; 5-chloro-N-(3-methyl-2-butenyl)-6-phenyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- amine; 5-dimethylamino-6-phenyl-N-cyclopentyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7- amine; 5-chloro-7-[(2-furylmethyl)sulfanyl]-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 6-[1 ,1 '-biphenyl]-4-yl-5-chloro-N-cyciopentyl[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7- amine; 6-[4-(benzyloxy)phenylj-5-chloro-N-isopropyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- amine; 5-chloro-N-[(2,2-dichlorocyclopropyl)methyl]-6-(3,4,5- trimethoxyphenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; N-cyclopentyl-6-(2-fluorophenyl)-5-hydrazino[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7- amine; 5-chloro-N-ethyl-6-(2-methylphenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 6-(4-tert-butylphenyl)-5-chloro-N-isopropyl[1 ,2,4Jtriazolo[1 ,5-ajpyrimidin-7- amine; 5-chloro-6-[2,6-difluoro-4-[(3-methyl-2-butenyl)oxy]phenyI]-N-(2,2,2-trif!uoro-1- methylethyl)-l[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-[2,6-difluoro-4-(1-propenyloxy)phenyl]-N-(2,2,2-trifluoro-1- methylethyl)-l[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-N-(3-tricyclo[2.2.1.0 2 ' 6 ]hept-1-yl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-azido-7-cyclohexyl-6-(2-fluoro-6-chlorophenyl) [1 ,2,4]triazolo[1 ,5- ' ajpyrimidine; 5-azido-6-[2-chloro-6-fluorophenyl]-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 2,5-dichloro-7-(4-methyl-1-piperidinyl)-6-[2-chloro-6- fluorophenyl][1 ,2,4]triazolo[1 ,5-ajpyrimidine. It is understood that the definition of compounds of Formula (I), when R 1 , R 2 , R 3 , R 4 , R a , R b , R c , R d , or R contain asymmetric carbons, encompass all possible stereoisomers and mixtures thereof which possess the activity discussed below. In particular, the definition encompasses racemic modifications and any optical isomers, (R) and (S), which possess the indicated activity. Optical isomers may be obtained in pure form by standard separation techniques or enantiomer specific synthesis. It is understood that this invention encompasses all crystalline forms of compounds of Formula (I). The pharmaceutically acceptable salts of the basic compounds of this invention are those derived from such organic and inorganic acids as: lactic, citric, acetic, tartaric, fumaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids. Where R 1 , R 2 , R 3 , R 4 , R a , R b , R c , R d , or R contains a carboxyl group, salts of the compounds in this invention may be formed with bases such as alkali metals (Na, K, Li) or alkaline earth metals (Ca or Mg). For the compounds defined above and referred to herein, unless otherwise noted, the following terms are defined. The term halogen atom may denote a bromine, iodine, chlorine or fluorine atom, and is especially a bromine, chlorine or fluorine atom. The terms alkyl, alkenyl, alkynyl, alkadienyl as used herein with respect to a radical or moiety refer to a straight or branched chain radical or moiety. As a rule, such radicals have up to 12, in particular up to 6 carbon atoms. Suitably an alkyl moiety has from 1 to 6 carbon atoms, preferably from 1 to 3 carbon atoms. A preferred alkyl moiety is an ethyl or especially a methyl group. Suitably an alkenyl moiety has from 2 to 12 carbon atoms. A preferred alkenyl moiety has from 2 to 6 carbon atoms. Most preferred is allyl or especially a 2- methylallyl group. Any of the alkyl, alkenyl, alkynyl, alkadienyl groups as used herein with respect to the radical or moiety may optionally be substituted with one or more of substituents which include for example, halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, aryl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl, especially furyl, and cycloalkyl, especially cyclopropyl, groups. Typically, 0-3 substituents may be present. Cycloalkyl or cycloalkenyl as used herein with respect to a radical or moiety refer to a cycloalkyl or cycloalkenyl group having 3 to 8 carbon atoms preferably 3 to 6 carbon atoms or a cycloalkenyl group having 5 to 8 carbon atoms, preferably 5 to 7 carbon atoms, in particular cyclopentyl, cyclohexyl or cyclohexenyl being optionally substituted by one or more of substituents which include for example, halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl, especially furyl, and cycloalkyl, especially cyclopropyl, groups. Typically, 0-3 substituents may be present. Optionally, -CH 2 - group of the cycloalkyl or cycloalkenyl radical or moiety may optionally be replaced with -O-, -S- or -NR' where R' is H or an alkyl group of 2 to 12 carbon atoms. A bicycloalkyl group may contain from 5 to 10 carbon atoms. Aryl as used herein with respect to the radical or moiety refers to an aryl group having 6, 10 or 14 carbon atoms, preferably 6 to 10 carbon atoms, in particular, phenyl, or naphthyl group being optionally substituted by one or more independently selected substituents which include, halogen atoms, nitro, cyano, alkenyl, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, alkenyloxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl, and cycloalkyl, groups. Typically, 0-5 substituents may be present. Aralkyl as used herein means an aryl-alkyl group in which the aryl and alkyl group are previously defined. Exemplary aralkyl groups include benzyl and phenethyl. Aralkyloxy as used herein refers to an aryl-alkyl-O- group in which the alkyl group and aryl group are previously described. Phenyl as used herein refers to a 6-membered aromatic ring. Heterocyclyl group may be a single ring, a bicyclic ring system or a system of annelated or spiro-fused rings as a saturated or unsaturated moiety or radical having 3 to 12 ring atoms with 5 to 8 ring atoms preferred with 5 or 6 ring atoms more preferred selected from carbon, oxygen, sulfur and nitrogen, one or more, typically one or two, of which being oxygen, nitrogen or sulfur, being optionally substituted by one or more of substituents which include for example, halogen atoms, preferably fluorine, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl of 1 to 12 carbon atoms, preferably 1 to 6 carbon atoms, haloalkyl, preferably haloalkyl of 1 to 6 carbon atoms, alkoxy, alkoxy of 1 to 12 carbon atoms, preferably alkoxy of 1 to 6 carbon atoms, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl, especially furyl, and cycloalkyl, especially cyclopropyl, groups. Typically, 0-3 substituents may be present. Optionally substituted heterocyclyl groups include pyrrolodinyl, pyrrazolidinyl, piperidinyl, piperazinyl or morpholin-4-yl, pyridinyl, 2,3-dehydropiperid-3-yl, tetrahydropyranyl, tetrahydrofuranyl or tetrahydrothienyl, N-methyl-2,3- dehydropiperid-3-yl. pyrimidinyl, pyrrolidinyl, furyl, pyranyl, morpholinyl, tetrahydropyridine, thienyl, pyrrolidinyl, piperidyl, dihydropiperidyl, dihydropyridinyl, thiazanyl, morpholinyl, thiazinyl, azepanyl, azocanyl and dioxa-aza- spiro-decyl. When any of the foregoing substituents are designated as being optionally substituted, the substituent groups which are optionally present may be any one or more of substituents which include for example, halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl, especially furyl, and cycloalkyl, especially cyclopropyl, groups. Typically, 0-3 substituents may be present. When any of the foregoing substituents represents or contains an alkyl substituent group, this may be linear or branched and may contain up to 12, preferably up to 6, and especially up to 4, carbon atoms. When any of the foregoing substituents represents or contains an aryl or cycloalkyl moiety, the aryl or cycloalkyl moiety may itself be substituted by one or more halogen atoms, nitro, cyano, alkyl, haloalkyl, alkoxy or haloalkoxy groups. In the case of cycloalkyl and heterocyclyl groups, optional substituents also include groups which together with two adjacent carbon atoms of the cycloalkyl or heterocyclyl group form a saturated or unsaturated hydrocarbyl ring. In other words, a saturated or unsaturated hydrocarbyl ring may be optionally fused with the cycloalkyl or heterocyclyl group. When any of the foregoing substituents represents or contains an aryl or cycloalkyl moiety, the aryl or cycloalkyl moiety may itself be substituted by one or more halogen atoms, nitro, cyano, alkyl, haloalkyl, alkoxy or haloalkoxy groups. In the case of cycloalkyl and heterocyclyl groups, optional substituents also include groups which together with two adjacent carbon atoms of the cycloalkyl or heterocyclyl group form a saturated or unsaturated hydrocarbyl ring. In other words, a saturated or unsaturated hydrocarbyl ring may be optionally fused with the cycloalkyl or heterocyclyl group. Optionally substituted moieties may be unsubstituted or have from one up to the maximal possible number of substituents. Typically, 0 to 3 substituents are present. The present invention accordingly provides a pharmaceutical composition which comprises a compound of this invention in combination or association with a pharmaceutically acceptable carrier. In particular, the present invention provides a pharmaceutical composition which comprises an effective amount of a compound of this invention and a pharmaceutically acceptable carrier. As used in accordance with this invention, the term providing an effective amount of a compound means either directly administering such compound, or administering a prodrug derivative, or analog which will form an effective amount of the compound within the body. DESCRIPTION OF THE INVENTION Compounds of this invention are prepared according to the procedures described in U.S. Patent Nos. 5,593,996; 5,756,509;5,948,783; 5,981 ,534; 5,612,345; 5,994,360; 6,020,338; 5,985,883; 5,854,252; 5,808,066; 5,817,663; 5,955,252; 5,965,561 ; 5,986,135 ; and 5,750,766 which are hereby incorporated herein by reference. Representative compounds of this invention were evaluated in several standard pharmacological test procedures that showed that the compounds of this invention possess significant activity as promoters of microtubule polymerization and are antineoplastic agents. Based on the activity shown in the standard pharmacological test procedures, the compounds of this invention are therefore useful as anticancer agents. Associated cancers are selected from the group consisting of breast, colon, lung, prostate, melanoma, epidermal, leukemia, kidney, bladder, mouth, larynx, esophagus, stomach, ovary, pancreas, liver, skin and brain. In particular the compounds of this invention possess an effect similar to Paclitaxel. The test procedures used and results obtained are shown below. CYTOTOX1CITY STANDARD PHARMACOLOGICAL TEST PROCEDURE USING MTS AS DETECTION REAGENT This standard pharmacological test procedure identifies representative examples of substituted triazolopyrimidine compounds of the invention, which further includes compounds of Formula (I), which kill various human cancer cell lines. The test is based on the conversion by viable cells, but not by dead cells, of the tetrazolium salt, MTS, into a water-soluble colored formazan which is detected by spectrophotometry. The test procedure was used to identify the most potent compounds within a series of related structures which were known or suspected to have a microtubule mechanism of action. The most potent compounds were then taken forward into other test procedures which specifically analyzed effects on microtubules. Part 1. Cytotoxicity with HeLa Cells In the first cytotoxicity test, representative compounds of the invention were tested with the HeLa human cervical carcinoma cell line at a single concentration. HeLa cells (ATCC CCL2.2) were routinely maintained by twice-weekly subculture in fresh medium. Medium was RPMI-1640 with L- glutamine, supplemented with 10% heat-inactivated fetal calf serum, 100 units/ml penicillin, and 100 μg/ml streptomycin. For assay, HeLa cells were harvested by trypsinization, washed, counted and distributed to wells of 96-well flat-bottom microtiter plates at 1000 cells per well in 100 μl of medium. The plates were incubated at 37° in humidified 5% CO 2 in air for about 24 hr. On day 2, compounds for test were diluted and added to wells. Compounds were dissolved in dimethyl sulfoxide (DMSO) at 10 mg/ml. These solutions were diluted into medium to give solutions of 20 μg/ml, and then 100 μl was added in duplicate to wells already containing cells, to give final drug concentrations of 10 μg/ml and a final DMSO concentration of 0.1 %. Each plate also contained the following controls: cells with no drug (uninhibited cell growth = maximal MTS response = control response); cells plus 100 nM paclitaxel (all cells killed = minimal MTS response); and medium only (MTS reagent control). The plates were returned to the incubator for three days. After three days of culture with test compounds (day 5 overall), the MTS assay was done on all wells of the plates. Twenty μl of the combined MTS/PMS reagent (Promega "CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay," catalog no. G5421 ; see Technical Bulletin No. 169, Revised 9/96) were added to each well with a repeating pipettor, and the plates were returned to the 37° incubator for 2 hr before recording the absorbance of each well at 490 nm using an ELISA plate reader. The absorbance values of the duplicate sample wells were averaged and expressed as a percentage of the average value of the control wells. Percentages less than 100 indicated that the test compounds had exerted a cytotoxic effect on the cells. The results of this pharmacological test procedure are displayed in Table 1. Table 1 Evaluation of Representative Compounds of the Invention in the MTS Cytotoxicity Standard Pharmacological Test Procedure with HeLa Cells Part 2. Cytotoxicity with COLO 205 Cells In the second cytotoxicity standard pharmacological test procedure, representative compounds of the invention were tested with the COLO 205 human colon adenocarcinoma cell line at six concentrations, in order to determine IC 50 values. COLO 205 cells (ATCC CCL 222) were routinely maintained by thrice-weekly subculture in fresh medium. Medium was RPMI- 1640 with L-glutamine, supplemented with 10% heat-inactivated fetal calf serum, 20 mM HEPES, 100 units/ml penicillin, and 100 μg/ml streptomycin. For the test procedure, COLO 205 ceils were harvested by trypsinization, washed, counted and distributed to wells of 96-well flat-bottom microtiter plates at 1000 cells per well in 100 μl of medium. In addition, one row of wells on an additional plate received cells as above ("time 0" plate). All plates were incubated at 37° in humidified 5% C0 2 in air for about 24 hr. On day 2, compounds for test were diluted and added to wells. Compounds were dissolved in DMSO at 10 mg/ml. For each compound, six serial 3-fold dilutions were prepared in medium. The highest drug concentration with cells was 5 μg/ml and the highest DMSO concentration was 0.05%. Drugs were added in duplicate to wells in 100 μl volume. Each plate also contained the following controls: cells with no drug (uninhibited cell growth = maximal MTS response); cells plus 100 nM paclitaxel (all cells killed = minimal MTS response); and medium only (MTS reagent control). The plates were returned to the incubator for three days. At the time of drug addition to the experimental plates, the MTS assay was run on the "time 0" plate. This produced the "time 0 MTS value" which was related to the number of viable cells per well at the time of drug addition. The MTS values of the wells of the experimental plates were lower than, higher than, or the same as the time 0 value, depending on whether a drug killed the cells, did not inhibit cell growth, or was cytostatic, respectively. After three days of culture with test compounds (day 5 overall), the MTS assay was done on all wells of the experimental plates. The results for each plate were calculated separately, using its own controls. The absorbance values of the duplicate sample wells were averaged and divided by the average of the "time 0" values. The average of the control wells without drug, divided by the average "time 0" value, gave the maximal relative increase in MTS color yield due to cell growth during the final three days of culture. The average of the control wells with paclitaxel, divided by the "time 0" value, gave the minimal relative color yield for cells that were completely killed. The six values for each compound were plotted against concentration, and the concentration that produced a relative color yield half way between the maximum and minimum was taken as the IC 5 o value. The most potent compounds had the lowest IC 50 values. Test results of representative compounds of the invention are displayed in Table 2. In addition, some compounds of the invention were tested in duplicate at 25 and 50 μg/ml with COLO 205 cells in the MTS cytotoxicity pharmacological test procedure. Results were expressed as a percent of the average value of the control wells. Percentages less than 100 indicated that the test compounds had exerted a cytotoxic effect on the cells. These test results are also displayed in Table 2. Table 2 Evaluation of Representative Compounds of the Invention in the MTS Cytotoxicity Standard Pharmacological Test Procedure with COLO 205 Cells Notes to Table 2: 1. n = number of independent assays (n = 1 unless stated otherwise) 2. a means that at 5 μg/ml the inhibition was between 30 and 50% Part 3. Cytotoxicity with H157, U87MG, PC-3 MM2, and DLD1 Cells The cytotoxicity standard pharmacological test procedure with MTS detection was applied to representative compounds of the invention with four additional human cancer cell lines in order to characterize the range of tumor types against which the compounds were active. The cell lines used were H157 human non-small cell lung carcinoma, U87MG human glioblastoma, PC-3 MM2 human prostate carcinoma, and DLD1 human colon adenocarcinoma. The procedure of the test and the method of data calculation were the same as described above in Part 2 with COLO 205 cells. The results are displayed in Table 3. Table 3 Evaluation of Representative Compounds of the Invention and Standard Cytotoxic Agents in the MTS Cytotoxicity Standard Pharmacological Test Procedure with Four Human Cancer Cell Lines Part 4. Cytotoxicity with KB Cells and Drug-Resistant Lines Derived from KB The cytotoxicity standard pharmacological test procedure with MTS detection was applied to representative compounds of the invention with the KB human epidermoid carcinoma cell line and two multidrug resistant lines derived from it. These derived lines were colchicine-resistant KB 8.5, which expresses a moderate level of the multidrug transporter P-glycoprotein, and vinblastine-resistant KB VI, which expresses a high level of P-glycoprotein. The purpose of these experiments was to determine if the compounds were able to overcome drug resistance mediated by P-glycoprotein. If the IC 50 's of the compounds are essentially the same on all three lines, then the compounds are not substrates of P-glycoprotein. If on the other hand, the compounds have much higher IC 5 o's on KB 8.5 and KB VI compared to KB (as do paclitaxel, vincristine, and many other standard anti-cancer drugs) then they would be substrates of P-glycoprotein. The procedure of the cytotoxicity test and the method of data calculation were the same as described above in Part 2 with COLO 205 cells. The results are displayed in Table 4. The results show that the compounds of this invention have essentially the same IC 50 's on all three cell lines, indicating that they would not be subject to multidrug resistance mediated by P-glycoprotein. Table 4 Evaluation of Representative Compounds of the Invention and Standard Cytotoxic Agents in the MTS Cytotoxicity Standard Pharmacological Test Procedure with Human Cancer Cell Lines that Overexpress the P-glycoprotein Transporter Part 5. Cytotoxicity with S1 Cells and a Drug-Resistant Line Derived from S1 The cytotoxicity standard pharmacological test procedure with MTS detection was applied to representative compounds of the invention with the S1 human colon carcinoma cell line and a multidrug resistant line derived from it. The derived line was mitoxantrone-resistant S1-M1 , which expresses the multidrug transporter MXR. The purpose of these experiments was to determine representative compounds of the invention able to overcome drug resistance mediated by MXR. If the IC 50 's of the compounds are essentially the same on both lines, then the compounds are not substrates of MXR. If on the other hand, the compounds have much higher ICso's on S1-M1 compared to S1 (as do many standard anti-cancer drugs) then they would be substrates of MXR. The procedure of the cytotoxicity test and the method of data calculation were the same as described above in Part 2 with COLO 205 cells. The results are displayed in Table 5. The results show that the compounds of this invention have essentially the same IC 50 's on both cell lines, indicating that they would not be subject to multidrug resistance mediated by MXR. Table 5 Evaluation of Representative Compounds of the Invention and Standard Cytotoxic Agents in the MTS Cytotoxicity Pharmacological Test Procedure with a Human Cancer Cell Line that Overexpresses the MXR Transporter Protein INHIBITION OF CELLULAR PROLIERATION STANDARD PHARMACOLOGICAL TEST PROCEDURE USING SULFORHODAMINE B AS DETECTION REAGENT This standard pharmacological test procedure measures the ability of compounds to inhibit cellular proliferation. Sulforhodamine B staining was used to estimate total cellular protein in each culture after exposure to compounds. A decrease in staining compared to untreated control cultures indicated an inhibition of proliferation. Two cell lines were used in these experiments: Reh human acute lymphocytic leukemia, and CCRF-CEM human acute lymphoblastic leukemia, both obtained from ATCC. Two types of experiments were done on each of the two cell lines. In the first, cells were cultured with Example 170 at several concentrations for either 24 or 72 hr, and the effect on cellular proliferation was determined. In the second, cells were cultured with Example 170 at several concentrations for 24 hr, the compound was removed and replaced with fresh medium without compound, culture was continued for another 48 hr, and the effect on cellular proliferation was determined. This second experiment determined the ability of cells to recover from the damage inflicted by compound during the first 24 hr of culture. At the end of the incubation periods, cells were fixed with trichloroacetic acid and stained with sulforhodamine B using the in vitro Toxicology Assay Kit (Sigma). Actinomycin D was used as a positive control in all experiments. Bound dye was measured spectrophotometrically at 565 nm with a reference wavelength of 690 nm. Cultures were done in 96-well assay plates with five replicates of each concentration. The absorbance values of the replicates were averaged and expressed as a percent of the vehicle control. Each experiment was repeated once, and the percent of control for a given concentration in each experiment were averaged to calculate the results displayed in Table 6. The results showed that Example 170 inhibited the proliferation of both cell lines, with a greater effect observed after 72 hr compared with 24 hr. In addition, the recovery experiment showed that neither cell line could recover from the toxicity induced by 24 hr of culture with Example 170. An additional experiment was done with HL-60 human promyelocytic leukemia in which the inhibition of cellular proliferation by several concentrations of Example 170 were determined after 24 or 72 hrs of culture using the Sulforhodamine B test procedure as described above. Concentrations of Example 170 ranged from 0.005-100 μg/ml. The calculated EC 50 value at 24 hr was 2.3 μg/ml, and the EC 50 value at 72 hr was 0.1 μg/ml. Table 6 Evaluation of Example 170 in the Sulforhodamine B Standard Pharmacological Test Procedure with Two Human Leukemia Cell Lines Actinomycin-D CELL CYCLE ANALYSIS STANDARD PHAMACOLOGICAL TEST PROCEDURE This standard pharmacological test procedure measures the percentages of cells in a population that are in the Gl, S and G2/M phases of the cell cycle, it utilizes staining of fixed cells with propidium iodide and analysis of these cells by flow cytometry. The procedure also gives an estimate of apoptosis induction caused by drug treatment by measurement of the appearance of particles with sub-G1 amounts of DNA. Microtubule-active drugs characteristically arrest cells in the G2/M phase of the cell cycle because of disruption of the function of the microtubules that comprise the mitotic spindle. HeLa cells were maintained in RPMI-1640 medium with L-glutamine, supplemented with 10% heat-inactivated fetal calf serum, 100 units/ml penicillin, and 100 μg/ml streptomycin. For assay, cells were harvested by trypsinization, washed, counted and distributed to wells of a 6-well plate at 50,000 cells per well in 3 ml of medium. Cells were cultured overnight at 37° in humidified 5% CO 2 in air. On day 2, compounds for test were diluted and added to wells at the final concentrations given in the tables. Twenty hours after drug addition, cells from each well were harvested, fixed with cold 80% ethanol, treated with 100 μg/ml RNAse and stained with propidium iodide before analysis by flow cytometry. The percentages of total cells in G1 , S, G2/M, and apoptosis (sub- G1 population) were estimated from the fluorescence histograms, and compared with those determined using untreated control cells in the same assay. Table 7 displays results for representative compounds of this invention tested at a low concentration and at a five-fold higher concentration. Table 8 displays results of a second experiment in which representative compounds were tested at six concentration levels each. In both experiments the compounds caused a profound increase in the percentage of cells in the G2/M phase of the cell cycle and induced substantial apoptosis. Table 7 Evaluation of Representative Compounds of the Invention in the Cell Cycle Analysis Standard Pharmacological Test Procedure with HeLa Cells Table 7 continued Note to Table 6: Apop = Apoptosis Table 8 Evaluation of Representative Compounds of the Invention in the Cell Cycle Analysis Standard Pharmacological Test Procedure with HeLa Cells Note to Table 7: Apop = Apoptosis TUBULIN POLYMERIZATION STANDARD PHARMACOLOGICAL TEST PROCEDURE USING HIGHLY PURIFIED TUBULIN This standard pharmacological test procedure determines the activity of representative compounds of this invention in promoting the polymerization of α/β tubulin heterodimers. The tubulin preparation used was over 99% pure so that any effects of test compounds on polymerization must be due to direct binding of the test compounds to tubulin protein. It is well known that in this assay paclitaxel promotes polymerization compared to the control reaction without drug, and that vincristine and colchicine inhibit polymerization. Highly purified tubulin does not exhibit substantial spontaneous polymerization at protein concentrations between 1 and 2 mg/ml. Therefore an agent such as glycerol is added to the reactions to lower the critical concentration for polymerization and yield a higher spontaneous control polymerization. In some experiments described below, either glycerol or guanosine 5'- triphosphate (the energy source of polymerization) was left out of the reaction mixtures in order to better compare the effects of paclitaxel and representative compounds of this invention. Part 1. Polymerization of Purified Tubulin in the Presence of Guanosine 5'-triphosphate and Glycerol Bovine brain tubulin, purchased from Cytoskeleton, Inc., was greater than 99% pure by polyacrylamide gel electrophoresis. The protein was dissolved at 1.5 mg/ml in ice-cold GPEM buffer (80 mM piperazine-N,N ! -bis[2- ethanesulfonic acid], pH 6.9, 1 mM ethylene glycol-bis(β-aminoethyi ether)- N,N,N',N'-tetraacetic acid, 1 mM magnesium chloride, 1 mM guanosine 5'- triphosphate, GTP) containing 10% (w/w) glycerol. The solution was centrifuged at top speed in an Eppendorf model 5415C microfuge for 10 min at 4° immediately before use. The tubulin solution was added to wells of a % area 96-well plate (Costar No. 3696) already containing the compounds of interest. Each compound was assayed at three concentrations as indicated. Final volume per well was 110 μl. Each sample was done in duplicate, and the control reaction, which received drug solvent only, was done in quadruplicate. The highest concentration of DMSO in any reaction was 1%. The plate was put in a Molecular Devices SpectraMax plate reader thermostated at 35° and the absorbance of each well at 340 nm was determined every minute for 60 minutes. The absorbance at time 0 for each well was subtracted from each of the subsequent absorbance readings for that well, and then the duplicates were averaged. The results of this standard pharmacological test procedure with representative compounds of this invention and with standard microtubule- active drugs are displayed in Tables 9 to 14. Compounds that enhanced the rate and/or extent of purified tubulin polymerization compared to the control (as does paclitaxel) were judged to be promoters of polymerization; compounds that reduced the rate or extent of polymerization (e.g., vincristine, colchicine) were judged to be inhibitors. Table 9 Evaluation of Examples 35 and 188 in the Tubulin Polymerization Standard Pharmacological Test Procedure Table 10 Evaluation of Example 170 and Paclitaxel in the Tubulin Polymerization Standard Pharmacological Test Procedure Table 11 Evaluation of Examples 169 and 175 in the Tubulin Polymerization Standard Pharmacological Test Procedure Table 12 Evaluation of Example 178 and Paclitaxel in the Tubulin Polymerization Standard Pharmacological Test Procedure Table 13 Evaluation of Examples 198 and 211 and Paclitaxel in the Tubulin Polymerization Standard Pharmacological Test Procedure * Time (min) ** Control Table 14 Evaluation of Vincristine, Colchicine, and Paclitaxel in the Tubulin Polymerization Standard Pharmacological Test Procedure * Time (min) ** Control Part 2. Polymerization of Purified Tubulin in the Absence of Either Guanosine 5'-triphosphate or Glycerol This standard pharmacological test procedure measures the ability of a representative example of the invention to induce polymerization of purified tubulin in the absence of glycerol or guanosine 5'-triphosphate (GTP). All other conditions and data calculation were as given above in Part 1. In the first experiment, the polymerization reaction mixture did not contain glycerol. In the absence of glycerol, highly purified tubulin undergoes very little spontaneous polymerization but paclitaxel is known to induce polymerization under these conditions. The data displayed in Table 15 show that Example 170 also induced polymerization in the absence of glycerol. In the second experiment, GTP was absent from the reaction mixture. Normal tubulin polymerization requires energy released from GTP hydrolysis to drive subunit assembly, but paclitaxel is able to induce polymer formation even in the absence of GTP. The data displayed in Table 16 show that Example 170 also induced polymerization in the absence of GTP. The results of both these experiments are consistent with the conclusion that Example 170 has a paclitaxel-iike mechanism of action on tubulin polymerization. Table 15 Evaluation of Example 170 and Paclitaxel in the Tubulin Polymerization Standard Pharmacological Test Procedure in the absence of glycerol Table 16 Evaluation of Example 170 and Paclitaxel in the Tubulin Polymerization Standard Pharmacological Test Procedure in the absence of GTP IMMUNOFLUORESCENCE STANDARD TEST PROCEDURE FOR ANALYSIS OF EFFECTS OF COMPOUNDS ON MORPHOLOGY OF MITOTIC SPINDLE MICROTUBULES IN CELLS Compounds that bind to tubulin or microtubules typically have profound and characteristic effects on the structure of the microtubules which comprise the mitotic spindle of dividing cells. Compounds such as vincristine and colchicine that inhibit normal tubulin polymerization cause a severe disruption and even disappearance of spindle microtubules. On the other hand, compounds such as paclitaxel that promote tubulin polymerization and stabilize microtubules cause the appearance of dense tubulin bundles or aggregates. These effects of compounds can be visualized by immunofluorescent staining of fixed cells. PC-3 MM2 human prostate carcinoma cells were plated at 5 X 10 4 cells/chamber in 8-chamber microscope slides that had been treated with poly-D-lysine (Biocoat 8-well CultureSlide, Becton Dickinson). The cells were allowed to attach and grow for 24 hr before addition of compounds at the indicated concentrations. After an additional 18-20 hr of culture with compounds, cells were fixed directly on the slides with methanol at minus 20°, rehydrated in phosphate-buffered saline, and stained with a mouse monoclonal antibody to α-tubulin (clone DM 1 A, Sigma) followed by F(ab') 2 fragments of goat anti-mouse IgG, FITC conjugate (Jackson Immunoresearch). Cells were also stained with Hoescht 33258 to visualize DNA. Cells were viewed with a Zeiss fluorescence microscope under epi- illumination, and digital images were captured with a MTI Model DC330 video camera using Optimas V software. Images were processed using Corel PhotoPaint. As displayed in Table 17, representative compounds or this invention produced marked bundling or aggregation of spindle microtubules in dividing cells. The patterns of microtubule bundling were similar to that produced by paclitaxel. When tested at equi-potent concentrations (i.e., at a concentration of each compound equal to eight times its IC 50 value in the 3-day MTS cytotoxicity assay), paclitaxel produced predominantly bipolar structures in which the microtubules appeared to be shortened and condensed. The compounds of this invention typically produced two, three, or four dense, circular bundles with intense fluorescence. The microtubule disrupting agents, vincristine and colchicine, produced patterns that were quite distinct from the compounds described here. These results are consistent with the conclusion that the compounds of this invention promote tubulin polymerization, as does paclitaxel. Table 17 Evaluation of Representative Compounds of this Invention on Morphology of Mitotic Spindle Microtubules in PC-3 MM2 Cells Determined by the Immunofluorescence Standard Pharmacological Test Procedure STANDARD PHARMACOLOGICAL TEST PROCEDURE OF ANTITUMOR ACTIVITY IN ATHYMIC MICE BEARING HUMAN TUMOR XENOGRAFTS The tumors used were H157 human non-small cell lung carcinoma, U87MG human glioblastoma, LOX human melanoma, and DLD1 human colon adenocarcinoma. Cells were cultured in RPMI-1640 medium with L-glutamine, supplemented with 10% heat-inactivated fetal calf serum, 100 units/ml penicillin and 100 μg/ml streptomycin. Cells were injected subcutaneously into the flank of outbred nu/nu mice. About 5 days later tumors were staged and those around 100 mg were selected for use. Tumor weights were calculated from measurements of length in two dimensions. Compounds for test were prepared in Klucel and administered to mice by intraperitoneal injection (0.5 ml volume) or by oral gavage (0.2 ml volume). Typically, the compounds of this invention were given twice per day for 14 days at the doses indicated in the tables. Each experimental group contained 10 animals unless otherwise indicated. The control group (also 10 animals) received Klucel only. Tumor weights were estimated every 3 to 5 days in most experiments (every 7 days in one experiment). Individual experiments are displayed in Tables 18-28. Table 18 Evaluation of Example 170 on Growth of Human H157 Non-small Cell Lung Carcinoma in Athymic Mice: Comparison of Intraperitoneal and Oral Dosing Notes: 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals. 2. Animals were staged on day 0 and dosed on days 1-14. 3. T/C = MTW of treated animals on day n/MTW of control animals on day n. 4. p = p value, Student's T-test. 5. No deaths in experimental groups. Table 19 Evaluation of Example 170 on Growth of Human H157 Non-small Cell Lung Carcinoma in Athymic Mice: Comparison of Oral Dosing at Three Levels Notes: 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals. 2. Animals were staged on day 0 and dosed on days 1-14. 3. T/C = MTW of treated animals on day n/MTW of control animals on day n. 4. p = p value, Student's T-test. 5. One death each in 25 and 12.5 groups. Table 20 Evaluation of Example 170 on Growth of Human H157 Non-small Cell Lung Carcinoma in Athymic Mice: Comparison of Oral Dosing Once or Twice Per Day Notes: 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals. 2. Animals were staged on day 0 and dosed on days 1-14. 3. T/C = MTW of treated animals on day n/MTW of control animals on day n. 4. p = p value, Student's T-test. 5. No deaths in experimental groups. Table 21 Evaiuation of Example 170, Example 169, and Example 133 on Growth of Human H157 Non-small Cell Lung Carcinoma in Athymic Mice: Notes: 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals. 2. Animals were staged on day 0 and dosed on days 1-14. 3. T/C = MTW of treated animals on day n/MTW of control animals on day n. 4. p = p value, Student's T-test. 5. One death in Example 170 group. Table 22 Evaluation of Example 170 and Example 208 on Growth of Human H157 Non-small Cell Lung Carcinoma in Athymic Mice Notes: 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals. 2. Animals were staged on day 0 and dosed on days 1-14. Dosing was bid days 1- 6, then qd days 7-14. 3. T/C = MTW of treated animals on day n/MTW of control animals on day n. 4. p = p value, Student's T-test. 5. Dosing of Example 208 was stopped after 10 days because of toxicity. 6. 1 death in Example 170 group. Table 23 Evaluation of Example 35 on Growth of Human H157 Non-small Cell Lung Carcinoma in Athymic Mice Notes: 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals. 2. Animals were staged on day 0 and dosed on days 1-14 3. T/C = MTW of treated animals on day n/MTW of control animals on day n. 4. p = p value, Student's T-test. 5. No deaths in experimental group. Table 24 Evaluation of Example 188 on Growth of Human H157 Non-smali Cell Lung Carcinoma in Athymic Mice Notes: 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals. 2. Animals were staged on day 0 and dosed on days 1-10. 3. T/C = MTW of treated animals on day n/MTW of control animals on day n. 4. p = p value, Student's T-test. 5. Dosing of Example 188 was stopped after 10 days because of toxicity. Table 25 Evaluation of Example 170 on Growth of Human U87MG Glioblastoma in Athymic Mice: Comparison of Intraperitoneal Dosing at Three Levels Notes: 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals. 2. Animals were staged on day 0 and dosed on days 1-14. 3. T/C = MTW of treated animals on day n/MTW of control animals on day n. 4. p = p value, Student's T-test. 5. No deaths in experimental groups. Table 26 Evaluation of Representative Compounds of this Invention on Growth of Human U87MG Glioblastoma in Athymic Mice Table 26 Continued Evaluation of Representative Compounds of this Invention on Growth of Human U87MG Glioblastoma in Athymic Mice Notes: 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals. 2. Animals were staged on day 0 and dosed on days 1-9. 3. T/C = MTW of treated animals on day n/MTW of control animals on day n. 4. Dosing of Example 178 was stopped after 4 days because of toxicity. Table 27 Evaluation of Example 170 on Growth of Human LOX Melanoma in Athymic Mice: Comparison of Intraperitoneal and Oral Dosing Notes: 1. RTG = relative tumor growth = mean tumor weight on day n/mean tumor weight of same group on day 0. 10 animals in control group, 5 in CL 376894 groups. 2. Animals were staged on day 0 and dosed on days 1-14. 3. T/C = RTG of treated animals on day n/RTG of control animals on day n. 4. p = p value, Student's T-test. 5. No deaths in experimental groups. Table 28 Evaluation of Example 170 on Growth of Human DLD1 Colon Carcinoma in Athymic Mice: Comparison of Intraperitoneal and Oral Dosing Notes: 1. RTG = relative tumor growth = mean tumor weight on day n/mean tumor weight of same group on day 0. Each group had 10 animals. 2. Animals were staged on day 0 and dosed on days 1-14. 3. T/C = RTG of treated animals on day n/RTG of control animals on day n. 4. p = p value, Student's T-test. 5. No deaths in experimental groups. Based on the results of these standard pharmacological test procedures, the compounds of this invention are useful as agents for treating, inhibiting or controlling the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules and promotion of microtubule polymerization. The compounds of the invention are also useful for the treaatment or prevention of multiple drug resistant (MDR). The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and severity of the condition being treated. However, in general satisfactory results are obtained when the compounds of the invention are administered in amounts ranging from about 0.10 to about 100 mg/kg of body weight per day. A preferred regimen for optimum results would be from about 1 mg to about 20 mg/kg of body weight per day and such dosage units are employed that a total of from about 70 mg to about 1400 mg of the active compound for a subject of about 70 kg of body weight are administered in a 24 hour period. The dosage regimen for treating mammals may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A decidedly practical advantage is that these active compounds may be administered in any convenient manner such as by the oral, intravenous, intramuscular or subcutaneous routes. The active compounds may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsules, or they may be compressed into tablets or they may be incorporated directly with the food of the diet. For oral therapeutic administration, these active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers and the like. Such compositions and preparations should contain at least 0.1 % of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between 10 and 1000 mg of active compound. The tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, com starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, > lactose, or saccharin may be added or a flavoring agnet such as peppermint, oil of wintergreen or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose, as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts used. In addition, these active compounds may be incorporated into sustained-release preparations and formulations. These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth or microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and starage and must be prepared against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid poly-ethylene glycol), suitable mixtures thereof, and vegetable oils. The following examples are representative compounds of this invention which are useful as promoters of microtubule polymerization and as anticancer agents. Example 1 7-(1-azepanyl)-5-chloro-6-phenylf1 ,2,41triazolori ,5-alpyrimidine Example 2 5-chloro-6-(2.6-difluorophenyl)-7-f4-methyl-1-piperidinyl)ri .2,41triazoloπ.5- alpyrimidine Example 3 5-chloro-6-(4-methoxyphenyl)-7-(1 -piperidinvDf 1 ,2.4ltriazolo| " 1 ,5-alpyrimidine Example 4 5-chloro-6-(2-chloro-6-fluorophenvQ-7-(4-methyl-1- piperidinvOH .2,4ltriazoloπ ,5-alpyrimidine Example 5 7-(1-azepanyl)-5-chioro-6-(2-chloro-6-fluorophenyl)π ,2,41triazolori ,5- alpyrimidine Example 6 5-chloro-6-(2-chloro-6-fluorophenylV7-(2-methyl-1- piperidinvDM ,2,41triazolori ,5-alpyrimidine Example 7 5-chloro-6-(2-chloro-6-fluorophenylV7-(4-thiomorpholinvπi ' 1.2,41triazolo 1.5- alpyrimidine Example 8 methyl rF5-chloro-6-(2-chloro-6-fluorQphenvθri ,2,4ltriazolo f 1 ,5-alpyrimidin-7- yll(methyl)amino1acetate Example 9 5-chloro-6-(2-chloro-6-fluorophenvn-N-(1 ,1.3.3- tetramethylbutvDf 1 ,2.4]triazolof1 ,5-alpyrimidin-7-amine Example 10 7-(1 -azepanvπ-5-chloro-6-(4-methoxyphenyl)π .2.41triazolori ,5-alpyrimidine Example 11 7-(1 -azepanylV6-(4-bromophenvπ-5-chlorof1 ,2,41triazoloH ,5-alpyrimidine Example 12 5-chloro-7-(1-piperidinvπ-6-f2-(trifluoromethvπphenvπf1.2,41triazolof1 ,5- alpyrimidine Example 13 6-(4-tert-butylphenvπ-5-chloro-7-(4-methyl-1-piperidinvππ ,2,4ltriazoioH ,5- alpyrimidine Example 14 5-chloro-6-(4-methoxyphenvD-7-(4-methyl-1 -piperidinvOπ ,2,41triazolori .5- alpyrimidine Example 15 5-chloro-6-(4-methoxyphenyl)-7-(3-methyl-1-piperidinyl)ri ,2,41triazoloπ ,5- alpyrimidine Example 16 6-(4-bromophenyl)-5-chloro-7-(3-methyl-1 -piperidinvPH .2.41triazoloπ ,5- alpyrimidine Example 17 -chloro-6-(3.4-difluorophenvn-7-(4-methyl-1-piperidinyl)f1.2,4ltriazolof1.5- alpyrimidine Example 18 -chloro-6-f2.6-dichlorophenyl)-7-f2-methyl-1-pyrrolidinyl)ri .2.41triazoloπ .5- alpyrimidine Example 19 5-chloro-6-(2-chlorophenvπ-7-(2-methyl-1-pyrrolidinvπri .2.4ltriazolo[1 ,5- alpyrimidine Example 20 7-(1-azepanyl)-5-ch[oro-6-(3-chloro-4-methoxyphenyl)ri ,2.4ltriazoloπ .5- alpyrimidine Example 21 5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(4-methyl-1- piperidinyDH .2,4ltriazolo[1 ,5-alpyrimidine Example 22 5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(2-methyl-1- piperidinvDf 1 ,2,41triazolori ,5-alpyrimidine Example 23 6-(4-tert-butylphenvπ-5-chloro-7-(2-methyl-1-piperidinyl)ri .2,4ltriazoloπ ,5- alpyrimidine Example 24 5-chloro-7-(2-methyl-1-piperidinyl)-6-r3- (trifluoromethyl)phenvπri ,2,4Ttriazolori .5-alpyrimidine Example 25 Diethyl 2-r6-(2,6-difluorophenyl)-5-ethoxyH .2,41triazolori .5-alpyrimidin-7- yllmalonate Example 26 -(azepanyl)-5-chloro-6-{2-chloro-6-nitrophenyl)ri ,2,4)triazoloπ ,5-alpyrimidine Example 27 5-chloro-6-(2-chloro-6-fluorophenvn-N-ethyl-N-(2-methyl-2- propenvPH ,2,41triazoloπ ,5-alpyrimidin-7-amine Example 28 -chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2- trifluoroethyDfl ,2,41triazoloπ ,5- alpyrimidin-7-amine Example 29 5-chloro-6-(2-chloro-6-fluorophenyl)-N-r(2,2-dichlorocvclopropyπmethvn-N- mβthyiri ,2,4ltriazolof1 ,5-alpyrimidin-7-amine Example 30 1-f5-chloro-6-(2-chloro-6-fluorophenyl)π ,2,4ltriazolof1 ,5-a1pyrimidin-7-yll-3- piperidinol Example 31 N-bicvclo[2.2.1lhept-2-yl-5-chloro-6-(3-chloro-4- methoxyphenyl)| " 1 ,2,41triazolof 1 ,5-a]pyrimidin-7-amine Example 32 5-chloro-6-(2,5-difluorophenyπ-N-dodecyl| " 1 ,2,4ltriazolo| " 1 ,5-a " }pyrimidin-7- amine Example 33 -chloro-7-(4-methyl-1-piperidinvπ-6-(2,3,6- trifluorophenvDfl ,2,41triazoloH ,5- alpyrimidine Example 34 N-r5-chloro-6-(2,3,6-trifluorophenv0f1 ,2,4ltriazolon ,5-alpyrimidin-7-yll-N- isopropylamine Example 35 5-chloro-N-ethyl-N-(2-methyl-2-propenvn-6-(2,3,6- trifluorophenvDπ ,2,41triazoloπ ,5-alpyrimidin-7-amine Example 36 N-allvi-5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2-methvi-2- propenvDf 1 ,2,4]triazofof 1 ,5-a]pyrimidin-7-amine Example 37 5-chloro-6-(2-chloro-6-fluorophenvπri ,2,41triazoloπ .5-alpyrimidin-7-amine Example 38 5-chloro-6-(3-chloro-4-methoxyphenyl)-N-cvcloheptyl[1,2,4ltriazoloπ,5- alpyrimidin-7-amine Example 39 5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(3,3-dimethyl-1- piperidinvPH ,2,4ltriazolo[1 ,5-alpyrimidine Example 40 5-chloro-N-(3-chloropropyl)-N-methyl-6-(2,3,6- trifluorophenvQfl ,2,4ltriazolo[1 ,5-alpyrimidin-7-amine Example 41 -(1-azocanvπ-5-chloro-6-(2.3,6-trifluorophenvπri ,2,4ltriazolori ,5-alpyrimidine Example 42 5-chloro-6-(2,6-difluorophenvn-7-(3,6-dihvdro-1(2H)- pyridinyl)f1 ,2,41triazolori ,5-alpyrimidine Example 43 -(1 -azocanyl)-5-chloro-6-(2,6-difluorophenyl)n ,2.41triazoloπ ,5-alpyrimidine Example 44 5-methoxy-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1- piperidinvPri ,2,4ltriazolof1 ,5-alpyrimidine Example 45 f5-chloro-6-('2-chloro-6-fluorophenvπri ,2,41triazolori .5-alpyrimidin-7- yllmethanol Example 46 1 -r5-chloro-6-(2,6-difiuorophenvθri ,2,41triazolof 1 ,5-alpyrimidin-7-yll-4- piperidinol Example 47 5-chloro-7-(4-chloro-1 -piperidinyl)-6-(2,6-difluorophenvOH ,2,41triazolori ,5- alpyrimidine Example 48 5-chloro-7-(4-thiomorpholinvπ-6-(2,3,6-trifluorophenvπri ,2.41triazoloπ ,5- alpyrimidine Example 49 5-chloro-6-(2,6-difluorophenyl)-7-(2,4-dimethyl-1- pjperidinvDM ,2.41triazoloπ ,5-alpyrimidine Example 50 7-(4-methyl-1-piperidinv0-5-amino-6-(2-chloro-6- fluorophenvππ ,2,41triazoloπ ,5-alpyrimidine Example 51 5-chloro-6-(2,6-difluorophenylV7-(2,5-dihvdro-1 H-pyrrol-1 - vOπ ,2,41triazoloπ .5-alpyrimidine Example 52 -chloro-6-(2-chloro-6-fluorophenvπ-7-(2.5-dimethyl-2,5-dihvdro-1 H-pyrrol-1- yl)ri ,2,4ltriazolof1.5-alpyrimidine Example 53 5-chloro-6-( , 2-chloro-6-fluorophenyl)-7-( ' 2-ethyl-1 H-imidazol-1- VDΠ ,2,4ltriazolo[ " 1 ,5-alpyrimidine Example 54 7-(4-bromo-1-piperidinyl)-5-chloro-6-(2-chloro-6- fluorophenvDfl ,2,4ltriazolof1 ,5-alpyrimidine Example 55 5-chloro-6-(2-methylphenyl)-7-(4-thiomorpholinyl)π ,2,4ltriazolo[1 ,5- alpyrimidine Example 56 -(2-bromophenvπ-N-(sec-butvπ-5-chlorori ,2,41triazoloπ .5-alPyrimidin-7- amine Example 57 5-chloro-N-ethyl-6-(4-methoχyphenyl)-N-(2-methyl-2- propenvDM .2,4ltriazolof1 ,5- alpyrimidin-7-amine Example 58 5-chloro-6-(4-methoxyphenylV7-(4-thiomorpholinvπri ,2,41triazoloπ ,5- alpyrimidine Example 59 5-chloro-7-(4-chloro-1 -piperidinyl )-6-F2- (trifluoromethyl)phenyπi ,2,4ltriazolori ,5-alpyrimidine Example 60 5-chloro-6-(2-chloro-6-fluorophenvπ-7-r4-(trifluoromethvπ-1- piperidinyliπ .2,41triazoloπ .5-alpyrimidine Example 61 7-(4-bromo-1-piperidinyl)-5-chloro-6-(2,6-difluorophenvπri ,2,4ltriazoloπ ,5- alpyrimidine Example 62 7-(4-bromo-1 -piperidinyl)-5-chloro-6-(2-chlorophenyl)ri ,2,41triazolori ,5- alpyrimidine Example 63 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,4,6- trifluorophenvDπ ,2,4]triazolo[1 τ 5-alpyrimidin-7-amine Example 64 -chloro-N-isopropyl-6-(2,4,6-trifluorophenyπri ,2,4ltriazolo[1 ,5- alpyrimidin-7- amine Example 65 5-chloro-7-(4-thiomorpholinyl)-6-(2,4,6-trifluorophenyl)ri ,2,41triazoloπ,5- alpyrimidine Example 66 7-(1 -azepanvD-5-chloro-6-(2.4.6-trifluorophenyl)ri ,2,41triazolori ,5- alpyrimidine Example 67 5-chloro-6-( , 2-chloro-6-fluorophenyl)-7-r2-(1-pyrrolidinvπ-1-cvclopenten-1- vHπ ,2,41triazolof 1 ,5-alpyrimidine Example 68 δ-chloro^-^-isopropyl-l-piperidinvπ-e^-methoxyphenvπfl^ ltriazolofl ,5- alpyrimidine Example 69 -chloro-7-(2,4rdimethyl-1 -piperidinvO-6-(4-methoxyphenyl)H ,2,4ltriazolo[1 ,5- alpyrimidine Example 70 5-chloro-7-fethyl(2-methyl-2-propenvπaminol-6-(4- nitrophenvDπ ,2,4ltriazolol " 1 ,5-alpyrimidine Example 71 7-(1-azepanvπ-5-chloro-6-{4-nitrophenyl)f1 ,2,41triazoloπ ,5-alpyrimidine Example 72 N-bicvclor2.2.1lhept-2-yl-5-chloro-6-(2.4.6-trifluorophenyl)ri .2,4ltriazolori .5- alpyrimidin-7-amine Example 73 5-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoroethyl)ri .2,41triazoloπ ,5- alpyrimidin-7-amine Example 74 5-chloro-6-(2-chlorophenvn-N-(2,2,2-trifluoroethvnπ ,2,4ltriazolo[1 ,5- alpyrimidin-7-amine Example 75 -chloro-6-(2-chloro-6-fluorobenzvπ-7-tetrahvdro-2-furanylf1 ,2,4ltriazoioπ ,5- alpyrimidine Example 76 7-Callylsulfanyl)-5-chloro-6-f2-chloro-6-fiuorophenyl)ri .2.41triazoloπ ,5- alpyrimidine Example 77 5-chloro-N-ethyl-6-mesityl-N-(2-methyl-2-propenvπf1 ,2,4ltriazoloπ .5- alpyrimidin-7-amine Example 78 5-chloro-N-ethyl-6-(2-methoxyphenvP-N-(2-methyl-2- propenvPH ,2,41triazoloπ ,5-alpyrimidin-7-amine Example 79 -chloro-6-(2-chloro-6-fluorophenyl)-N-hexyiπ ,2,41triazolof1 ,5-alpyrimidin-7- amine Example 80 5-chloro-7-(4-methyl-1-piperidinyl)-6-[4- (methylsulfanyl)phenyllfl ,2,41triazolori ,5-alpyrimidine Example 81 5-chloro-N-ethyl-N-(2-methyl-2-propenvD-6-r4- (methylsulfanvPphenyliri ,2,41triazolori ,5-alpyrimidin-7-amine Example 82 N-(sec-butvP-5-chloro-6-r4-(methylsulfanvPphenvπri ,2,41triazoloπ .5- alpyrimidin-7-amine Example 83 -chloro-6-f4-(methylsulfanvPphenyl1-7-(4-thiomorpholinvPπ ,2,4ltriazolo[1 ,5- alpyrimidine Example 84 5-chloro-6-l " 2,6-dichloro-4-(trifluoromethvPphenyl1-7-f4-methyl-1- piperidinvPπ .2.4TtriazoloH ,5-alpyrimidine Example 85 7-(1-azepanvP-5-chloro-6-r2,6-dichloro-4- (trifluoromethyl)phenyliπ ,2,4]triazolo| " 1 ,5-alpyrimidine Example 86 5-chloro-6-(2-chloro-6-fluorophenyl)-7-r(2,2,2- trifluoroethypsulfanyliπ ,2,41triazolo| " 1 ,5-alpyrimidine Example 87 5-chloro-6-(2-chloro-6-fluorophenvP-7-(4,4-dimethyl-1- piperidinvPπ ,2,41triazolori ,5-alpyrimidine Example 88 5-chloro-6-r2,6-dichloro-4-(trifluoromethvPphenvπ-N-ethyl-N-(2-methyl-2- propenvDH ,2,41triazolori .5-alPyrimidin-7-amine Example 89 5-chloro-6-r2,6-dichloro-4-(trifluoromethvPphenyll-7-(4- thiomorpholinvPπ ,2,41triazoloπ ,5-alpyrimidine Example 90 -chloro-6-(3,5-difluorophenvP-7-(4-methyl-1-piperidinvPri ,2,4ltriazoloπ ,5- alpyrimidine Example 91 5-chloro-6-(2-chloro-6-fluorophenvP-7-(isopropylsulfanvPπ ,2,41triazoloπ ,5 : alpyrimidine Example 92 5-chloro-6-(2-chloro-6-fluorophenvP-7-tetrahvdro-2-furanviri ,2,41triazoloπ ,5- alpyrimidine Example 93 -f5-chloro-7-(4-methyl-1 -piperidinvPπ ,2,41triazolori ,5-alpyrimidin-6-yllaniline Example 94 N-f4-r5-chloro-7-(4-methyl-1-piperidinvP| " 1 ' 2,4ltriazolo[1 ,5-alpyrimidin-6- yllphenyllacetamide Example 95 f5-chloro-6-(2-chloro-6-fluorophenvP[1 ,2,4ltriazolo 1 ,5-alpyrimidin-7-yl1methyl acetate Example 96 5-chloro-6-(2-chloro-6-fluorophenvP-7-(chloromethyl)ri,2,4ltriazolo| " 1 ,5- alpyrimidine Example 97 diethyl 2-f6-(2-chloro-6-fluoroρhenvP-7-(4-methyl-1 - piperidinvPf 1 ,2,41triazoloπ ,5-alpyrimidin-5-vnmalonate Example 98 7-(1 -azepanylmethvP-5-chloro-6-(2-chloro-6-fluorophenvP[1.2.41triazoloπ .5- alpyrimidine Example 99 N-allyl-5-chloro-6-( , 2-chloro-6-fluorophenvP-N-hexyiri ,2.41triazoloπ ,5- alpyrimidin-7-amine Example 100 5-chloro-7-(4-methyl-1-piperidinvP-6-r4- (trifluoromethoxy)phenyll[1 ,2,4ltriazolof1 ,5-alpyrimidine Example 101 5-chloro-7-(4-methyl-1-piperidinvP-6-(4-phenoxyphenvPf1 ,2.4ltriazoloπ ,5- alpyrimidine Example 102 5-chloro-6-(2-chloro-6-fluorophenvP-N-(cvclopropylmethvP-N- propylfl ,2,41triazolori ,5-alpyrimidin-7-amine Example 103 5-chloro-7-(2-methyl-1 -piperidinvP-6-(4-phenoχyphenvPri .2.41triazolori ,5- alpyrimidine Example 104 5-chloro-6-(2-chloro-4-nitrophenyll-7-(4-methyl-1- piperidinvPri ,2,41triazoloH ,5-alpyrimidine Example 105 5-chloro-6-(4-chloro-2,3,5,6-tetrafluorophenvP-N- cyciopentviπ ,2,41triazoloπ ,5-alpyrimidin-7-amine Example 106 -f5-chloro-2-methyl-7-(4-methyl-1 -piperidinvPfl ,2,41triazoloπ ,5-alPyrimidin- 6-vπ-N,N-dimethylaniline Example 107 6-(2-chloro-6-fluorophenylV5-methyl-7-(4-methyl-1- piperidinvPfl ,2,41triazolof1 ,5-alpyrimidine Example 108 5-chloro-6-(2-chloro-6-flυorophenyl)-7-f2-(1-pyrrolidinvπ-1 -cyclohexen-1 - yliπ ,2,41triazolof 1 ,5-alpyrimidine Example 109 5-chloro-6-(2-chloro-6-fluorophenvP-7-(methoxymethvPf1 ,2,4ltriazolof1 ,5- alpyrimidine Example 110 5-chloro-6-(2-chloro-4-nitrophenyl>-7-[ethyl(2-methyl-2- propenvPaminolf 1 ,2,4ltriazoloF1 ,5-alpyrimidine Example 111 5-bromo-6-(2-chloro-6-fluorophenvP-7-(isopropylsulfanvPπ ,2,41triazoloπ ,5- alpyrimidine Example 112 5-chloro-N-cvclopentyl-6-(4-ethoxy-2,3,5,6- tetrafluorophenvPπ ,2,41triazoloπ ,5-a1pyrimidin-7-amine Example 113 5-chioro-N-methyl-N-(2-methyl-2-propenvP-6-(2,4,6- trifluorophenypπ ,2,41triazoloπ ,5-alpyrimidin-7-amine Example 114 -bromo-1-f5-chloro-6-(2-chioro-6-fluorophenyP[1 ,2,4ltriazolo 1 ,5-alpyrimidin- 7-vnbutvi acetate Example 115 diethyl 2-allyl-2-(r5-chloro-6-(2-chloro-6-fluorophenvP[1 ,2,4Ttriazolof 1 ,5- alpyrimidin-7-ylloxy)malonate Example 116 -(2-chloro-6-fluorophenvP-N-ethyl-5-methylf 1 ,2,4ltriazolo[1 ,5-alpyrimidin- 7- amine Example 117 N-butyl-5-chloro-N-ethyl-6-f2,3,4.5,6-pentafluorophenvPf1 ,2,4ltriazoloπ .5- a pyrimidin-7-amine Example 118 6-(2-chloro-6-fluorophenvP-5-( ' difluoromethoxy)-7-(4-methyl-1- piperidinvPH ,2,4ltriazolo| " 1 ,5-alpyrimidine Example 119 5-chloro-6-(2-chloro-6-fluorophenvD-7- r (4- chlorophenvPsulfanyliπ ,2,41triazoloH ,5-alpyrimidine Example 120 5-chloro-6-f2-chloro-6-fluorophenvP-7-K2- methoxyphenvPsulfanyllfl ,2,4ltriazolof1 ,5-alpyrimidine Example 121 5-chloro-6-(2-chloro-6-fluorophenvP-N-(1 ,2,2- trimethylpropyDfl ,2,4ltriazolo[1 ,5-alpyrimidin-7-amine Example 122 δ-chloro-e-^^^.δ.e-pentafiuorophenvP-N-d ^^- trimethvipropyPl ' 1 ,2.41triazoloπ ,5-alpyrimidin-7-amine Example 123 -chloro-6-(2 A6-trifluorophenvP-N-(1.2,2-trimethylpropyππ .2,41triazoloπ .5- alpyrimidin-7-amine Example 124 5-chloro-6-(4-fluorophenvP-N-(1 ,2,2- trimethylpropyPfl .2,4ltriazolof1 ,5- alpyrimidin-7-amine Example 125 5,7-bis(4-methyl-1-piperidinvP-6-(2,4,6-trifluorophenvPri .2,4ltriazoloπ ,5- alpyrimidine Example 126 5-chloro-6-(2-methylphenvP-N-(1 ,2,2-trimethylpropyPπ ,2,41triazoloM ,5- ' alpyrimidin-7-amine Example 127 -chloro-6-(2,4,5-trifluorophenvP-N-M ,2.2-trimethylpropynri ,2,41triazoloπ ,5- alpyrimidin-7-amine Example 128 6-(2-bromophenvP-5-chioro-N-(1 ,2,2-trimethylpropyPπ .2.41triazolori ,5- alpyrimidin-7-amine Example 129 5-chloro-N-isobutyl-N-(2,2.2-trifluoroethvP-6-ι:2,4,6- trifluorophenvPπ ,2,4ltriazolo| " 1 ,5-alpyrimidin-7-amine Example 130 5-chloro-N-isobutyl-6-(2-methylphenvD-N-f2,2.2- trifluoroethvPπ ,2,41triazoloπ ,5-alpyrimidin-7-amine Example 131 5-chloro-6-(2-chloro-6-fluorophenvP-N-(2,2,2-trifluoro-1- methylethvPri ,2,41triazoloπ ,5-a]pyrimidin-7-amine Example 132 5-chloro-6-(2,6-difluorophenvP-N-(2,2,2-trifluoro-1- methylethypri ,2,41triazoloπ .5-alpyrimidin-7-amine Example 133 5-chloro-N-(2,2,2-trifluoro-1-methylethvP-6-(2.4,6- trifluorophenvPπ ,2,4ltriazolo[1 ,5-alpyrimidin-7-amine Example 134 N-allyl-5-chloro-N-isobutyl-6-f2.4.6-trifluorophenvPf1 ,2.4ltriazoloπ ,5- alpyrimidin-7-amine Example 135 -chloro-N-(1 ,2-dimethylpropyP-6-(2.4,6-trifluorophenvPM ,2,41triazolon ,5- alpyrimidin-7-amine Example 136 -chloro-N-isopropyl-N-methyl-6-(2.4.6-trifluorophenvPri .2,41triazoloπ ,5- alpyrimidin-7-amine Example 137 5-chloro-N-isopropyl-N-(2,2,2-trifluoroethvD-6-(2.4.6- trifluorophenvP[1 ,2,4ltriazolo[1 ,5-alpyrimidin-7-amine Example 138 7-butyl-5-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4ltriazolo[1 ,5-alpyrimidine Example 139 5-chloro-N-(1-phenylethvP-6-(2,4,6-trifluorophenvPri ,2,4ltriazoloπ ,5- alpyrimidin-7-amine Example 140 -chloro-6-(2-chlorophenvP-N-(2,2,2-trifluoro-1-methylethvPri ,2,4ltriazoloπ ,5- alpyrimidin-7-amine Example 141 δ-chloro-N-ethyl-N-isobutyl-e-^ ^-trifluorophenvPπ ^^ltriazolofl .δ- alpyrimidin-7-amine Example 142 5-chloro-6-(2-chloro-6-fluorophenvP-7-hexyl[1 ,2,41triazolof1 ,5-alpyrimidine Example 143 5-chloro-6-(2-methylphenvP-N.N-bis(2,2,2-trifluoroethvPf1 ,2,4ltriazoloπ ,5- alpyrimidin-7-amine Example 144 5-chloro-N-cvclopentyl-N-methyl-6-(2,3,4,5,6- pentafluorophenvPπ ,2,41triazoloπ ,5-alpyrimidin-7-amine Example 145 7-butyl-5-chloro-6-(2,6-difluorophenyl)ri ,2,41triazoloπ ,5-alpyrimidine Example 146 5-chloro-N-(1 ,2-dimethylpropyP-N-methyl-6-(2,3,4,5,6- pentafluorophenvPH ,2,41triazoloH ,5-alpyrimidin-7-amine Example 147 5-chloro-6-(2-chloro-6-fluorophenvP-7-phenviri ,2,4ltriazoloF1 ,5-alpyrimidine Example 148 5-chloro-6-(2-chloro-6-fluorophenvP-7-(2-methylpropanvPπ ,2,4ltriazolof1 ,5- alpyrimidine Example 149 5-chloro-6-(2-chloro-6-fluorophenvP-7-pentylf1 ,2,4ltriazolori ,5-alpyrimidine Example 150 5-chloro-N-(1 ,2-dimethylpropyP-N-methyl-6-(2,4,6- trifluorophenvPri ,2,41triazolori ,5-alpyrimidin-7-amine Example 151 5-chloro-6-(2-chloro-6-fluorophenvP-7-cvclohexylf1.2.4ltriazoloπ ,5- alpyrimidine Example 152 5-chloro-6-(2-bromo-5-chlorophenvP-N-(2,2,2-trifluoro-1- methylethvPπ ,2,41triazoloπ .5-alpyrimidin-7-amine Example 153 -chloro-6-(2-chloro-6-fluorophenvP-7-(3,3,3-trifluoropropyPri ,2.41triazolori ,5- alpyrimidine Example 154 5-chloro-6-(2-chloro-6-fluorophenvP-7-(3-methylphenvPπ ,2,4ltriazolol " 1.5- alpyrimidine Example 155 r5-chloro-6-C2,4,6-trifluorophenvP-ri ,2,4ltriazolori ,5-alpyrimidin-7-vn-(1-p-tolyl- ethvP-amine Example 156 5-chloro-6-(2,4,6-trifluoro-phenvP-7-cvclohexylf1 ,2,41triazolori ,5-alpyrimidine Example 157 5-chloro-7-cvclohexyl-6-(2,3,4,5,6-pentafluorophenvPπ,2,41triazoloπ ,5- alpyrimidine Example 158 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-difluoro-1- piperidinvPπ .2.41triazolori ,5-alpyrimidine Example 159 7-(bicvclor2.2.1lhept-2-ylamino)-5-chloro-6-f2-fluoro-4- nitrophenvDH .2.4Ttriazolori .5-alpyrimidine Example 160 5-chloro-6-{2-fluoro-4-nitrophenyl)-7-(4-methyl-1 -piperidinvDM ,2,41triazoloπ .5- alpyrimidine Example 161 5-(methylsuifanvP-6-(2-chloro-6-fiuorophenvP-7-cvclohexyiri ,2,41triazoloπ ,5- alpyrimidine Example 162 r5-chloro-6-(2,4,6-trifluorophenvPπ ,2,41triazoloπ ,5-alpyrimidin-7-yll (2,2,2- trifluoro-1 -phenylethvP-amine Example 163 5-chloro-N-ri-(trifluoromethvPpropyll-6-(2,4,6- trifluorophenvPfl ,2,41triazoloπ ,5-alpyrimidin-7-amine Example 164 5-bromo-6-(2-chloro-6-fluorophenvP-7-cvclohexyiπ,2,41triazoloπ ,5- alpyrimidine Example 165 6-(2-chloro-6-fluorophenvP-7-cvclohexyl[1 ,2,4ltriazolof1,5-alpyrimidin-5-amine Example 166 r5-chloro-6-(2,4,6-trifluorophenvPri,2,41triazolori,5-alpyrimidin-7-vn-(2-methyl- 1 -trifluoromethyl-propyPamine Example 167 5-chloro-7-(3-cvclohexen-1 -vP-6-(2,4.6-trifluorophenvPπ ,2,41triazoloπ ,5- alpyrimidine Example 168 5-chloro-7-(1-cvclohexen-1-vP-6-(2,4,6-trifluorophenvPπ,2,4ltriazoloπ.5- alpyrimidine Example 169 5-chloro-N-r(1R)-2,2.2-trifluoro-1-methylethvn-6-(2,4.6- trifluorophenyl)f1 ,2,41triazolori ,5-alpyrimidin-7-amine Example 170 5-chloro-N-r(1 R)-2,2,2-trifluoro-1 -methylethyll-6-(2.4,6- trifluorophenvPπ ,2,4ltriazolof1 ,5-alpyrimidin-7-amine Example 171 6-(2,4-difluorophenvP-5-chloro-N-(2,2,2-trifluoro-1- methylethvPπ ,2,41triazolo[1 ,5-alpyrimidin-7-amine Example 172 5-chloro-6-(2,6-difluoro-4-methoxyphenvP-7-(4-methyl-1- piperidinvPfl ,2,41triazolof1 ,5-alpyrimidine Example 173 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethvPH ,2,4ltriazolof1 ,5-alpyrimidin-7-amine Example 174 5-chloro-7-cvclohexyl-6-(2,6-difluoro-4-methoxyphenvPri ,2,41triazoloπ .5- alpyrimidine Example 175 5-chloro-6-(2,6-difluoro-4-methoxyphenvP-N-r(1S)-2,2,2-trifluoro-1- methylethyliπ .2.41triazoloπ .5-a1pyrimidin-7-amine Example 176 -cvclohexyl-6-f2,6-difluoro-4-methoxyphenvP-5-methoxyπ .2,4ltriazoloF1.5- alpyrimidine Example 177 5-chloro-7-(4-fluorocvclohexyP-6-(2,4,6-trifluorophenvP[1 ,2,4ltriazoloπ .5- alpyrimidine Example 178 5-chloro-6-(2,6-dichloro-4-fluorophenvP-7-(3,3,3- trifluoropropyPπ ,2,4ltriazolo[1 ,5-alpyrimidin-7-amine Example 179 N-(sec-butvP-5-chloro-6-( , 2,6-dichloro-4-fluorophenvPri,2,41triazoloπ,5- alpyrimidin-7-amine Example 180 ' 4-(5-chloro-7-[Y2,2,2-trifluoro-1 -methylethvPaminolM ,2,41triazoloM .5- alpyrimidin-6-yl}-3,6-difluorophenol Example 181 5-chloro-7-(3-cvclohexen-1-vP-6-(2,6-difluoro-4- methoxyphenvPfl ,2,4ltriazolo| " 1 ,5-alpyrimidine ' Example 182 -chloro-6-(2.6-difluoro-4-methoxyphenvPπ ,2,4ltriazolo[1 ,5-alpyrimidin-7- amine Example 183 -chloro-N-cvclopentyl-6-(2,6-difluoro-4-methoxyphenvPri ,2,41triazoloπ .5- alpyrimidin-7-amine Example 184 5-chloro-6-(2,6-difiuoro-4-metho χ yphenvP-7-(3,6-dihvdro-1(2HV pyridinvPπ ,2,4ltriazoio[1 ,5-alpyrimidine Example 185 5-chloro-6-(2,6-difiuoro-4-methoxyphenvP-7-(4- thiomorpholinvPfl ,2,4ltriazoloF1 ,5-alpyrimidine Example 186 -(1 -azepanvP-5-chloro-6-(2,6-difluoro-4-methoxyphenvPf 1 ,2,41triazolof 1 ,5- alpyrimidine Example 187 5-chloro-6-(2,6-difluoro-4-methoxyphenvP-N-(1 ,2,2- trimethylpropyPri ,2,4ltriazolof1 ,5-alpyrimidin-7-amine Example 188 5-chloro-6-(2,6-difluoro-4-methoxyphenvP-N-ethyl-N-(2-methyl-2- propenvPH ,2,41triazoloH ,5-a1pyrimidin-7-amine Example 189 5-chloro-6-(2,6-difluoro-4-methoχyphenvP-7-(4- fluorocvclohexyPπ ,2,4ltriazolo[1 ,5-alpyrimidine Example 190 6-(4-(5-chloro-7-r(2.2.2-trifluoro-1 -methylethvPaminoin ,2,41triazoloM ,5- alpyrimidin-6-ylV3.5-difluorophenoxy)hexanoic acid Example 191 2,6-difluoro-4-(2-fluoroethoxy)phenvn-N-(2,2,2-trifluoro-1- methylethvPfl .2,41triazoloπ .5-alpyrimidin-7-amine Example 192 -chloro-N-isopropyl-6-f2-f(trifluoromethvPsulfanyllphenyl>π ,2,41triazoloπ ,5- alpyrimidin-7-amine Example 193 5-chloro-N-[4-(trifluoromethvPphenyll-6-(2,4,6- trifluorophenvPfl ,2,4ltriazolof1 ,5-alpyrimidin-7-amine Example 194 5-chloro-N-(4,4,4-trifluoro-2-methylbutvP-6-(2,4,6- trifluorophenvPri ,2,4ltriazolo[1 ,5-a1pyrimidin-7-amine Example 195 5-chloro-6-(2.6-difluoro-4-methoχyphenvP-7-(3-methyl-3- butenvPfl ,2,41triazolori .5-alpyrimidine Example 196 5-chloro-6-C2,6-difluoro-4-methoxyphenyP-7-isobutviri,2,41triazoloπ,5- alpyrimidine Example 197 7-cvclopentyl-6-(2,6-difluoro-4-methoxyphenvP-5-methoxyπ ,2,41triazolo[1 ,5- alpyrimidine Example 198 5-chloro-6-(2-thienvP-N-r(1 R)-2.2.2-trifluoro-1-methylethviπ ,2,41triazoloM .5- alpyrimidin-7-amine Example 199 4-(5-chloro-7-(2,2,2-trifluoro-1 -methyl-ethylamino)n .2.41triazoloM .5- alpyrimidin-6-vn-3,5-difluoro-phenol Example 200 {5-chloro-6-r2,6-difiuoro-4-(2,2.2-trifluoro-ethoxy)-phenvn-ri ,2,41triazoloπ ,5- alpyrimidin-7-ylH2,2,2-trifluoro-1-methyl-ethvPamine Example 201 5-chloro-6-(2,6-difluoro-4-(methoxyphenvP-N-(2,2,2-trifluoro-1- methylethvPπ ,2,41triazolori ,5-alpyrimidin-7-amine Example 202 (5-chloro-6-(4-r2-(2-ethoxyethoxyl-ethoxyl-2,6-difluoro- phenvDf 1 ,2,4ltriazoloF1 ,5-alpyrimidin-7-yl-)-(2,2.2-trifluoro-1 - methylethyPamine Example 203 (5-chloro-6-(2,6-difluoro-4-r2-(2-methoxy-ethoxy)ethoxyl-phenyl>- [1 ,2,4ltriazolo[1 ,5-alpyrimidin-7-yl-)-(2,2,2-trifluoro-1 -methylethyPamine Example 204 -chloro-6-r2,6-difluoro-4-(3-furan-3-ylmethoxy)phenyl| " 1 ,2,4ltriazolof1 ,5- a1pyrimidin-7-yl)-N-(2,2,2-trifluoro-1 -methylethyPamine Example 205 5-chloro-6-(2.5-difluoro-4-methoχyphenvP-N-(1 ,2,2- trimethylpropyPπ ,2,41triazoloπ ,5-alpyrimidin-7-amine Example 206 7-cvclohexyl-6-r2,6-difluoro-4-(2-methoxyethoxy)phenvn-5- methoxyπ ,2,4ltriazolo| " 1 ,5-alpyrimidine Example 207 5-chloro-6-(2-fluoro-4-methoxy-6-chlorophenvP-N-(2,2,2-trifluoro-1- methylethyPπ ,2,4ltriazolo[1 ,5-alpyrimidin-7-amine Example 208 -chloro-6-r2,6-difluoro-4-(2-fluoroethoxy)phenyll-N-ethyl-N-(2-methyl-2- propenvPfl ,2,41triazoloπ ,5-alpyrimidin-7-amine Example 209 -r2- 4-f5-chloro-7-r(2,2,2-trifluoro-1-methylethvPaminoiri .2.4ltriazolori,5- a1pyrimidin-6-yl)-3,5-difluorophenoxy)ethoxylethanol Example 210 5-chloro-6-(2,3-difluoro-4-methoxyphenvP-N-(2,2,2-trifluoro-1- methylethvPπ ,2,4ltriazolo[1.5-alpyrimidin-7-amine Example 211 5-chloro-6-l4-(2-fluoroethoxy)-2,6-difluorphenyl)-N-(2,2,2-trifluoro-1- methylethvPM ,2,41triazolof1 ,5-alpyrimidin-7-amine Example 212 -chloro-N-(4-chlorobenzvP-6-(2-chloro-6-fluorophenvPH .2.41triazoloπ .5- alpyrimidin-7-amine Example 213 5-chloro-6-(2-chloro-6-fluorophenvP-7-r4-(2-pyridinyl)-1- piperazinyliπ .2.41triazoloπ ,5-alpyrimidine Example 214 5-chloro-6-(2-chloro-6-fluorophenvP-N-(1 -ethylpentvPH ,2,41triazoloπ .5- alpyrimidin-7-amine Example 215 5-chloro-6-(2-chloro-6-fluorophenvP-7-r4-(2-chlorophenvP-1- piperazinyliπ ,2,41triazoloπ ,5-alpyrimidine Example 216 -chioro-6-(2-chloro-6-fluorophenvP-7-r4-(4-methoxyphenvP-3-methyl-1- piperazinyliri ,2,4ltriazoloF1 ,5-alpyrimidine Example 217 5-chloro-N-cvclopentyl-6-(2-chloro-6-fluorophenvPri .2.41triazoloπ ,5- alpyrimidin-7-amine Example 218 5-chloro-7-phenoxy-6-(4-methoxy-phenvP[1 ,2,4ltriazoloπ ,5-alpyrimidine Example 219 5-chloro-N-cvclopentyl-6-(4-methylphenvPπ ,2,4ltriazolo[1 ,5-alpyrimidin-7- amine Example 220 5,7-diphenoxy-6-(4-methoxyphenyl)π ,2,41triazoloπ ,5-alpyrimidine Example 221 5-chloro-N-cvclopentyl-6-(2-chlorophenvPri .2,4ltriazolof1 ,5-alpyrimidin-7- amine Example 222 5-chloro-N,N-diethyl-6-r4-methoxyphenvnri ,2,4ltriazolof1 ,5-alpyrimidin-7- amine Example 223 5-chloro-N,N-diethyl-6-r2.4-dichlorophenvnf1 ,2.4ltriazoloπ ,5-alpyrimidin-7- amine Example 224 N-bicvclor2.2.11hept-2-yl-5-chioro-6-(2,4-dichlorophenvPri ,2,4ltriazoloπ ,5- alpyrimidin-7-amine Example 225 -chloro-6-(2-chloro-6-fluorophenvP-7-(1 ,4-dioxa-8-azaspiror4.51dec-8- yl)[1 ,2,41triazoloM ,5-alpyrimidine Example 226 5-cvano-7-(4-methyl-1-piperidinvP-6-(2-chloro-5- fluorophenvPn ,2,41triazolori ,5-alpyrimidine Example 227 5-(methylsulfanvP-7-(4-methyl-1-piperidinvP-6-(2-chloro-6- fluorophenvDH ,2,41triazolori ,5-alpyrimidine Example 228 5-(methylsulfanvP-7-(4-methyl-1-piperidinyl)-6-(2-chloro-5- (methylsulfanvPphenvPπ ,2,41triazoloπ ,5-alpyrimidine Example 229 5-chloro-7-(1 ,4-dioxa-8-azaspiror4.51dec-8-vP-6-(4- methoxyphenvPπ .2,41triazoloπ ,5-alpyrimidine Example 230 5-chloro-N-ethyl-N-(2-methyl-2-propenvP-6-(4- (methylsulfanvPphenvPH ,2.41triazoloπ .5-alpyrimidin-7-amine Example 231 2-methyl-6.7-di-(4-methoxyphenyPri ,2,41triazoloπ ,5-alpyrimidine Example 232 2-methyl-6-phenyl-7-(4-chlorophenvP[1 ,2,4ltriazolof1 ,5-alpyrimidine Example 233 -trifluoromethyl-6-phenyl-7-(4-methoxyphenvPπ ,2,41triazoloπ ,5-alpyrimidine Example 234 5,7-diphenoxy-6-(2-methylpropyPri ,2,41triazoloπ ,5-alPyrimidine Example 235 5-chloro-6-(3.4-difluorophenvP-N-(isopropyP[1 ,2,41triazoloπ ,5-alpyrimidin-7- amine Example 236 5-bromo-6-(4-bromophenvP-7-dimethylamino[1 ,2,4ltriazolo[1 ,5-alpyrimidine Example 237 5-bromo-6-(4-trifluoromethylphenyl)-7-dimethylaminof1 ,2,4ltriazolof1 ,5- alpyrimidine Example 238 -chloro-6-(3,4-difluorophenvP-7-dimethylaminoπ ,2.41triazoloπ ,5-alpyrimidine Example 239 -chloro-6-(4-trifluoromethylphenvP-N-(ethvPπ ,2,41triazoloπ .5-alpyrimidin-7- amine Example 240 7-(1 -azepanvD-5-chloro-6-(4-tert-butylphenvDri ,2,41triazoloπ ,5-alpyrimidine Example 241 ethyl {| " 5-chloro-6-(2-chloro-6-fluorophenvDri ,2,41triazoloπ ,5-a1pyrimidin-7- yllaminotøcetate Example 242 diethyl 5-chloro-6-(2.6-difluorophenvPri ,2,4ltriazolof1.5-alpyrimidin-7- malonate Example 243 5-chloro-6-(2,5-difluorophenyl)-N-(3-methyl-2-butenvPπ ,2,41triazoloπ ,5- alpyrimidin-7-amine Example 244 r5-chloro-6-(2-chloro-6-fluorophenvP-f1 ,2,4ltriazolori ,5-alpyrimidin-7-vnacetic acid methyl ester Example 245 5-chloro-6-(2,6-difluorophenvP-7-(2-ethyl-1 H-imidazol-1-vPπ ,2,41triazoloM ,5- alpyrimidine Example 246 5-chloro-N.N-diethyl-6-f4-(methylsulfanvPphenvn[1 ,2,4ltriazoloπ ,5- alpyrimidin-7-amine Example 247 ethyl r6-(2-chloro-6-fluorophenvP-7-(4-methyl-1 -piperidinyl)- H ,2,4ltriazolo[1 ,5- alpyrimidin-5-vnacetate Example 248 5-chloro-N-ethyl-N-(2-methyl-2-propenvP-6-(4- phenoxyphenvPπ ,2,41triazoloπ .5-alpyrimidin-7-amine Example 249 dimethyl 2-r5-chloro-6-f2-chloro-6-fluorophenvPf1 ,2,4ltriazolof1 ,5-alpyrimidin- 7-yllmalonate Example 250 diethyl 2-([5-chloro-6-(2-chloro-6-fluorophenvP[1 ,2,41triazoloπ ,5-alpyrimidin-7- ylloxy>-2-isobutylmalonate Example 251 2-f5-chloro-6-(2-chloro-6-fluorophenvDri ,2,41triazoloπ ,5-alpyrimidin-7-vn-1 ,3- cvclohexanedione Example 252 2-f5-chloro-6-(2-chloro-6-fluorophenvP[1 ,2,4ltriazolof1 ,5-a1pyrimidin-7- yllcyclohexanone Example 253 5-chloro-7-(3-nitro-4-methylanilino)-6-(2, 4, 6-trifluorophenvP f1 ,2,4ltriazolof1 ,5-alpyrimidine Example 254 7-cvclohexyl-6-f2.6-difluoro-4-(2-methoxyethoxy)phenyll5-(2- methoxyethoxy)ri ,2,41triazolori .5-alPyrimidine Example 255 7-(3-bromophenvP-2-ethyl-6-(4-methoxyphenvPri ,2,41triazoloπ ,5-alpyrimidine Example 256 7-(3-bromophenvP-6-(3-chlorophenvP-2-ethviri ,2,41triazolon ,5-alpyrimidine Example 257 7-(4-bromophenvP-2-ethyl-6-r4-(trifiuoromethvPphenvnπ ,2,41triazolo[1 ,5- alpyrimidine Example 258 5-chloro-6-(2-chloro-6-fluorophenvP-N-(3,4,5- trimethoxybenzvPπ ,2,4ltriazolof1 ,5-alpyrimidin-7-amine Example 259 7-(2-benzyl-4,5-dihvdro-1 H-imidazol-1-vP-5-chloro-6-(2-chloro-6- fluorophenvPπ ,2,41triazoloπ ,5-alpyrimidine Example 260 N-4-F5-chloro-6-(2-chloro-6-fluorophenvP[1 ,2,41triazolo 1 ,5-alpyrimidin-7-yl- N,N-1-diethyl-1 ,4-pentanediamine Example 261 5-chloro-N-(3-methyl-2-butenvP-6-phenviπ ,2,4ltriazolo[1.5-alpyrimidin-7- amine Example 262 5-dimethylamino-6-phenyl-N-cvclopentyl( " 1 ,2,4ltriazolof1 ,5-alpyrimidin-7- amine Example 263 5-chloro-7-f(2-furylmethvPsulfanvn-6-(4-methoxyphenvPf1.2,41triazoloπ ,5- alpyrimidine Example 264 -H ,1 '-biphenyll-4-yl-5-chloro-N-cvclopentyiri ,2,4ltriazolof1 ,5-alpyrimidin-7- amine Example 265 -f4-(benzyloxy)phenyll-5-chloro-N-isopropylf1 ,2,4ltriazolof1 ,5-alpyrimidin-7- amine Example 266 5-chloro-N-f(2,2-dichlorocvclopropyPmethyll-6-(3,4,5- trimethoxyphenvDri ,2,4ltriazolof1 ,5-alpyrimidin-7-amine Example 267 N-cvclopentyl-6-(2-fluorophenyl)-5-hvdrazinori ,2,41triazoloπ .5-alpyrimidin-7- amine Example 268 5-chloro-N-ethyl-6-(2-methylphenvPri ,2,41triazolo[1 ,5-alpyrimidin-7-amine Example 269 6-(4-tert-butylphenvP-5-chloro-N-isopropyiπ ,2,4ltriazolo 1 ,5-alpyrimidin-7- amine Example 270 -chloro-6-r2,6-difluoro-4-r(3-methyl-2-butenvPoxylphenvn-N-(2,2,2-trifluoro-1- methylethyl)-l[1 ,2,41triazolori ,5-alpyrimidin-7-amine Example 271 5-chloro-6-f2,6-difluoro-4-( , 1-propenyloxy)phenvn-N-(2,2,2-trifluoro-1- methylethvP-l[1 ,2,4ltriazolof1 ,5-alpyrimidin-7-amine Example 272 5-chloro-N-(3-tricvclor2.2.1.0 2 ' 6 lhept-1-vP-6-(2.4,6- trifluorophenvPH ,2,41triazoloπ ,5-alpyrimidin-7-amine Example 273 5-azido-7-cvclohexyl-6-(2-fluoro-6-chiorophenvP f1 ,2,4ltriazolof1 ,5- alpyrimidine Example 274 5-azido-6-r2-chloro-6-fluorophenvH-7-(4-methyl-1- piperidinvPH ,2,41triazolori ,5-alpyrimidine Example 275 ,5-dichloro-7-(4-methyl-1-piperidinvP-6-r2-chloro-6- fluorophenyliπ ,2,41triazoloπ ,5-alpyrimidine

Claims: We claim: 1. A method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof which comprises administering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof. 2. The method according to Claim 1 wherein the substituted triazolopyrimidine derivative is a compound selected from those of the formula: ® wherein: R 1 is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -S0 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b ; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms.optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl, -S-alkenyl, -S0 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl, -SO 2 alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may optionally be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R 2 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen; R 3 is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 ; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or alkyl of 1 to 12 carbon atoms; R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF 3 ; provided that when: a) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4- methoxyphenyl; b) R 1 is diethylamino, R 3 is bromo, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl; c) R 1 is isopropylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-benzyloxyphenyl or 3,4,5-trimethoxyphenyl; d) R 1 is cyclopentylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,5- trimethoxyphenyl, 2-napthyl or 2-stilbene; e) R 1 is 2-amino- bicyclo(2.2.1.)heptyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,5- trimethoxyphenyl and f) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl and g) R 1 is 1 ,1 ,1 -trifluoroethoxy, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6-fluorophenyl h) R 1 is -SO 2 ethyl or -SO 2 cyclopentyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6- fluorophenyl; i) R 4 is hydrogen, R 2 is 2-chloro-6-fluorophenyl, R 1 and R 3 are not 1 ,2,4-triazole; j) R 1 is cyclohexyl, R 4 is hydrogen, R 2 is 2,4,6- trifluorophenyl, and R 3 is not -OCH 2 O 2 C(CH 3 )3 ; k) R 1 is 2-thienyl, R 4 is ethyl, R 3 is hydrogen and R 2 is not 2-methoxyphenyl, 4-methoxyphenyl, and 4-trifluorophenyl; I) R 2 is phenyl, R 3 is chloro, R 4 is hydrogen R 1 is not (2E)-3,7-dimethyl-2,6-octadienyl or a pharmaceutically acceptable salt thereof. 3. The method according to claim 2 wherein R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -S0 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b or a pharmaceutically acceptable salt thereof is administered. 4. The method according to claim 2 wherein R a and R b each independently represent the moiety -C*H(R e )(R f ) where R e and R f independently represent an optionally halo-substituted alkyl group of 1 to 12 carbon atoms where C* represents the (R) or (S) isomer or a pharmaceutically acceptable salt thereof is administered. 5. The method according to claim 2 wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms, aryloxy, thienyl, benzyloxy, heterocyclyl or halogen or a pharmaceutically acceptable salt thereof is administered. 6. The method according to claim 2 wherein R 3 is halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, hydroxy, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 7. The method according to claim 2 wherein R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF 3 or a pharmaceutically acceptable salt thereof is administered. 8. The method according to claim 2 wherein R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -0-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -S0 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached or a pharmaceutically acceptable salt thereof is administered. 9. The method according to claim 2 wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms or heterocyclyl or a pharmaceutically acceptable salt thereof is administered. 10. The method according to claim 2 wherein R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 11. The method according to claim 2 wherein R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF 3 or a pharmaceutically acceptable salt thereof is administered. 12. The method according to claim 2 wherein R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -0-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms,-S0 2 aryl of 6, 10 or 14 carbon atoms, -S0 2 cycloalkyl of 5 to 10 carbon atoms, -S0 2 alkyl of 1 to 12 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached or a pharmaceutically acceptable salt thereof is administered. 13. The method according to claim 2 wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms or a pharmaceutically acceptable salt thereof is administered. 14. The method according to claim 2 wherein R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 15. The method according to claim 2 wherein R 4 is H or a pharmaceutically acceptable salt thereof is administered. 16. The method according to claim 2 wherein R 1 is selected from the group consisting of an optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alky! group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 17. The method according to claim 2 wherein R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 18. The method according to claim 2 wherein R 1 is the moiety -NR a a π Rb ! wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 toδ carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 2 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or alkyl of 2 to 20 carbon atoms or a pharmaceutically acceptable salt thereof is administered. 19. The method according to claim 2 wherein R 1 is the moiety -NR a R b wwhheerreeiinn R R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is selected from R 3 is halogen, alkoxy, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 20. the method according to claim 2 wherein R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached and wherein R is selected from >-N(C 2 H 5 ) 2 , > -N(CH 3 ) 2 -NHC 2 H 5 R • > 2 is optionally substituted phenyl; R is halogen, alkoxy of 1 to 12 carbon atoms, -NR co Rd , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 21. The method according to claim 2 wherein R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached and wherein R is selected from ξ-NHC Hs R 2 is optionally substituted thienyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 22. The method according to claim 2 wherein said compound selected from: 7-(1 -azepanyl)-5-chloro-6-phenyl[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-chloro-6-(2,6-difluorophenyl)-7-(4-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,5- alpyrimidine; 5-chioro-6-(4-methoxyphenyl)-7-(1 -piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1 - piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 7-(1 -azepanyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5- alpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-thiomorpholinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; methyl [[5-ch!oro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- yl](methyl)amino]acetate; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 ,1 ,3,3- tetramethylbutyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 7-(1 -azepanyl)-5-chloro-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 7-(1 -azepanyl)-6~(4-bromophenyl)-5-chloro[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-chloro-7-(1 -piperidinyl)-6-[2-(trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,5- ajpyrimidine; 6-(4-tert-butylphenyl)-5-chloro-7-(4-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(4-methoxyphenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(4-methoxyphenyl)-7-(3-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 6-(4-bromophenyl)-5-chloro-7-(3-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(3,4-difluorophenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2,6-dichlorophenyl)-7-(2-methyl-1 -pyrrolidinyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; 5-chioro-6-(2-chlorophenyl)-7-(2-methyl-1-pyrrolidinyi)[1 ,2,4Jtriazolo[1 > 5- ajpyrimidine; 7-(1 -azepanyl)-5-chloro-6-(3-chloro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(2-methyl-1- piperidinyl)[1 ,2,4Jtriazolo[1 ,5-ajpyrimidine; 6-(4-tert-butylphenyl)-5-chloro-7-(2-methyl-1 -piperidinyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; 5-chloro-7-(2-methyl-1-piperidinyl)-6-[3- (trifluoromethyl)phenyl][1 ,2,4Jtriazolo[1 ,5-ajpyrimidine; i Diethyl 2-[6-(2,6-difluorophenyl)-5-ethoxy[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- yljmalonate; 7-(azepanyl)-5-chloro-6-{2-chloro-6-nitrophenyl}[1 ,2,4}triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4Jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2- trifluoroethyl)[1 ,2,4Jtriazoio[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-[(2,2-dichlorocyclopropy!)methy!J-N- methyl[1 ,2,4]triazolo[1 ,5-aJpyrimidin-7-amine; 1-[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4Jtriazolo[1 ,5-aJpyrimidin-7-ylJ-3- piperidinol; N-bicyclo[2.2.1 ]hept-2-yl-5-chloro-6-(3-chloro-4- methoxyphenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2,5-difluorophenyl)-N-dodecyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- amine; 5-chloro-7-(4-methyl-1-piperidinyl)-6-(2,3,6- trifluorophenyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; N-[5-chloro-6-(2,3,6-trifluorophenyl)[1 ,2,4Jtriazolo[1 ,5-a]pyrimidin-7-yl]-N- isopropylamine; 5-chloro-N-ethyl-N-(2-methyl-2-propeny!)-6-(2,3,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; N-allyl-5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(3-chloro-4-methoxyphenyl)-N-cycloheptyl[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(3,3-dimethy!-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-chloro-N-(3-chloropropyl)-N-methy!-6-(2,3,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 7-(1 -azocanyl)-5-chloro-6-(2,3,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- alpyrimidine; 5-chloro-6-(2,6-difluorophenyl)-7-(3,6-dihydro-1(2H)- pyridinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 7-(1 -azocanyl)-5-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-methoxy-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; [5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- yljmethanol; 1 -[5-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-ylj-4- piperidinol; 5-chloro-7-(4-chloro-1 -piperidinyl)-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-7-(4-thiomorpholinyl)-6-(2,3,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2,6-difluorophenyl)-7-(2,4-dimethyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 7-(4-methyl-1 -piperidinyl)-5-amino-6-(2-chloro-6- fiuorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-chloro-6-(2,6-difluoropheny!)-7-(2,5-dihydro-1 H-pyrrol-1 - yl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2,5-dimethyl-2,5-dihydro-1 H-pyrroi-1- yl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-ethyl-1 H-imidazol-1 - yl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 7-(4-bromo-1-piperidinyl)-5-chloro-6-(2-chioro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-methylphenyl)-7-(4-thiomorpholinyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 6-(2-bromophenyl)-N-(sec-butyl)-5-chloro[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7- amine; 5-chloro-N-ethyl-6-(4-methoxyphenyl)-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(4-methoxyphenyl)-7-(4-thiomorpholinyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-7-(4-chloro-1-piperidinyl)-6-[2- (trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(trifluoromethyl)-1- piperidinylj[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 7-(4-bromo-1 -piperidinyl)-5-ch!oro-6-(2,6-difluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 7-(4-bromo-1 -piperidinyl )-5-chloro-6-(2-chlorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-N-isopropyl-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7- amine; 5-chloro-7-(4-thiomorpholinyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 7-(1 -azepanyl)-5-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1 -pyrrolidinyl )-1 -cyclopenten-1 - ylj[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-7-(4-isopropyl-1 -piperidinyl)-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-7-(2,4-dimethyl-1 -piperidinyl)-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-7-[ethyl(2-methyl-2-propenyl)amino]-6-{4- nitrophenyl}[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 7-(1 -azepanyl)-5-chIoro-6-{4-nitrophenyl}[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; N-bicyclo[2.2.1 jhept-2-yl-5-chloro-6-(2,4,6-trifiuorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoroethyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2-chiorophenyl)-N-(2 ) 2,2-trifluoroethyi)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorobenzyl)-7-tetrahydro-2-furanyl[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 7-(allylsulfanyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-N-ethyl-6-mesityl-N-(2-methyl-2-propenyl)[1 ,2,4]triazolo[1,5- a]pyrimidin-7-amine; 5-chloro-N-ethyl-6-(2-methoxyphenyl)-N-(2-methyl-2- propenyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1 ,2,4jtriazolo[1 ,5-aJpyrimidin-7- amine; 5-chloro-7-(4-methyl-1-piperidinyl)-6-[4- (methylsulfanyl)phenylj[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-[4- (methylsulfanyl)phenylj[1,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; N-(sec-butyl)-5-chloro-6-[4-(methylsulfanyl)phenyl][1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; I* \ 5-chloro-6-[4-(methylsulfanyl)phenylj-7-(4-thiomorpholinyl)[1 ,2,4jtriazo!o[1 ,5- ajpyrimidine; 5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenylj-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 7-(1-azepanyl)-5-chloro-6-[2,6-dichloro-4- (trifluoromethyl)phenylj[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2,2,2- trifluoroethyl)sulfanylj[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-dimethyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenylj-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenylj-7-(4- thiomorpholinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(3,5-difluorophenyl)-7-(4-methyl-1-piperidinyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-tetrahydro-2-furanyl[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 4-[5-chloro-7-(4-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-6-yljaniline; N-{4-[5-chloro-7-(4-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-6- yl]phenyl}acetamide; [5-chloro-6-(2-chloro-6-ffuorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-yl]methyl acetate; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(chloromethyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; diethyl 2-[6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-5-yl]malonate; 7-(1-azepanylmethyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; N-allyl-5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-7-(4-methyl-1-piperidinyl)-6-[4- (trifluoromethoxy)phenyl][1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-7-(4-methyl-1 -piperidinyl)-6-(4-phenoxyphenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(cyclopropylmethyl)-N- propyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-7-(2-methyl-1 -piperidinyl)-6-(4-phenoxyphenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-{2-chloro-4-nitrophenyl}-7-(4-methyl-1 - piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(4-chloro-2,3,5,6-tetrafluorophenyl)-N- cyclopentyl[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 4-[5-chloro-2-methyl-7-(4-methyl-1 -piperidinyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin- 6-ylj-N,N-dimethylaniline; 6-(2-chloro-6-fluorophenyl)-5-methyl-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1 -pyrrolidinyl )-1 -cyclohexen-1 - yl][1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(methoxymethyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-{2-chloro-4-nitrophenyl}-7-[ethyl(2-methyl-2- propenyl)aminoj[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-bromo-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-N-cyclopentyl-6-(4-ethoxy-2,3,5,6- tetrafluorophenyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-N-methyl-N-(2-methyl-2-propenyl)-6-(2,4,6- trifluorophenyi)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 4-bromo-1-[5-chloro-6-(2-ch!oro-6-f!uorophenyl)[1,2,4]triazolo[1 ,5-ajpyrimidin- 7-yljbutyl acetate; diethyl 2-allyl-2-{[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidin-7-yljoxy}malonate; 6-(2-chloro-6-fluorophenyl)-N-ethyl-5-methyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidin- 7- amine; a]pyrimidin-7-amine; 6-(2-chloro-6-fluorophenyl)-5-(difluoromethoxy)-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(4- chlorophenyl)sulfanylj[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2- methoxyphenyl)sulfanyl][1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2,3,4,5,6-pentafluorophenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2,4,6-trifluorophenyl)-N-(1 ,2,2-trimethy!propyl)[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(4-fluorophenyl)-N-(1 ,2,2- trimethyipropy!)[1 ,2,4]triazolo[1 ,5- ajpyrimidin-7-amine; 5,7-bis(4-methyl-1 -piperidinyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-methylphenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2,4,5-trifluorophenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 6-(2-bromopheny!)-5-chloro-N-(1 ,2,2-trimethyipropyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-N-isobutyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-N-isobutyI-6-(2-methylphenyl)-N-(2,2,2- trifluoroethyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-N-(2,2,2-trifluoro-1-methylethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; N-aiIyl-5-chloro-N-isobutyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-N-(1 ,2-dimethylpropyl)-6-(2,4,6-trifluorophenyi)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-N-isopropyl-N-methyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazo!o[1 ,5- a]pyrimidin-7-amine; 5-chloro-N-isopropyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 7-butyl-5-chloro-6-(2,4,6-trifluorophenyl)[1,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-N-(1 -phenyIethyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2-chlorophenyl)-N-(2,2 ) 2-trifluoro-1-methylethyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-N-ethyl-N-isobutyl-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-hexyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-methylphenyl)-N,N-bis(2,2,2-trifluoroethyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chIoro-N-cyclopentyl-N-methyl-6-(2,3,4,5,6- pentafluorophenyi)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 7-butyl-5-chloro-6-(2,6-difluorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chIoro-N-(1 ,2-dimethylpropyl)-N-methyl-6-(2,3,4,5,6- pentafluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-phenyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-f!uorophenyl)-7-(2-methylpropanyl)[1 ,2,4]triazolo[1 , ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-pentyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-N-(1 ,2-dimethylpropyl)-N-methyl-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-bromo-5-chlorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(3,3,3-trifluoropropyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(3-methylphenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; [5-chloro-6-(2,4,6-trifluorophenyl)-[1 ,2,4jtriazolo[1 , 5-a] pyri mid i n-7-yl]-( 1 -p- tolyl-ethyl)-amine; 5-chloro-6-(2,4,6-trifluoro-phenyl)-7-cycIohexyl[1 ,2,4Jtriazolo[1 ,5-ajpyrimidine; 5-chloro-7-cyclohexyl-6-(2,3,4,5,6-pentafluorophenyI)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-difluoro-1- piperidinyl)[1 ,2,4jtriazoio[1 ,5-ajpyrimidine; 7-(bicyclo[2.2.1jhept-2-ylamino)-5-chloro-6-{2-fluoro-4- nitrophenyl}[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5-chloro-6-{2-fluoro-4-nitrophenyl}-7-(4-methyl-1 -piperidinyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-(methylsulfanyl)-6-(2-chIoro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; [5-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4Jtriazolo[1 ,5-ajpyrimidin-7-yl] (2,2,2- trifluoro-1 -phenylethyl)-amine; 5-chloro-N-[1-(trifluoromethyl)propylj-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 5-bromo-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 6-(2-chloro-6-fluorophenyl)-7-cyciohexyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-5- amine; methyl-1-trifluoromethyl-propyl)amine; δ-chloro-7-(3-cyclohexen-1 -yl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-7-(1 -cyclohexen-1 -yl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chloro-N-[(1 R)-2,2,2-trifluoro-1 -methylethylj-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-N-[(1 R)-2,2,2-trifluoro-1-methylethylj-6-(2,4,6- trifluorophenyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 6-(2,4-difluorophenyl)-δ-chloro-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidin-7-amine; • δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-[(1 S)-2,2,2-trifluoro-1 - methylethyl][1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; 7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)-δ-methoxy[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chIoro-7-(4-fluorocyclohexyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 5-chloro-6-(2,6-dichloro-4-fIuorophenyl)-7-(3,3,3- trifluoropropyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; N-(sec-butyl)-5-chloro-6-(2,6-dichloro-4-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; 4-{δ-chloro-7-[(2,2,2-trifluoro-1 -methylethyl)aminoj[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-6-yl}-3,6-difluorophenol; δ-chloro-7-(3-cyclohexen-1-yl)-6-(2,6-difluoro-4- methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7- amine; 5-chloro-N-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-7-amine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3,6-dihydro-1(2H)- pyridinyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; 5-chioro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4- thiomorpholinyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; 7-(1 -azepanyl)-δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4jtriazoio[1 ,δ- ajpyrimidine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4- fluorocyclόhexyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 6-(4-{5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)aminoj[1 ,2,4jtriazolo[1 ,5- ajpyrimidin-6-yl}-3,5-difluorophenoxy)hexanoic acid; 2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; δ-chloro-N-isopropyl-6-{2-[(trifluoromethyl)sulfanyl]phenyl}[1 ,2,4]triazolo[1 ,δ- ajpyrimidin-7-amine; δ-chloro-N-[4-(trifluoromethyl)phenyl]-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-N-(4,4,4-trifluoro-2-methylbutyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3-methyl-3- butenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-isobutyl[1 ,2,4]triazolo[1 ! δ- ajpyrimidine; 7-cyclopentyI-6-(2,6-difluoro-4-methoxyphenyl)-δ-methoxy[1 ,2,4]triazolo[1 ,5- ajpyrimidine; δ-chloro-6-(2-thienyl)-N-[(1 R)-2,2,2-trifIuoro-1-methyfethyl[1 ,2,4Jtriazolo[1 ,5- a]pyrimidin-7-amine; 4-(δ-chloro-7-(2,2,2-trifluoro-1 -methyl-ethylamino)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-6-yl]-3,δ-difluoro-phenol; {δ-chloro-6-[2,6-difluoro-4-(2,2,2-trifluoro-ethoxy)-phenylj-[1 ,2,4jtriazolo[1 ,5- a]pyrimidin-7-yl}-(2,2,2-trifluoro-1-methyl-ethyl)amine; δ-chloro-6-{2,6-difluoro-4-(methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; (5-chloro-6-{4-[2-(2-ethoxyethoxyj-ethoxy]-2,6-difluoro- phenyl}[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1 - methylethyl)amine; (5-chloro-6-{2,6-difluoro-4-[2-(2-methoxy-ethoxy)ethoxyj-phenyl}- [1 ,2,4jtriazolo[1 ,δ-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1 -methylethyl)amine; δ-chloro-6-[2,6-difluoro-4-(3-furan-3-ylmethoxy)phenyl[1 ,2,4jtriazolo[1 ,δ- a]pyrimidin-7-yl}-N-(2,2,2-trifluoro-1-methylethyl)amine; δ-chloro-6-(2,δ-difluoro-4-methoxyphenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidin-7-amine; 7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenylj-δ- methoxy[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; δ-chloro-6-(2-fluoro-4-methoxy-6-chlorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7-amine; 5-chloro-6-[2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 2-[2-(4-{δ-chloro-7-[(2,2,2-trifluoro-1 -methylethyI)aminoj[1 ,2,4jtriazolo[1 ,δ- a]pyrimidin-6-yl}-3,δ-difluorophenoxy)ethoxy]ethanol; δ-chloro-6-(2,3-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-6-{4-(2-fluoroethoxy)-2,6-difluorphenyl}-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-N-(4-chlorobenzyl)-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-pyridinyl)-1- piperazinyl][1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1-ethylpentyl)[1,2,4jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-chlorophenyl)-1 - piperazinylj[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyi)-7-[4-(4-methoxyphenyl)-3-methyl-1- piperazinylj[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; 5-chloro-N-cyclopentyl-6-(2-chloro-6-fluorophenyI)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidin-7-amine; δ-chloro-7-phenoxy-6-(4-methoxy-phenyl)[1 ,2,4]triazoIo[1 ,δ-ajpyrimidine; 5-chloro-N-cyclopentyl-6-(4-methylphenyl)[1 ,2,4jtriazoIo[1 ,5-ajpyrimidin-7- amine; 5,7-diphenoxy-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-N-cyclopentyl-6-(2-chlorophenyl)[1 ,2,4]triazoIo[1 ,5-a]pyrimidin-7- amine; 5-chloro-N,N-diethyl-6-[4-methoxyphenyl][1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7- amine; δ-chloro-N.,N-diethyl-6-[2,4-dichlorophenylj[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; N-bicyclo[2.2.1 jhept-2-yl-δ-chloro-6-(2,4-dichlorophenyl)[1 ,2,4jtriazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyi)-7-(1 ,4-dioxa-8-azaspiro[4.δ]dec-8- yl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; 5-cyano-7-(4-methyl-1-piperidinyl)-6-(2-chloro-δ- fluorophenyi)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-(methylsuIfanyl)-7-(4-methyl-1-piperidinyl)-6-(2-chIoro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; 5-(methylsuifanyl)-7-(4-methyl-1-piperidinyl)-6-(2-chloro-δ- (methylsulfanyl)phenyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-7-(1,4-dioxa-8-azaspiro[4,δjdec-8-yl)-6-(4- methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4- (methylsulfanyl)phenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; 2-methyl-6,7-di-(4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; 2-methyl-6-phenyl-7-(4-chlorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 2-trifluoromethyl-6-phenyl-7-(4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidine; 5,7-diphenoxy-6-(2-methylpropyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; δ-chloro-6-(3,4-difluorophenyl)-N-(isopropyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7- amine; 5-bromo-6-(4-bromophenyl)-7-dimethylamino[1,2,4jtriazolo[1 ,5-ajpyrimidine; 5-bromo-6-(4-trifluoromethylphenyl)-7-dimethylamino[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(3,4-difluorophenyl)-7-dimethylamino[1 ,2,4jtriazolo[1 ,5- ajpyrimidine; δ-chloro-6-(4-trifluoromethylphenyl)-N-(ethy!)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7- amine; 7-(1-azepanyl)-δ-chloro-6-(4-tert-butylphenyl)[1 ,2,4]triazolo[1,δ-ajpyrimidine; ethyl {[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7- yl]amino}acetate; diethyl δ-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- malonate; δ-chloro-6-(2,δ-difluorophenyl)-N-(3-methyl-2-butenyl)[1 ,2,4jtriazoIo[1 ,δ- ajpyrimidin-7-amine; [δ-chloro-6-(2-chloro-6-fluorophenyl)-[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7-yljacetic acid methyl ester; δ-chloro-6-(2,6-difluorophenyl)-7-(2-ethyl-1 H-imidazol-1-yl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-N,N-diethyl-6-[4-(methylsulfanyl)phenyl][1 ,2,4jtriazolo[1 ,δ- ajpyrimidin-7-amine; ethyl [6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1 -piperidinyl)- [1 ,2,4]triazolo[1 ,δ- ajpyrimidin-5-yl]acetate; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4- phenoxyphenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; dimethyl 2-[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidin- 7-yl]malonate; diethyl 2-{[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidin-7- yl]oxy}-2-isobutylmalonate; 2-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-ylj-1 ,3- cyclohexanedione; 2-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4jtriazolo[1,5-ajpyrimidin-7- yljcyclohexanone; δ-chloro-7-(3-nitro-4-methylanilino)-6-(2, 4, 6-trifluorophenyl) [1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; 7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenyljδ-(2- methoxyethoxy)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; 7-(3-bromophenyl)-2-ethyl-6-(4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; 7-(3-bromophenyl)-6-(3-chlorophenyl)-2-ethyl[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; 7-(4-bromophenyl)-2-ethyl-6-[4-(trifluoromethyl)phenyij[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(3,4,δ- trimethoxybenzyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; 7-(2-benzyl-4,δ-dihydro-1 H-imidazol-1-yl)-δ-chloro-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazo!o[1 ,δ-a]pyrimidine; N-4-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidin-7-yl- N,N-1-diethyl-1 ,4-pentanediamine; δ-chloro-N-(3-methyi-2-butenyl)-6-pheny![1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7- amine; 5-dimethylamino-6-phenyI-N-cyclopentyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-7-[(2-furylmethyl)sulfanyl]-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 6-[1 ,1 '-biphenylj-4-yl-5-chloro-N-cyclopentyl[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7- amine; 6-[4-(benzyloxy)phenylj-5-chloro-N-isopropyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7- amine; δ-chloro-N-[(2,2-dichlorocyclopropyl)methyl]-6-(3,4,δ- trimethoxyphenyl)[1 ,2,4Jtriazolo[1 ,δ-a]pyrimidin-7-amine; N-cyclopentyl-6-(2-fluorophenyl)-δ-hydrazino[1,2,4jtriazolo[1 ,5-ajpyrimidin-7- amine; 5-chloro-N-ethyl-6-(2-methylphenyl)[1 ,2,4]triazolo[1,δ-ajpyrimidin-7-amine; 6-(4-tert-butylphenyl)-δ-chloro-N-isopropyl[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7- amine; δ-chloro-6-[2,6-difluoro-4-[(3-methyl-2-butenyI)oxyjphenylj-N-(2,2,2-trifluoro-1- methylethyl)-l[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-6-[2,6-difluoro-4-(1-propenyloxy)phenylj-N-(2,2,2-trifluoro-1- methylethyl)-i[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; δ-chioro-N-(3-tricyclo[2.2.1.0 2,6 ]hept-1-yl)-6-(2,4,6- trifluorophenyl)[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 5-azido-7-cyclohexyl-6-(2-fluoro-6-chlorophenyl) [1 ,2,4jtriazolo[1 ,5- ajpyrimidine; 5-azido-6- 2-chloro-6-fluorophenylj-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazoio[1 ,5-ajpyrimidine; 2,5-dichioro-7-(4-methyl-1-piperidinyl)-6-[2-chloro-6- fluorophenyl][1 ,2,4jtriazolo[1 ,δ-a]pyrimidine or a pharmaceutically acceptable salt thereof is administered. 23. A method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules and promoting microtubule polymerization which comprises administering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof. 24. The method according to Claim 23 wherein the substituted triazolopyrimidine derivative is a compound selected from those of the formula: (D wherein: R 1 is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or - NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b ; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms.optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl, -S-alkenyl, -S0 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl, -SO 2 alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may optionally be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R 2 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen; R 3 is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 ; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-', or-NR' where R' is H or alkyl of 1 to 12 carbon atoms; R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF 3 ; provided that when: a) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro- 4-methoxyphenyl; b) R 1 is diethylamino, R 3 is bromo, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl; c) R 1 is isopropylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-benzyloxyphenyl or 3,4,δ-trimethoxyphenyl; d) R 1 is cyclopentylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,6- trimethoxyphenyl, 2-napthyl or 2-stiIbene; e) R 1 is 2-amino- bicyclo(2.2.1.)heptyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,δ- trimethoxyphenyl and f) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl and g) R 1 is 1,1 ,1 -trifluoroethoxy, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6-fluorophenyl h) R 1 is -SO 2 ethyl or -S0 2 cyclopentyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6- fluorophenyl; i) R 4 is hydrogen, R 2 is 2-chloro-6-fluorophenyl, R 1 and R 3 are not 1,2,4-triazole; j) R 1 is cyclohexyl, R 4 is hydrogen, R 2 is 2,4,6- trifluorophenyl, and R 3 is not -OCH 2 O 2 C(CH 3 ) 3 ; k) R 1 is 2-thienyl, R 4 is ethyl, R 3 is hydrogen and R 2 is not 2-methoxyphenyl, 4-methoxyphenyl, and 4-trifluorophenyl; I) R 2 is phenyl, R 3 is chloro, R 4 is hydrogen R 1 is not (2E)- 3,7-dimethyl-2,6-octadienyl or a pharmaceutically acceptable salt thereof. 2δ. The method according to claim 24 wherein R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -S0 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b or a pharmaceutically acceptable salt thereof is administered. 26. The method according to claim 24 wherein R a and R b each independently represent the moiety -C*H(R e )(R f ) where R e and R f independently represent an optionally halo-substituted alkyl group of 1 to 12 carbon atoms where C* represents the (R) or (S) isomer or a pharmaceutically acceptable salt thereof is administered. 27. The method according to claim 24 wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms, aryloxy, thienyl, benzyloxy, heterocyclyl or halogen or a pharmaceutically acceptable salt thereof is administered. 28. The method according to claim 24 wherein R 3 is halogen, alkyi of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, hydroxy, cyano, amino, alkyiamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 29. The method according to claim 24 wherein R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF 3 or a pharmaceutically acceptable salt thereof is administered. 30. The method according to claim 24 wherein R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -S0 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached or a pharmaceutically acceptable salt thereof is administered. 31. The method according to claim 24 wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms or heterocyclyl or a pharmaceutically acceptable salt thereof is administered. 32. the method according to claim 24 wherein R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 33. The method according to claim 24 wherein R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF 3 or a pharmaceutically acceptable salt thereof is administered. 34. The method according to claim 24 wherein R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of δ to 10 carbon atoms, -SO alkyl of 1 to 12 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached or a pharmaceutically acceptable salt thereof is administered. 3δ. The method according to claim 24 wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms or a pharmaceutically acceptable salt thereof is administered. 36. The method according to claim 24 wherein R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 37. The method according to claim 24 wherein R 4 is H or a pharmaceutically acceptable salt thereof is administered. 38. The method according to claim 24 wherein R 1 is selected from the group consisting of an optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -S0 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 39. The method according to claim 24 wherein R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 40. The method according to claim 24 wherein R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyi; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -S0 2 cycloalkyl of 3 toδ carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 2 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or alkyl of 2 to 20 carbon atoms or a pharmaceutically acceptable salt thereof is administered. 41. The method according to claim 24 wherein R 1 is the moiety -NR a R b wwhheerreeiinn R R a R are optionally taken together with the nitrogen to which each is attached; R is selected from R 3 is halogen, alkoxy, -NR C R , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 42. The method according to claim 24 wherein R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached and wherein R 1 is selected from >-N(C 2 H 5 ) 2 , l- N rv R is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 43. The method according to claim 24 wherein R is the moiety -NR a R wherein R a R b are optionally taken together with the nitrogen to which each is attached and wherein R 1 is selected from 3-N(C2H 5 ) 2 , -N(CH 3 ) 2 <-NHC 2 H 5 R is optionally substituted thienyl; R is halogen, alkoxy of 1 to 12 carbon atoms, -NR en Rd , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 44. The method according to claim 24 wherein said compound selected from: 7-(1 -azepanyl)-δ-chloro-6-phenyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluorophenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(4-methoxyphenyl)-7-(1-piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(1 -azepanyl)-δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyI)-7-(4-thiomorpholinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; methyl [[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yl](methyl)amino]acetate; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 ,1 ,3,3- tetramethyl butyl )[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 7-(1 -azepanyl)-δ-chloro-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(1 -azepanyl)-6-(4-bromophenyl)-δ-chloro[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chioro-7-(1 -piperidinyl)-6-[2-(trifiuoromethyl)phenyl][1 ,2,4]triazolo[1 ,δ- a]pyrimidine; 6-(4-tert-butylphenyl)-δ-chloro-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(4-methoxyphenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazoio[1 ,δ- a]pyrimidine; δ-chloro-6-(4-methoxyphenyl)-7-(3-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 6-(4-bromophenyl)-δ-chloro-7-(3-methyl-1-ρiperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(3,4-difluorophenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2,6-dichlorophenyl)-7-(2-methyl-1-pyrrolidinyI)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2-chlorophenyl)-7-(2-methyl-1 -pyrrolidinyl)[1 i2,4]triazolo[1 ,δ- a]pyrimidine; 7-(1 -azepanyl)-δ-chloro-6-(3-chloro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(3-chloro-4-methoxyphenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(3-chloro-4-methoxyphenyl)-7-(2-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 6-(4-tert-butylphenyl)-δ-chloro-7-(2-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-7-(2-methyl-1 -piperidinyl )-6-[3- (trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; Diethyl 2-[6-(2,6-difluorophenyl)-δ-ethoxy[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yl]malonate; 7-(azepanyl)-δ-chloro-6-{2-chloro-6-nitrophenyl}[1 ,2,4}triazolo[1 ,δ- a]pyrimidine; ■ δ-chloro-6-(2-chloro-6-fluorophenyl)-N-ethyi-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2- trifluoroethyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-[(2,2-dichlorocyclopropyl)methyl]-N- methyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 1 -[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-ylj-3- piperidinoi; N-bicyclo[2.2.1]hept-2-yl-δ-chloro-6-(3-chloro-4- methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,δ-difluorophenyl)-N-dodecyl[1,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-7-(4-methyl-1-piperidinyl)-6-(2,3,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; N-[δ-chloro-6-(2,3,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]-N- isopropylamine; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,3,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; N-allyl-δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(3-chloro-4-methoxyphenyl)-N-cycloheptyl[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(3-chloro-4-methoxyphenyl)-7-(3,3-dimethyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-(3-chloropropyl)-N-methyl-6-(2,3,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 7-(1 -azocanyl)-δ-chloro-6-(2,3,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2,6-difluorophenyl)-7-(3,6-dihydro-1(2H)- pyridinyi)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(1 -azocanyl)-δ-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-methoxy-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; [δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yi]methanol; 1 -[δ-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]-4- piperidinol; δ-chloro-7-(4-chloro-1 -piperidinyl)-6-(2,6-difluorophenyl)[1 ,2,43triazolo[1 ,δ- a]pyrimidine; δ-chloro-7-(4-thiomorpholinyl)-6-(2,3,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2,6-difluorophenyl)-7-(2,4-dimethyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(4-methyl-1-piperidinyl)-δ-amino-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluorophenyl)-7-(2,δ-dihydro-1 H-pyrrol-1 - yl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(2,δ-dimethyl-2,δ-dihydro-1 H-pyrrol-1 • yl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyi)-7-(2-ethyl-1 H-imidazol-1 - yi)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(4-bromo-1 -piperidinyl )-δ-chloro-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-methylphenyl)-7-(4-thiomorpholinyl)[1 ,2,4]triazolo[1,δ- ajpyrimidine; 6-(2-bromophenyl)-N-(sec-butyl)-δ-chloro[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N-ethyl-6-(4-methoxyphenyl)-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(4-methoxyphenyl)-7-(4-thiomorpholinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-7-(4-chloro-1-piperidinyl)-6-[2- (trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(trifluoromethyl)-1- piperidinyl][1 ,2,4]triazolo[1 ,δa]pyrimidine; 7-(4-bromo-1 -piperidinyl )-δ-chloro-6-(2,6-difluorophenyl)[1 ,2,43triazolo[1,δ- ajpyrimidine; 7-(4-bromo-1-piperidinyl)-δ-chloro-6-(2-chlorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-isopropyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7- amine; δ-chloro-7-(4-thiomorpholinyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1,δ- ajpyrimidine; 7-(1 -azepanyl)-δ-chloro-6-(2,4,6-trifluorophenyi)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1-pyrrolidinyl)-1-cyclopenten-1- yl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-7-(4-isopropyl-1 -piperidinyl)-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-7-(2,4-dimethyl-1 -piperidinyl)-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-7-[ethyl(2-methyl-2-propenyl)amino]-6-{4- nitrophenyl}[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(1-azepanyl)-δ-chloro-6-{4-nitrophenyl}[1,2,43triazolo[1,δ-a]pyrimidine; N-bicyclo[2.2.1]hept-2-yl-δ-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoroethyl)[1,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoroethyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorobenzyl)-7-tetrahydro-2-furanyl[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; 7-(allylsulfanyl)-δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-N-ethyl-6-mesityl-N-(2-methyl-2-propenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-ethyl-6-(2-methoxyphenyl)-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-7-(4-methyl-1-piperidinyl)-6-[4- (methylsulfanyl)phenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-[4- (methylsulfanyl)phenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; N-(sec-butyl)-δ-chloro-6-[4-(methylsulfanyl)phenyl][1 ,2,4]triazolo[1,δ- a]pyrimidin-7-amine; δ-chloro-6-[4-(methylsulfanyl)phenyl]-7-(4-thiomorpholinyl)[1 ,2,4]triazoio[1 ,δ- ajpyrimidine; δ-chloro-6-[2,6-dich!oro-4-(trifluoromethyl)phenyl]-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(1-azepanyl)-δ-chloro-6-[2,6-dichloro-4- (trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2,2,2- trifluoroethyl)sulfanyl][1 ,2,4]triazo!o[1.δ-ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-dimethyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; δ-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-7-(4- thiomorpholinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(3,δ-difluorophenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1 ,2,4]triazolo[1,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-tetrahydro-2-furanyl[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 4-[δ-chloro-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-6-yl]aniline; N-{4-[δ-chloro-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-6- yl]phenyi}acetamide; [δ-chioro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]methyi acetate; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(chloromethyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; diethyl 2-[6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1 - piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-δ-yi]malonate; 7-(1 -azepanyimethyl)-δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; N-allyl-δ-chloro-6 r (2-chloro-6-fluorophenyl)-N-hexyl[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-7-(4-methyl-1 -piperidinyl )-6-[4- (trifluoromethoxy)phenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-7-(4-methyl-1-piperidinyl)-6-(4-phenoxyphenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(cyclopropylmethyl)-N- propyl[1 ,2,4]triazoIo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-7-(2-methyl-1 -piperidinyl)-6-(4-phenoxyphenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-{2-chloro-4-nitrophenyl}-7-(4-methyl-1 - piperidiny!)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(4-chloro-2,3,δ,6-tetrafiuorophenyl)-N- cyclopentyl[1 ,2,4]triazolo 1 ,δ-a]pyrimidin-7-amine; 4-[δ-chloro-2-methyl-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin- 6-yl]-N,N-dimethylaniline; 6-(2-chloro-6-fluorophenyl)-δ-methyl-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1 -pyrrolidinyl)-1 -cyciohexen-1 - yl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(methoxymethyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-{2-chloro-4-nitrophenyl}-7-[ethyl(2-methy!-2- propenyl)amino][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-bromo-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-N-cyclopentyl-6-(4-ethoxy-2,3,δ,6- tetrafluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-methyl-N-(2-methyl-2-propenyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 4-bromo-1 -[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin- 7-yl]butyl acetate; diethyl 2-allyl-2-{[δ-chioro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-yl]oxy}maionate; 6-(2-chloro-6-fluorophenyl)-N-ethyl-δ-methyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin- 7- amine; N-butyl-δ-chloro-N-ethyl-6-(2,3,4 J δ,6-pentafluorophenyI)[1 ,2,4]triazolo[1,δ- a]pyrimidin-7-amine; 6-(2-chloro-6-fluorophenyl)-δ-(difluoromethoxy)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[(4- chlorophenyl)sulfanylJ[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2- methoxyphenyl)sulfanyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,3,4,δ,6-pentafluorophenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; δ-chloro-6-(2,4,6-trifluorophenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(4-fluorophenyi)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ,7-bis(4-methyl-1 -piperidinyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; δ-chloro-6-(2-methylphenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2,4,δ-trifluorophenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 6-(2-bromophenyl)-δ-chloro-N-(1 ,2,2-trimethylpropyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-isobutyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-isobutyl-6-(2-methylphenyl)-N-(2,2,2- trifluoroethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-(2,2,2-trifluoro-1-methylethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; N-allyl-δ-chloro-N-isobutyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; δ-chloro-N-(1 ,2-dimethyipropyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-isopropyl-N-methyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; δ-chloro-N-isopropyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6- trifluorophenyi)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 7-butyl-δ-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; δ-chloro-N-(1 -phenylethyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoro-1 -methylethyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; 5-chloro-N-ethyl-N-isobutyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-hexyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-methylphenyl)-N,N-bis(2,2,2-trifluoroethyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-cyclopentyl-N-methyl-6-(2,3,4,δ,6- pentafluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 7-butyl-δ-chloro-6-(2,6-difluorophenyl)[1,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chioro-N-(1 ,2-dimethylpropyl)-N-methyl-6-(2,3,4,δ,6- pentafluorophenyI)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-phenyl[1 ,2,4]triazoIo[1 ,5-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methylpropanyl)[1 ,2,4]triazoio[1 ,δ- a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-pentyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-(1 ,2-dimethylpropyl)-N-methy!-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-bromo-δ-chlorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(3,3,3-trifluoropropyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(3-methylphenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; [δ-chloro-6-(2,4,6-trifluorophenyl)-[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-ylj-(1 -p-tolyl- ethyl)-amine; δ-chloro-6-(2,4,6-trifluoro-phenyl)-7-cyclohexyi[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; δ-chloro-7-cyciohexyl-6-(2,3,4,δ,6-pentafluorophenyl)[1 ,2,4jtriazolo[1 s δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-f!uorophenyl)-7-(4,4-difluoro-1- piperidinyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; 7-(bicyclo[2.2.1jhept-2-ylamino)-δ-chloro-6-{2-fluoro-4- nitrophenyl}[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-{2-fluoro-4-nitrophenyl}-7-(4-methyi-1-piperidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-(methylsulfanyl)-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; [δ-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-ylj (2,2,2- trifluoro-1 -phenylethyl)-amine; δ-chloro-N-[1-(trifluoromethyl)propylj-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-bromo-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; 6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-δ- amine; [δ-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1,δ-a]pyrimidin-7-yl]-(2- methyl-1-trifluoromethyl-propyl)amine; δ-chloro-7-(3-cyciohexen-1 -yl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazoio[1 ,δ- ajpyrimidine; δ-chioro-7-(1 -cyclohexen-1 -yl)-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-N-[(1 R)-2,2,2-trifluoro-1 -methylethyl]-6-(2,4,6- trifiuorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 5-chioro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 6-(2,4-difluorophenyi)-δ-chloro-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyi)-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; δ-chloro-7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-[(1S)-2,2,2-trifluoro-1- methylethylj[1 ,2,4jtriazolo[1 ,5-a]pyrimidin-7-amine; 7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)-δ-methoxy[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-7-(4-fluorocyclohexyi)-6-(2,4,6-trifluorophenyi)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2,6-dichloro-4-fluorophenyl)-7-(3,3,3- trifiuoropropyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; N-(sec-butyl)-δ-chloro-6-(2,6-dichloro-4-fluorophenyl)[1,2,4jtriazolo[1 ,δ- ajpyrimidin-7-amine; 4-{δ-chloro-7-[(2,2,2-trifluoro-1 -methylethyl)amino][1 ,2,4]triazolo[1 ,δ- a]pyrimidin-6-yl}-3,6-difluorophenol; δ-chloro-7-(3-cyclohexen-1-yl)-6-(2,6-difluoro-4- methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7- amine; δ-chloro-N-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3,6-dihydro-1(2H)- pyridinyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4- thiomorpholinyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; 7-(1 -azepanyl)-δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4- fluorocy ohexyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; 6-(4-{δ-chloro-7-[(2,2,2-trifluoro-1 -methylethyl)aminoj[1 ,2,4]triazolo[1 ,δ- ajpyrimidin-6-yl}-3,δ-difluorophenoxy)hexanoic acid; 2,6-difluoro-4-(2-fluoroethoxy)phenylj-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-N-isopropyl-6-{2-[(trifluoromethyl)sulfanyl]phenyl}[1 ,2,4]triazolo[1 ,δ- ajpyrimidin-7-amine; δ-chloro-N-[4-(trifluoromethyl)phenylj-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-(4,4,4-trifluoro-2-methylbutyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3-methyl-3- butenyl)[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-isobutyl[1 ,2,4jtriazoio[1 ,5- ajpyrimidine; 7-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)-5-methoxy[1 ,2,4]triazoIo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-thienyl)-N-[(1 R)-2,2,2-trifluoro-1-methylethyl[1 ,2,4jtriazolo[1 ,δ- ajpyrimidin-7-amine; 4-(5-chloro-7-(2,2,2-trifluoro-1 -methyl-ethylamino)[1 ,2,4]triazolo[1 ,δ- ajpyrimidin-6-ylj-3,5-difluoro-phenol; {δ-chloro-6-[2,6-difluoro-4-(2,2 ) 2-trifluoro-ethoxy)-phenylj-[1 ,2,4]triazoio[1 ,δ- a]pyrimidin-7-yl}-(2,2,2-trifluoro-1 -methyl-ethyl)amine; δ-chloro-6-{2,6-difluoro-4-(methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidin-7-amine; (δ-chloro-6-{4-[2-(2-ethoxyethoxyj-ethoxyj-2,6-difluoro- phenyl}[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7-yl-)-(2,2,2-trifluoro-1 - methylethyl)amine; (δ-chloro-6-{2,6-difluoro-4-[2-(2-methoxy-ethoxy)ethoxyj-phenyl}- [1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1-methylethyl)amine; δ-chloro-6-[2,6-difluoro-4-(3-furan-3-ylmethoxy)phenyl[1 ,2,4jtriazolo[1 ,δ- ajpyrimidin-7-yl}-N-(2,2,2-trifluoro-1-methylethyl)amine; 5-chloro-6-(2,δ-difluoro-4-methoxyphenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; , 7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenyl]-δ- methoxy[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; 5-chloro-6-(2-fluoro-4-methoxy-6-chlorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; 5-chloro-6-[2,6-difiuoro-4-(2-fiuoroethoxy)phenylj-N-ethyl-N-(2-methy!-2- propenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidin-7-amine; 2-[2-(4-{δ-chloro-7-[(2,2,2-trifluoro-1 -methylethyl)amino][1 ,2,4jtriazolo[1 ,5- ajpyrimidin-6-yl}-3,δ-difluorophenoxy)ethoxyjethanol; δ-chloro-6-(2,3-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-6-{4-(2-fluoroethoxy)-2,6-difluorphenyl}-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-N-(4-chlorobenzyl)-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-pyridinyl)-1- piperazinyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(1-ethylpentyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-chlorophenyl)-1- piperazinyl][1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(4-methoxyphenyl)-3-methyl-1- piperazinylj[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; δ-chloro-N-cyclopentyl-6-(2-chloro-6-fluorophenyl)[1 ,2,4jtriazo!o[1 ,δ- a]pyrimidin-7-amine; δ-chloro-7-phenoxy-6-(4-methoxy-phenyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; δ-chloro-N-cyciopentyl-6-(4-methylphenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7- amine; δ,7-diphenoxy-6-(4-methoxyphenyl)[1,2,4jtriazolo[1 ,δ-ajpyrimidine; 5-chloro-N-cyclopentyl-6-(2-chlorophenyl)[1 ,2,4jtriazolo[1 ,5-ajpyrimidin-7- amine; δ-chloro-N,N-diethyl-6-[4-methoxyphenylj[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N,N-diethyl-6-[2,4-dichlorophenyl][1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7- arriine; N-bicyclo[2.2.1 ]hept-2-yl-δ-chloro-6-(2,4-dichlorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(1 ,4-dioxa-8-azaspiro[4.δjdec-8- yl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; δ-cyano-7-(4-methyl-1-piperidinyl)-6-(2-chloro-δ- fluorophenyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-(methylsulfanyl)-7-(4-methyl-1 -piperidinyl )-6-(2-chloro-6- fluorophenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; 5-(methylsulfany!)-7-(4-methyl-1-piperidinyl)-6-(2-chloro-5- (methylsuifanyl)phenyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chioro-7-(1 ,4-dioxa-8-azaspiro[4,δjdec-8-yl)-6-(4- methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; δ-chloro-N-ethyl-N-(2-methyl-2-propenyi)-6-(4- (methylsulfanyl)phenyi)[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7-amine; 2-methyl-6,7-di-(4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; 2-methyl-6-phenyl-7-(4-chlorophenyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; 2-trifluoromethyl-6-phenyl-7-(4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ,7-diphenoxy-6-(2-methy!propyl)[1,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(3,4-difluorophenyl)-N-(isopropyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidin-7- amine; δ-bromo-6-(4-bromophenyl)-7-dimethylamino[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-bromo-6-(4-trifluoromethylphenyl)-7-dimethylamino[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(3,4-difluorophenyl)-7-dimethylamino[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(4-trifluoromethylphenyl)-N-(ethyl)[1,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; 7-(1 -azepanyl)-δ-chloro-6-(4-tert-butylphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; ethyl {[δ-chloro-6-(2-chloro-6-fluoropheny!)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yl]amino}acetate; diethyl δ-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- malonate; δ-chloro-6-(2,δ-difluorophenyl)-N-(3-methyl-2-butenyl)[1 ,2,4]triazoio[1 ,5- a]pyrimidin-7-amine; [δ-chloro-6-(2-chloro-6-fluorophenyl)-[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]acetic acid methyl ester; δ-chloro-6-(2,6-difluorophenyl)-7-(2-ethyl-1 H-imidazol-1-yl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-N,N-diethyl-6-[4-(methylsulfanyl)phenyl][1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; ethyl [6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1 -piperidinyl)- [1 ,2,4]triazolo[1 ,δ- a]pyrimidin-δ-yl]acetate; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4- phenoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; dimethyl 2-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin- 7-yl]malonate; diethyl 2-{[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yl]oxy}-2-isobutylmalonate; 2-[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-a3pyrimidin-7-yl]-1 ,3- cyclohexanedione; 2-[δ-chloro-6-(2-chloro-6-fiuorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- y!]cyclohexanone; δ-chloro-7-(3-nitro-4-methylaniiino)-6-(2, 4, 6-trifluorophenyl) [1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenyl]δ-(2- methoxyethoxy)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; 7-(3-bromophenyl)-2-ethyl-6-(4-methoxyphenyl)[1,2,4]triazolo[1 ,δ- ajpyrimidine; 7-(3-bromophenyl)-6-(3-chlorophenyl)-2-ethyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(4-bromophenyl)-2-ethyl-6-[4-(trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(3,4,δ- trimethoxybenzyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 7-(2-benzyl-4,δ-dihydro-1 H-imidazol-1 -yl)-δ-chloro-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; N-4-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl- N,N-1 -diethyl-1 ,4-pentanediamine; δ-chloro-N-(3-methyl-2-butenyl)-6-phenyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-dimethylamino-6-phenyl-N-cyclopentyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-7-[(2-furylmethyi)su!fanyl]-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 6-[1 ,1 '-biphenyl]-4-yl-δ-chloro-N-cyclopentyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; 6-[4-(benzyloxy)phenyI]-δ-chloro-N-isopropyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N-[(2,2-dichlorocyclopropyl)methyl]-6-(3,4,δ- trimethoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; N-cyclopentyl-6-(2-fluorophenyl)-δ-hydrazino[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N-ethyl-6-(2-methylphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 6-(4-tert-butylphenyl)-δ-chloro-N-isopropyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-6-[2,6-difluoro-4-[(3-methyl-2-butenyi)oxy]phenyl]-N-(2,2,2-trifluoro-1 - methylethyl)-l[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-[2,6-difluoro-4-(1-propenyloxy)phenyl]-N-(2,2,2-trifluoro-1- methylethyl)-l[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-(3-tricyclo[2.2.1.0 2,6 ]hept-1-yl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-azido-7-cyclohexyl-6-(2-fluoro-6-chlorophenyl) [1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-azido-6-[2-chloro-6-fluorophenyl]-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 2,5-dichloro-7-(4-methyl-1-piperidinyl)-6-[2-chloro-6- fluorophenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine or a pharmaceutically acceptable salt thereof is administered. 4δ. A method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof by administering to said mammal an effective amount of a substituted triazolopyrimidine derivative having a paclitaxel like mechanism of action on tubulin polymerization or a pharmaceutically acceptable salt thereof . 46. The method according to Claim 4δ wherein the substituted triazolopyrimidine derivative is a compound selected from those of the formula: 0) wherein: R 1 is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or - NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b ; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms.optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl, -S-alkenyl, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl, -SO alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may optionally be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R 2 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen; R 3 is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or ~N 3 ; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or alkyl of 1 to 12 carbon atoms; R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF 3 ; provided that when: a) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4- methoxyphenyl; b) R 1 is diethylamino, R 3 is bromo, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl; c) R 1 is isopropylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-benzyloxyphenyl or 3,4,δ-trimethoxyphenyl; d) R 1 is cyclopentylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4, δ- trimethoxyphenyl, 2-napthyl or 2-stilbene; e) R 1 is 2-amino- bicyclo(2.2.1.)heptyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,δ- trimethoxyphenyl and f) R is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl and g) R 1 is 1 ,1 ,1 -trifluoroethoxy, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6-fluorophenyl h) R is -S0 2 ethyl or -SO 2 cyclopentyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6- fluorophenyl; i) R 4 is hydrogen, R 2 is 2-chloro-6-fluorophenyl, R 1 and R 3 are not 1 ,2,4-triazole; j) R 1 is cyclohexyl, R 4 is hydrogen, R 2 is 2,4,6- trifluorophenyl, and R 3 is not -OCH 2 O 2 C(CH 3 ) 3 ; k) R 1 is 2-thienyl, R 4 is ethyl, R 3 is hydrogen and R 2 is not 2-methoxyphenyl, 4-methoxyphenyl, and 4-trifluorophenyl; I) R 2 is phenyl, R 3 is chloro, R 4 is hydrogen R 1 is not (2E)-3,7-dimethyl-2,6-octadienyl - or a pharmaceutically acceptable salt thereof. 47. The method according to claim 46 wherein R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b or a pharmaceutically acceptable salt thereof is administered. 48. The method according to claim 46 wherein R a and R b each independently represent the moiety -C * H(R e )(R f ) where R e and R f independently represent an optionally halo-substituted alkyl group of 1 to 12 carbon atoms where C* represents the (R) or (S) isomer or a pharmaceutically acceptable salt thereof is administered. 49. The method according to claim 46 wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms, aryloxy, thienyl, benzyloxy, heterocyclyl or halogen or a pharmaceutically acceptable salt thereof is administered. δO. The method according to claim 46 wherein R 3 is halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, hydroxy, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 51. The method according to claim 46 wherein R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF3 or a pharmaceutically acceptable salt thereof is administered. δ2. The method according to claim 46 wherein R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -S0 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached or a pharmaceutically acceptable salt thereof is administered. δ3. The method according to claim 46 wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms or heterocyclyl or a pharmaceutically acceptable salt thereof is administered. 64. The method according to claim 46 wherein R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 5δ. The method according to claim 46 wherein R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF 3 or a pharmaceutically acceptable salt thereof is administered. δ6. The method according to claim 46 wherein R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -S0 2 cycloalkyl of δ to 10 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached or a pharmaceutically acceptable salt thereof is administered. 57. The method according to claim 46 wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms or a pharmaceutically acceptable salt thereof is administered. 58. The method according to claim 46 wherein R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 59. The method according to claim 46 wherein R 4 is H or a pharmaceutically acceptable salt thereof is administered. 60. The method according to claim 46 wherein R is selected from the group consisting of an optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 61. The method according to claim 46 wherein R is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 62. The method according to claim 46 wherein R is the moiety -NR a R b wherein R R are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H: R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 -.may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -S0 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 toδ carbon atoms, -S0 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 2 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one ~CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or alkyl of 2 to 20 carbon atoms or a pharmaceutically acceptable salt thereof is administered. 63. The method according to claim 46 wherein R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is selected from R is halogen, alkoxy, -NR 5 Cr R-,d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to12 carbon atoms, cyano, or-N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 64. The method according to claim 46 wherein R 1 : i,s the moiety -NR ja R Q b wherein R ia 0 Rb are optionally taken together with the nitrogen to which each is attached and wherein R 1 is selected from »-N(C2H 5 ) 2 t 5-N(CH3) 2 <-NHC2H 5 R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 6δ. The method according to claim 46 wherein R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached and wherein R is selected from R is optionally substituted thienyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 66. The method according to claim 46 wherein said compound selected from: 7-(1 -azepanyl)-δ-chloro-6-phenyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluorophenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(4-methoxyphenyl)-7-(1-piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 7-(1 -azepanyl)-δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-thiomorpholinyl)[1 ,2,4]triazoio[1,5- ajpyrimidine; methyl [[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yl](methyl)amino]acetate; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 , 1 ,3,3- tetramethylbutyl)[1 ,2,4]triazolo 1 ,δ-a]pyrimidin-7-amine; 7-(1 -azepanyl)-5-chloro-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 7-(1 -azepanyi)-6-(4-bromophenyi)-5-chloro[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 5-chloro-7-(1 -piperidinyl)-6-[2-(trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 6-(4-tert-butylphenyl)-δ-chloro-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 5-chIoro-6-(4-methoxyphenyI)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 5-chloro-6-(4-methoxyphenyl)-7-(3-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 6-(4-bromophenyl)-δ-chloro-7-(3-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(3,4-difluorophenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2,6-dichlorophenyl)-7-(2-methyl-1 -pyrrolidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 5-chloro-6-(2-chlorophenyl)-7-(2-methyl-1 -pyrrolidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 7-(1 -azepanyl)-δ-chloro-6-(3-chloro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; 5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(3-chloro-4-methoxyphenyl)-7-(2-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 6-(4-tert-butylphenyl)-δ-chloro-7-(2-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; δ-chloro-7-(2-methyl-1-piperidinyl)-6-[3- (trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,δ-ajpyrimidine; Diethyl 2-[6-(2,6-difluorophenyl)-δ-ethoxy[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7- yljmalonate; 7-(azepanyl)-δ-chloro-6-{2-chloro-6-nitrophenyl}[1 ,2,4}triazolo[1 ,5- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4Jtriazolo[1 ,5-aJpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2- trifluoroethyl)[1 ,2,4]triazolo[1 ,5- aJpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-[(2,2-dichlorocyclopropyl)methylJ-N- methyl[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; 1 -[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4Jtriazolo[1 ,5-a]pyrimidin-7-yl]-3- piperidinol; N-bicyclo[2.2.1Jhept-2-yl-δ-chloro-6-(3-chioro-4- methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-aJpyrimidin-7-amine; δ-chloro-6-(2,δ-difluorophenyl)-N-dodecyl[1 ,2,4]triazolo[1 ,δ-aJpyrimidin-7- amine; δ-chloro-7-(4-methyl-1-piperidinyl)-6-(2,3,6- trifluorophenyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; N-[δ-chloro-6-(2,3,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-aJpyrimidin-7-ylJ-N- isopropylamine; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,3,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-aJpyrimidin-7-amine; N-allyl-δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-aJpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-aJpyrimidin-7-amine; δ-chloro-6-(3-chloro-4-methoxyphenyl)-N-cycloheptyl[1 ,2,4Jtriazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(3-chloro-4-methoxyphenyl)-7-(3,3-dimethyl-1- piperidinyl)[1 ,2,4Jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-N-(3-chloropropyi)-N-methyl-6-(2,3,6- trifluorophenyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; 7-(1 -azocanyl)-δ-chloro-6-(2,3,6-trifluorophenyi)[1 ,2,4Jtriazo!o[1 ,δ- ajpyrimidine; δ-chloro-6-(2,6-difluorophenyl)-7-(3,6-dihydro-1 (2H)- pyridinyl)[1 ,2,4Jtriazolo[1 ,δ-a]pyrimidine; 7-(1-azocanyl)-5-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 5-methoxy-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; [δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7- yljmethanol; 1 -[δ-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,δ-aJpyrimidin-7-ylJ-4- piperidinol; 5-chloro-7-(4-chloro-1 -piperidinyl)-6-(2,6-difluorophenyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; 5-chloro-7-(4-thiomorpholinyl)-6-(2,3,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-chlσro-6-(2,6-difluorophenyl)-7-(2,4-dimethyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 7-(4-methyl-1-piperidinyl)-5-amino-6-(2-chloro-6- fluorophenyl)[1 ,2,4Jtriazolo[1 ,5-ajpyrimidine; δ-chloro-6-(2,6-difluorophenyl)-7-(2,δ-dihydro-1 H-pyrrol-1 - yl)[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2,5-dimethyl-2,5-dihydro-1H-pyrrol-1- yl)[1 ,2,4Jtriazolo[1 ,5-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-ethyl-1 H-imidazol-1 - yl)[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; 7-(4-bromo-1-piperidinyl)-5-chloro-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-methylphenyl)-7-(4-thiomorpholinyl)[1,2,4Jtriazolo[1 ,δ- ajpyrimidine; 6-(2-bromophenyl)-N-(sec-butyl)-δ-chloro[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7- amine; δ-chloro-N-ethyl-6-(4-methoxyphenyl)-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ- aJpyrimidin-7-amine; δ-chloro-6-(4-methoxyphenyl)-7-(4-thiomorpholinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; δ-chloro-7-(4-chloro-1-piperidinyl)-6-[2- (trifluoromethyl)phenylJ[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(trifluoromethyl)-1- piperidinylj[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 7-(4-bromo-1 -piperidinyl)-5-chloro-6-(2,6-difluorophenyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; 7-(4-bromo-1 -piperidinyl)-δ-chloro-6-(2-chlorophenyl)[1 ,2,4Jtriazolo[1 ,6- ajpyrimidine; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,4,6- trifluorophenyi)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; δ-chloro-N-isopropyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- aJpyrimidin-7- amine; δ-chloro-7-(4-thiomorpholinyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 7-(1 -azepanyl)-δ-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyi)-7-[2-(1-pyrrolidinyl)-1-cyclopenten-1- ylj[1 ,2,4Jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-7-(4-isopropyl-1 -piperidinyl )-6-(4-methoxyphenyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; • δ-chloro-7-(2,4-dimethyl-1 -piperidinyl)-6-(4-methoxyphenyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; δ-chloro-7-[ethyl(2-methyl-2-propeny!)amino]-6-{4- nitrophenyl}[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; 7-(1 -azepanyl)-δ-chloro-6-{4-nitrophenyl}[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4Jtriazolo[1 ,5- aJpyrimidin-7-amine; δ-chloro-6-(2,6-difluoropheny!)-N-(2,2,2-trifluoroethyl)[1 ,2,4Jtriazolo[1 ,δ- aJpyrimidin-7-amine; δ-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoroethyl)[1 ,2,4Jtriazolo[1 ,δ- aJpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorobenzyl)-7-tetrahydro-2-furanyl[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; 7-(allylsulfanyl)-δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-N-ethyl-6-mesityl-N-(2-methyl-2-propenyl)[1 ,2,4Jtriazolo[1 ,5- aJpyrimidin-7-amine; δ-chloro-N-ethyl-6-(2-methoxyphenyl)-N-(2-methyl-2- propenyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1 ,2,4Jtriazolo[1 ,5-a]pyrimidin-7- amine; δ-chloro-7-(4-methyl-1-piperidinyl)-6-[4- (methylsulfanyl)phenylj[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-[4- (methylsulfanyl)phenylj[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; N-(sec-butyi)-δ-chioro-6-[4-(methylsuifanyl)phenylJ[1,2,4Jtriazolo[1,δ- aJpyrimidin-7-amine; δ-chloro-6-[4-(methylsulfanyl)phenyiJ-7-(4-thiomorpholinyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenylJ-7-(4-methyl-1- piperidinyl)[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; 7-(i-azepanyi)-5-chloro-6-[2,6-dichloro-4- (trifluoromethyl)phenylJ[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2,2,2- trifluoroethyl)sulfanyl][1 ,2,4]triazolo[1 ,δ-ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-dimethyl-1- piperidinyl)[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; δ-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenylJ-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4Jtriazolo[1 ,5-aJpyrimidin-7-amine; 5-chloro-6-[2 I 6-dichloro-4-(trifluoromethyl)phenyl]-7-(4- thiomorpholinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(3,δ-difluorophenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1,2,4Jtriazolo[1 ,δ- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-tetrahydro-2-furanyl[1,2,4Jtriazolo[1,5- ajpyrimidine; 4-[δ-chloro-7-(4-methyl-1 -piperidinyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-6-ylJaniline; N-{4-[δ-chloro-7-(4-methyl-1 -piperidinyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-6- yijphenyl}acetamide; [δ-chloro-6-(2-chioro-6-fluoropheny!)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-ylJmethyl acetate; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(chloromethyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; diethyl 2-[6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-δ-ylJmalonate; 7-(1 -azepanylmethyl)-δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; N-allyl-δ-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1 ,2,4Jtriazolo[1 ,δ- aJpyrimidin-7-amine; δ-chloro-7-(4-methyl-1 -piperidinyl )-6-[4- (trifluoromethoxy)phenyl][1 ,2,4Jtriazolo[1 ,δ-a]pyrimidine; δ-chloro-7-(4-methyl-1 -piperidinyl )-6-(4-phenoxyphenyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(cyclopropylmethyl)-N- propyl[1 ,2,4Jtriazolo[1 ,5-a]pyrimidin-7-amine; δ-chloro-7-(2-methyl-1 -piperidinyl)-6-(4-phenoxyphenyl)[1 ,2,4Jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-{2-chloro-4-nitrophenyl}-7-(4-methyl-1 - piperidinyi)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; δ-chloro-6-(4-chloro-2,3,δ,6-tetrafluorophenyl)-N- cyciopentyl[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; 4-[δ-chloro-2-methyl-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidin- 6-yl]-N,N-dimethylaniline; 6-(2-chloro-6-fluorophenyl)-δ-methyl-7-(4-methyl-1 - piperidinyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1-pyrrolidinyl)-1 -cyclohexen-1 - ylj[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(methoxymethyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-{2-chloro-4-nitrophenyl}-7-[ethyl(2-methyl-2- propenyl)aminoJ[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; δ-bromo-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-N-cyclopentyl-6-(4-ethoxy-2,3,5,6- tetrafluorophenyl)[1 ,2,4]triazolo[1 ,5-aJpyrimidin-7-amine; δ-chloro-N-methyl-N-(2-methyl-2-propenyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; 4-bromo-1 -[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4Jtriazolo[1 ,5-a]pyrimidin- 7-ylJbutyl acetate; diethyl 2-allyl-2-{[5-chloro-6-(2-chloro-6-fluorophenyi)[1 ,2,4]triazolo[1 ,5- aJpyrimidin-7-yl]oxy}maIonate; 6-(2-chloro-6-fluorophenyl)-N-ethyl-δ-methyl[1 ,2,4]triazolo[1 ,δ-ajpyrimidin- 7- amine; N-butyl-δ-chloro-N-ethyl-6-(2,3,4,δ l 6-pentafluorophenyl)[1 ,2,4Jtriazolo[1 ,δ- aJpyrimidin-7-amine; 6-(2-chloro-6-fluorophenyl)-δ-(difluoromethoxy)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-f luorophenyl)-7-[(4- chlorophenyl)sulfanyl][1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2- methoxyphenyl)sulfanylJ[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4Jtriazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,3,4,δ,6-pentafluorophenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; 5-chloro-6-(2,4,6-trifluorophenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4Jtriazolo[1 ,5- aJpyrimidin-7-amine; δ-ch!oro-6-(4-fluorophenyl)-N-(1 ,2,2- trimethyl propyl )[1 ,2,4Jtriazolo[1 ,6- aJpyrimidin-7-amine; δ,7-bis(4-methyl-1 -piperidinyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-methylphenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4Jtriazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2,4,δ-trifluorophenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4Jtriazolo[1 ,5- aJpyrimidin-7-amine; 6-(2-bromophenyl)-δ-chloro-N-(1 ,2,2-trimethylpropyl)[1 ,2,4Jtriazoio[1 ,δ- aJpyrimidin-7-amine; δ-chloro-N-isobutyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; δ-chloro-N-isobutyl-6-(2-methylphenyl)-N-(2,2,2- trifluoroethyl)[1 ,2,4]triazolo[1 ,5-aJpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; δ-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; δ-chloro-N-(2,2,2-trifluoro-1-methylethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; N-allyl-δ-chloro-N-isobutyl-6-(2,4,6-trifiuorophenyl)[1 ,2,4Jtriazolo[1 ,δ- aJpyrimidin-7-amine; δ-chloro-N-(1 ,2-dimethylpropyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- aJpyrimidin-7-amine; δ-chloro-N-isopropyl-N-methyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- aJpyrimidin-7-amine; 5-chloro-N-isoρropyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 7-butyl-δ-chloro-6-(2,4,6-trifiuorophenyl)[1 ,2,4]triazolo[1 ,δ-aJpyrimidine; δ-chloro-N-(1-phenylethyl)-6-(2,4,6-trifluorophenyl)[1,2,4Jtriazolo[1,δ- aJpyrimidin-7-amine; δ-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoro-1 -methylethyl)[1 ,2,4Jtriazolo[1 ,δ- aJpyrimidin-7-amine; δ-chloro-N-ethyl-N-isobutyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- aJpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-hexyl[1 ,2,4]triazolo[1 ,δ-aJpyrimidine; δ-chloro-6-(2-methylphenyl)-N,N-bis(2,2,2-trifluoroethyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-cyclopentyl-N-methyl-6-(2,3,4,δ,6- pentafluorophenyl)[1 ,2,4]triazolo[1 ,δ-aJpyrimidin-7-amine; 7-butyl-δ-chloro-6-(2,6-difluorophenyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidine; δ-chloro-N-(1 ,2-dimethylpropyl)-N-methyl-6-(2,3,4,δ,6- pentafluorophenyl)[1 ,2,4]triazolo[1 ,δ-aJpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-phenyl[1,2,4Jtriazolo[1 ,δ-aJpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methylpropanyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-pentyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-(1 ,2-dimethylpropyl)-N-methyl-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin~7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1,2,4Jtriazolo[1 ,5- ajpyrimidine; 5-chloro-6-(2-bromo-δ-chlorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(3,3,3-trifluoropropyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(3-methylphenyl)[1 ,2,4Jtriazolo[1,δ- ajpyrimidine; [6-chloro-6-(2,4,6-trifluorophenyl)-[1 ,2,4Jtriazolo[1 , 5-a] pyri mid i n-7-yl]-( 1 -p- tolyl-ethy!)-amine; 5-chloro-6-(2,4,6-trifluoro-phenyl)-7-cyclohexyl[1 ,2,4Jtriazolo[1 ,5-a]pyrimidine; δ-chloro-7-cyclohexyl-6-(2,3,4,δ,6-pentafluorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-difluoro-1- piperidinyl)[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; 7-(bicyclo[2.2.1Jhept-2-ylamino)-δ-chloro-6-{2-fluoro-4- nitrophenyl}[1 ,2,4Jtriazolo[1 ,δ-ajpyrimidine; δ-chloro-6-{2-fluoro-4-nitrophenyi}-7-(4-methyl-1 -piperidinyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; δ-(methylsulfanyl)-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; [δ-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,6-a]pyrimidin-7-ylJ (2,2,2- trifluoro-1 -phenylethyl)-amine; 5-chloro-N-[1-(trifluoromethyl)propylJ-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-aJpyrimidin-7-amine; δ-bromo-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; 6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-5- amine; [5-chloro-6-(2,4,6-trifluorophenyi)[1 ,2,4]triazolo[1 ,δ-aJpyrimidin-7-ylJ-(2- methyl-1-trifiuoromethyl-propyl)amine; δ-chloro-7-(3-cyclohexen-1 -yl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazoio[1 ,δ- ajpyrimidine; δ-chloro-7-(1 -cyclohexen-1 -yl)-6-(2,4,6-trifiuorophenyl)[1 ,2,4Jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-N-[(1 R)-2,2,2-trifluoro-1 -methylethylJ-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-aJpyrimidin-7-amine; δ-chloro-N-[(1 R)-2,2,2-trifluoro-1 -methylethylJ-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazoio[1 ,δ-a]pyrimidin-7-amine; 6-(2,4-difluorophenyl)-δ-chloro-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4Jtriazolo[1 ,δ-aJpyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4-methyl-1 - piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-[(1S)-2,2,2-trifluoro-1- methylethyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)-δ-methoxy[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-7-(4-fluorocyclohexyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2,6-dichloro-4-fluorophenyl)-7-(3,3,3- trifluoropropyi)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; N-(sec-butyl)-5-chloro-6-(2,6-dichIoro-4-fluorophenyl)[1,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 4-{5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)amino][1 ,2,4]triazolo[1 ,5- a]pyrimidin-6-yl}-3,6-difluorophenol; δ-chIoro-7-(3-cyclohexen-1-yl)-6-(2,6-difluoro-4- methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3,6-dihydro-1(2H)- pyridinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4- thiomorpholinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 7-(1 -azepanyl)-δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4]triazo!o[1 ,δ- ajpyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4]triazoio[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4- fluorocyclohexyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 6-(4-{δ-chloro-7-[(2,2,2-trifluoro-1 -methylethyl)amino][1 ,2,4]triazolo[1 ,δ- a]pyrimidin-6-yl}-3,δ-difluorophenoxy)hexanoic acid; 2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-isopropyl-6-{2-[(trifluoromethyl)sulfanyl]phenyl}[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-[4-(trifluoromethyl)phenyl]-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-(4,4,4-trifluoro-2-methylbutyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3-methyl-3- butenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-isobutyl[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 7-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)-δ-methoxy[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-thienyl)-N-[(1 R)-2,2,2-trifluoro-1 -methylethyl[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 4-(δ-chloro-7-(2,2,2-trifluoro-1 -methyl-ethylamino)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-6-yl]-3,δ-difluoro-phenol; {δ-chloro-6-[2,6-difluoro-4-(2,2,2-trifluoro-ethoxy)-phenyl]-[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-yl}-(2,2,2-trifluoro-1-methyl-ethyl)amine; δ-chioro-6-{2,6-difluoro-4-(methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; (δ-chloro-6-{4-[2-(2-ethoxyethoxy]-ethoxy]-2,6-difluoro- phenyl}[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1 - methylethyl)amine; (δ-chloro-6-{2,6-difluoro-4-[2-(2-methoxy-ethoxy)ethoxy]-phenyl}~ [1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1-methylethyl)amine; 5-chloro-6-[2,6-difluoro-4-(3-furan-3-ylmethoxy)phenyl[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-yI}-N-(2,2,2-trifluoro-1-methylethyl)amine; δ-chloro-6-(2,5-difluoro-4-methoxyphenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenyl]-δ- methoxy[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-fluoro-4-methoxy-6-chiorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-ch!oro-6-[2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-ethyl-N-(2-methyi-2- propenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 2-[2-(4-{δ-chloro-7-[(2,2,2-trifluoro-1 -methylethyl)amino][1 ,2,4]triazolo[1 ,δ- a]pyrimidin-6-yl}-3,δ-difluorophenoxy)ethoxy]ethanol; δ-chloro-6-(2,3-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-{4-(2-fluoroethoxy)-2,6-difluorphenyl}-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-(4-chlorobenzyl)-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-pyridinyl)-1- piperazinyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 -ethylpentyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-chlorophenyl)-1- piperazinyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(4-methoxyphenyl)-3-methyl-1- piperazinyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-cyclopentyl-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chioro-7-phenoxy-6-(4-methoxy-phenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chioro-N-cyclopentyl-6-(4-methylphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; 5,7-diphenoxy-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 6-chloro-N-cycIopentyl-6-(2-chlorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7- amine; 5-chloro-N,N-diethyl-6-[4-methoxyphenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N.N-diethyl-e-p^-dichlorophenylJtl ^^triazolotl .δ-alpyrimidin^- amine; N-bicyclo[2.2.1]hept-2-yl-δ-chloro-6-(2,4-dichlorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(1 ,4-dioxa-8-azaspiro[4.δ]dec-8- yl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; δ-cyano-7-(4-methyl~1-piperidinyl)-6-(2-chloro-δ- fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-(methylsulfanyl)-7-(4-methyl-1-piperidinyl)-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-(methylsulfanyl)-7-(4-methyl-1 -piperidinyl )-6-(2-chloro-δ- (methylsulfanyl)phenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-7-(1 ,4-dioxa-8-azaspiro[4,δ]dec-8-yl)-6-(4- methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-ethyl-N-(2-methyi-2-propenyl)-6-(4- (methylsulfanyi)phenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 2-methyl-6,7-di-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 2-methyl-6-phenyl-7-(4-chlorophenyl)[1,2,4]triazolo[1 ,δ-a]pyrimidine; 2-trifluoromethyl-6-phenyl-7-(4-methoxyphenyl)[1 ,2,4]triazoio[1 ,δ-a]pyrimidine; δ,7-diphenoxy-6-(2-methylpropyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(3,4-difluorophenyl)-N-(isopropyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-bromo-6-(4-bromophenyl)-7-dimethylamino[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-bromo-6-(4-trifluoromethylphenyl)-7-dimethylamino[1 ,2,4]triazolo[1 ,5- ajpyrimidine; δ-chloro-6-(3,4-difluorophenyl)-7-dimethylamino[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(4-trifluoromethylphenyl)-N-(ethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; 7-(1-azepanyl)-δ-chloro-6-(4-tert-butylphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; ethyl {[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- y!]amino}acetate; diethyl δ-chloro-6-(2,6-difluorophenyi)[1 ,2,4]triazoio[1 ,δ-a]pyrimidin-7- malonate; δ-chloro-6-(2,δ-difluorophenyl)-N-(3-methyl-2-butenyl)[1 ,2,4]triazoio[1 ,5- a]pyrimidin-7-amine; [δ-chloro-6-(2-chloro-6-fluorophenyl)-[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]acetic acid methyl ester; δ-chloro-6-(2,6-difluorophenyl)-7-(2-ethyl-1 H-imidazol-1-yl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chioro-N,N-diethyl-6-[4-(methylsulfanyl)phenyl][1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; ethyl [6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1 -piperidinyl)- [1 ,2,4]triazolo[1 ,δ- a] pyri m id in-δ-yl]acetate ; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4- phenoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; dimethyl 2-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidin- 7-yl]malonate; diethyl 2-{[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yl]oxy}-2-isobutylmalonate; 2-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]-1 ,3- cyclohexanedione; 2-[δ-chloro-6-(2-chioro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yi]cyclohexanone; δ-chloro-7-(3-nitro-4-methylanilino)-6-(2, 4, 6-trifluorophenyl) [1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenyl]δ-(2- methoxyethoxy)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(3-bromophenyl)-2-ethyl-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 7-(3-bromophenyl)-6-(3-chlorophenyl)-2-ethyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(4-bromophenyl)-2-ethyl-6-[4-(trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,5- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(3,4,δ- trimethoxybenzy!)[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; 7-(2-benzyl-4,δ-dihydro-1 H-imidazol-1 -yl)-δ-chloro-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; N-4-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl- N,N-1-diethyl-1 ,4-pentanediamine; δ-chloro-N-(3-methyl-2-butenyI)-6-phenyl[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7- amine; δ-dimethyiamino-6-phenyl-N-cyclopentyl[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7- amine; δ-chloro-7-[(2-furylmethyl)sulfanylj-6-(4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; 6-[1 , 1 '-biphenyl]-4-yi-δ-chloro-N-cyclopentyl[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7- amine; 6-[4-(benzyloxy)phenyl]-δ-chloro-N-isopropyl[1 ,2,4jtriazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N-[(2,2-dichlorocyciopropyl)methyl]-6-(3,4,δ- trimethoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; N-cyclopentyl-6-(2-fluorophenyl)-δ-hydrazino[1 ,2,4jtriazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N-ethyl-6-(2-methylphenyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7-amine; 6-(4-tert-butylphenyl)-δ-chloro-N-isopropyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-6-[2,6-difluoro-4-[(3-methyl-2-butenyl)oxy]phenyl]-N-(2,2,2-trifluoro-1- methylethyl)-l[1 ,2,4jtriazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-6-[2,6-difluoro-4-(1-propenyloxy)phenylj-N-(2,2,2-trifluoro-1- methylethyl)-l[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-(3-tricyclo[2.2.1.0 2,6 jhept-1 -yl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-azido-7-cyclohexyl-6-(2-fluoro-6-chlorophenyl) [1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-azido-6-[2-chloro-6-fiuorophenylj-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 2,5-dichloro-7-(4-methyl-1-piperidinyl)-6-[2-chloro-6- fluorophenylj[1 ,2,4jtriazolo[1 ,5-ajpyrimidine or a pharmaceutically acceptable salt thereof is administered. 67. The method according to claim 1 wherein the cancerous tumor cells are selected from the group consisting of breast, colon, lung, prostate, melanoma, epidermal, leukemia, kidney, bladder, mouth, larynx, esophagus, stomach, ovary, pancreas, liver, skin and brain. 68. The method according to claim 23 wherein the cancerous tumor cells are selected from the group consisting of breast, colon, lung, prostate, melanoma, epidermal, leukemia, kidney, bladder, mouth, larynx, esophagus, stomach, ovary, pancreas, liver, skin and brain. 69. The method according to claim 45 wherein the cancerous tumor cells are selected from the group consisting of breast, colon, lung, prostate, melanoma, epidermal, leukemia, kidney, bladder, mouth, larynx, esophagus, stomach, ovary, pancreas, liver, skin and brain. 70. A pharmaceutical composition comprising an effective amount of a compound of Formula (I): 0) wherein: R 1 is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or - NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -S0 2 cycloalkyl of 3 to 8 carbon atoms, -S0 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b ; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms.optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-aikyl, -S-alkenyl, -SO 2 aryl of 6, 10 or 14 carbon atoms, -S0 2 cycloalkyl, -SO 2 alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may optionally be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R 2 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen; R 3 is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 ; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or alkyl of 1 to 12 carbon atoms; R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF 3 ; provided that when: a) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifiuoromethylpheny!, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4- methoxyphenyl; b) R is diethylamino, R 3 is bromo, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl; c) R 1 is isopropylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-benzyloxyphenyl or 3,4,δ-trimethoxyphenyI; d) R 1 is cyclopentylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,5- trimethoxyphenyl, 2-napthyl or 2-stilbene; e) R 1 is 2-amino- bicyclo(2.2.1.)heptyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,5- trimethoxyphenyl and f) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl and g) R 1 is 1 ,1 ,1 -trifluoroethoxy, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6-fluorophenyl h) R 1 is -SO 2 ethyl or - SO 2 cyclopentyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6-fluorophenyl; i) R 4 is hydrogen, R 2 is 2-chloro-6-fluorophenyl, R 1 and R 3 are not 1 ,2,4- triazole; j) R 1 is cyclohexyl, R 4 is hydrogen, R 2 is 2,4,6-trifluorophenyl, and R 3 is not -OCH 2 O 2 C(CH 3 ) 3 ; k) R 1 is 2-thienyl, R 4 is ethyl, R 3 is hydrogen and R 2 is not 2-methoxyphenyl, 4-methoxyphenyl, and 4- trifluorophenyl; I) R 2 is phenyl, R 3 is chloro, R 4 is hydrogen R 1 is not (2E)-3,7- dimethyl-2,6-octadienyl or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier. 71. A pharmaceutical composition for treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of a compound of Formula (I): (I) wherein: R 1 is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b ; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms.optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted tricycioalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl, -S-alkenyl, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl, -SO 2 alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may optionally be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R 2 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen; R 3 is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 ; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or alkyl of 1 to 12 carbon atoms; R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF 3 ; provided that when: a) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4- methoxyphenyl; b) R 1 is diethylamino, R 3 is bromo, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl; c) R 1 is isopropylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-benzyloxyphenyl or 3,4,δ-trimethoxyphenyl; d) R 1 is cyclopentylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,δ- trimethoxyphenyl, 2-napthyl or 2-stilbene; e) R 1 is 2-amino- bicyclo(2.2.1.)heptyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,δ- trimethoxyphenyl and f) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl and g) R is 1,1,1 -trifluoroethoxy, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6-fluorophenyl h) R 1 is -SO 2 ethyl or -SO 2 cyclopentyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro- 6-fluorophenyl; i) R 4 is hydrogen, R 2 is 2-chloro-6-fluorophenyI, R 1 and R 3 are not 1 ,2,4-triazole; j) R 1 is cyclohexyl, R 4 is hydrogen, R 2 is 2,4,6- trifluorophenyl, and R 3 is not -OCH 2 O 2 C(CH 3 ) 3 ; k) R 1 is 2-thienyl, R 4 is ethyl, R 3 is hydrogen and R 2 is not 2-methoxyphenyl, 4-methoxyphenyl, and 4- trifluorophenyl; I) R 2 is phenyl, R 3 is chloro, R 4 is hydrogen R 1 is not (2E)-3,7- dimethyl-2,6-octadienyl or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier. ' 72. A pharmaceutical composition comprising a compound of Formula (I): (I) wherein: R 1 is selected from the group consisting of halogen, an optionally substituted alky! of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-aikyl of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyi of 2 to 12 carbon atoms, -S0 2 aryl of 6, 10 or 14 carbon atoms, -S0 2 cycioalkyl of 3 to 8 carbon atoms, -S0 2 a!kyi of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b ; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms,optional!y substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycioalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 ' carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be repiaced by -0-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl, -S-alkenyl, -S0 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycioalkyl, -S0 2 alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may optionally be replaced by -0-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R 2 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of δ, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen; R 3 is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 ; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be repiaced by -0-, -S-, or -NR where R * is H or an alky! group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -0-, -S-, or -NR where R is H or an alky! group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R d is H, amino, optionally substituted alky! of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or alky! of 1 to 12 carbon atoms; R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF 3 ; provided that when: a) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifiuoromethyiphenyi, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4- methoxyphenyl; b) R 1 is diethylamino, R 3 is bromo, R 4 is hydrogen, R 2 is not 4-trifiuoromethyiphenyl; c) R 1 is isopropylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-benzyloxyρπenyl or 3,4,5-trimethoxyphenyl; d) R 1 is cyclopentylamino, R 3 is chloro, R 4 is hydrogen, R is not 3,4,5- trimethoxyphenyl, 2-napthyi or 2-sfilbene; e) R 1 is 2-amino- bicyclo(2.2.1.)heptyl, R 3 is chloro, R 4 is hydrogen, R 2 ls not 3,4,5- trimethoxyphenyl and f) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifiuoromethylphenyl and g) R 1 is 1 ,1 ,1 -trifluoroethoxy, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6-fluoropheny! h) R 1 is -SO 2 ethyi or -SO 2 cyclopentyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro- 6-fluorophenyl; i) R 4 is hydrogen, R 2 is 2-chloiO-6-fluorophenyi, R 1 and R 3 are not 1 ,2,4-triazoie; j) R 1 is cyclohexyl, R 4 is hydrogen, R 2 is 2,4,6- trifluorophenyl, and R 3 is not -OCH 2 O 2 C(CH 3 ) 3 ; k) R 1 is 2-thienyl, R 4 is ethyl, R 3 is hydrogen and R 2 is not 2-methoxyphenyl, 4-methoxyphenyl, and 4- trifluorophenyi; I) R 2 is phenyl, R 3 is chloro, R 4 is hydrogen R 1 is not (2E)-3,7- dimethyl-2,6-octadieny! or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier. 73. A method for the treatment or prevention of multiple drug resistance (MDR) in a mammal in need thereof which method comprises administering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof. 74. The method of claim 73 wherein the multiple drug resistance (MDR) is mediated by p-glycoprotein or MXR. 7δ. The method according to Claim 73 wherein the substituted triazolopyrimidine derivative is a compound selected from those of the formula: (I) wherein: R 1 is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cyc!oalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b ; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms,optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl, -S-alkenyl, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl, -S0 2 alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring ; R a R b together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may optionally be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R 2 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen; R 3 is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 ; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by-O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by-O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -0-, -S-, or -NR' where R' is H or alkyl of 1 to 12 carbon atoms; R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF 3 ; provided that when: a) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4- methoxyphenyl; b) R 1 is diethylamino, R 3 is bromo, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl; c) R 1 is isopropylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-benzyloxyphenyl' or 3,4,δ-trimethoxyphenyl; d) R is cyclopentylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,δ- trimethoxyphenyi, 2-napthyl or 2-stilbene; e) R 1 is 2-amino- bicyclo(2.2.1.)heptyi, R 3 is chloro, R 4 is hydrogen, R 2 is not 3,4,δ- trimethoxypheny! and f) R 1 is diethylamino, R 3 is chloro, R 4 is hydrogen, R 2 is not 4-trifluoromethylphenyl and g) R 1 is 1 ,1 ,1 -trifluoroethoxy, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6-fluorophenyl h) R 1 is -SO 2 ethyl or -S0 2 cyclopentyl, R 3 is chloro, R 4 is hydrogen, R 2 is not 2-chloro-6- fluorophenyl; i) R 4 is hydrogen, R 2 is 2-chloro-6-fluorophenyl, R 1 and R 3 are not 1 ,2,4-triazole; j) R 1 is cyclohexyl, R 4 is hydrogen, R 2 is 2,4,6- trifluorophenyl, and R 3 is not -OCH 2 O 2 C(CH 3 ) 3 ; k) R 1 is 2-thienyl, R 4 is ethyl, R 3 is hydrogen and R 2 is not 2-methoxyphenyl, 4-methoxyphenyl, and 4-trifluorophenyl; I) R 2 is phenyl, R 3 is chloro, R 4 is hydrogen R 1 is not (2E)-3,7-dimethyl-2,6-octadienyl or a pharmaceutically acceptable salt thereof. 76. The method according to claim 7δ wherein R is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of δ to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b or a pharmaceutically acceptable salt thereof is administered. 77. The method according to claim 7δ wherein R a and R each independently represent the moiety -C*H(R e )(R f ) where R e and R f independently represent an optionally halo-substituted alkyl group of 1 to 12 carbon atoms where C* represents the (R) or (S) isomer or a pharmaceutically acceptable salt thereof is administered. 78. The method according to claim 7δ wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms, aryloxy, thienyl, benzyloxy, heterocyclyl or halogen or a pharmaceutically acceptable salt thereof is administered. 79. The method according to claim 75 wherein R 3 is halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR c R d , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, hydroxy, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 80. The method according to claim 7δ wherein R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF 3 or a pharmaceutically acceptable salt thereof is administered. 81. The method according to claim 75 wherein R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO 2 aryl of 6, 10 or 14 carbon atoms, -S0 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached or a pharmaceutically acceptable salt thereof is administered. 82. The method according to claim 7δ wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms or heterocyclyl or a pharmaceutically acceptable salt thereof is administered. 83. The method according to claim 7δ wherein R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 84. The method according to claim 7δ wherein R 4 is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF 3 or a pharmaceutically acceptable salt thereof is administered. 86. The method according to claim 75 wherein R 1 is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -0-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms,-S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms,-SO 2 aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of δ to 10 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached or a pharmaceutically acceptable salt thereof is administered. 86. The method according to claim 7δ wherein R 2 is optionally substituted aryl of 6, 10 or 14 carbon atoms or a pharmaceutically acceptable salt thereof is administered. 87. The method according to claim 7δ wherein R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR G R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 or a pharmaceutically acceptable salt thereof is administered. 88. The method according to claim 75 wherein R 4 is H or a pharmaceutically acceptable salt thereof is administered. 89. The method according to claim 75 wherein R 1 is selected from the group consisting of an optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH 2 - may also be replaced by -0-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -Sθ2aryl of 6, 10 or 14 carbon atoms, -S0 2 cycloalkyl of 3 to 8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, and the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 90. The method according to claim 7δ wherein R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 91. The method according to claim 75 wherein R 1 is the moiety -NR a R b wherein R a R b are optionally taken together with the nitrogen to which each is attached; R 2 is optionally substituted phenyl; R 3 is halogen, alkoxy, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H; R a is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH2- may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl; R b is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH 2 - may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of δ to 10 carbon atoms in which one -CH 2 - may also be replaced by -0-, -S-, or-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO aryl of 6, 10 or 14 carbon atoms, -SO 2 cycloalkyl of 3 to8 carbon atoms, -SO 2 alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms; R a R together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 2 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused; R c is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or-NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl; R d is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of δ to 10 carbon atoms, in which one -CH 2 - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of δ to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, heterocyclyl; R c R d together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one -CH 2 - may also be replaced by -O-, -S-, or -NR ! where R' is H or alkyl of 2 to 20 carbon atoms or a pharmaceutically acceptable salt thereof is administered. 92. The method according to claim 7δ wherein R 1 is the moiety -NR a aR D 'b j ar-)b wherein R a R υ are optionally taken together with the nitrogen to which each is attached; R^ is selected from R 3 is halogen, alkoxy, -NR C R , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to12 carbon atoms, cyano, or -N 3 ; R ι4 is H or a pharmaceutically acceptable salt thereof is administered. 93. The method according to claim 75 wherein R 1 is the moiety -NR a aR 0 ! b ι a π b wherein R R are optionally taken together with the nitrogen to which each is attached and wherein R 1 is selected from >-N(C 2 H 5 ) 2 , -N(CH 3 ) 2 ξ-NHC 2 H 5 R is optionally substituted phenyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 94. The method according to claim 75 wherein R 1 is the moiety -NR a aRr->'b >a r ,b wherein R R are optionally taken together with the nitrogen to which each is attached and wherein R 1 is selected from J-NHQHS > R 2 is optionally substituted thienyl; R 3 is halogen, alkoxy of 1 to 12 carbon atoms, -NR c R d , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N 3 ; R 4 is H or a pharmaceutically acceptable salt thereof is administered. 9δ. The method according to claim 7δ wherein said compound selected from: 7-(1 -azepanyl)-δ-chloro-6-phenyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluorophenyl)-7-(4-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(4-methoxyphenyl)-7-(1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1 - piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(1 -azepanyi)-δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-thiomorpholinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; methyl [[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yl](methyl)amino]acetate; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 ,1 ,3,3- tetramethylbutyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 7-(1-azepanyl)-δ-chloro-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(1 -azepanyl)-6-(4-bromophenyl)-δ-chloro[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chioro-7-(1 -piperidinyl)-6-[2-(trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,δ- a]pyrimidine; 6-(4-tert-butylphenyl)-δ-chloro-7-(4-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(4-methoxyphenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(4-methoxyphenyl)-7-(3-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; 6-(4-bromophenyl)-δ-chloro-7-(3-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(3,4-difluorophenyl)-7-(4-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2,6-dichlorophenyl)-7-(2-methyl-1 -pyrrolidiny!)[1 ,2,4]triazoio[1 ,δ- ajpyrimidine; δ-chIoro-6-(2-chlorophenyi)-7-(2-methyi-1 -pyrrolidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 7-(1 -azepanyl)-5-chloro-6-(3-chloro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(3-chIoro-4-methoxyphenyl)-7-(4-methyi-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(3-chloro-4-methoxyphenyl)-7-(2-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 6-(4-tert-butylphenyl)-δ-chloro-7-(2-methyl-1-piperidinyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-7-(2-methyl-1 -piperidinyl )-6-[3- (trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; Diethyl 2-[6-(2,6-difluorophenyl)-δ-ethoxy[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yljmalonate; 7-(azepanyl)-δ-chloro-6-{2-chloro-6-nitrophenyl}[1 ,2,4}triazolof1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2- trifluoroethyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; δ-chloro-6-(2-ch!oro-6-fluorophenyl)-N-[(2,2-dichlorocyclopropy!)methyl]-N- methyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 1 -[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]-3- piperidinol; N-bicyclo[2.2.1]hept-2-yl-δ-chloro-6-(3-chloro-4- methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,δ-difluorophenyl)-N-dodecyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-7-(4-methyl-1-piperidinyl)-6-(2,3,6- trifluoroρhenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; N-[δ-chloro-6-(2,3,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-y!]-N- isopropylamine; 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,3,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; N-allyl-δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(3-chloro-4-methoxyphenyl)-N-cycloheptyl[1,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(3-chloro-4-methoxyphenyl)-7-(3,3-dimethyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-(3-chloropropyl)-N-methyl-6-(2,3,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 7-(1 -azocanyl)-δ-ch!oro-6-(2,3,6-trifluorophenyl)[1 ,2,4]triazoio[1 ,δ- a]pyrimidine; δ-chloro-6-(2,6-difiuorophenyl)-7-(3,6-dihydro-1 (2H)- pyridinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(1 -azocanyl)-δ-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-methoxy-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; [δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yl]methanol; 1 -[δ-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]-4- piperidinol; δ-chloro-7-(4-chloro-1-piperidinyl)-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-7-(4-thiomorpholinyl)-6-(2,3,6-trifluorophenyl)[1,2,4]triazolo[1 ,δ- a]pyrimidine; 5-chloro-6-(2,6-difluorophenyl)-7-(2,4-dimethyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 7-(4-methyl-1-piperidinyl)-5-amino-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluorophenyl)-7-(2,δ-dihydro-1 H-pyrrol-1 - yl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2,δ-dimethyl-2,δ-dihydro-1 H-pyrrol-1 ■ yl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-ethyl-1 H-imidazol-1 - yl)[1 ,2,4]triazolo[1 ,5-ajpyrimidine; 7-(4-bromo-1-piperidinyl)-δ-chloro-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; δ-chloro-6-(2-methylphenyl)-7-(4-thiomorpholinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; 6-(2-bromophenyl)-N-(sec-butyl)-δ-chloro[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N-ethyl-6-(4-methoxyphenyl)-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidin-7-amine; δ-chloro-6-(4-methoxyphenyl)-7-(4-thiomorpholinyl)[1 ,2,4]triazolo[1 ,5- ajpyrimidine; δ-chloro-7-(4-chloro-1-piperidinyl)-6-[2- (trifluoromethyl)phenylj[1 ,2,4jtriazolo[1 ,δ-ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(trifluoromethyl)-1- piperidinylj[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; 7-(4-bromo-1 -piperidinyl)-δ-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 7-(4-bromo-1 -piperidinyl)-δ-chloro-6-(2-chlorophenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4jtriazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-isopropyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- aJpyrimidin-7- amine; δ-chloro-7-(4-thiomorpholinyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; 7-(1-azepanyl)-δ-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1 -pyrrolidinyl)-1 -cyclopenten-1 - ylj[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; δ-chloro-7-(4-isopropyl-1 -piperidinyl )-6-(4-methoxyphenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-7-(2,4-dimethyl-1 -piperidinyl)-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-7-[ethyl(2-methyl-2-propenyl)amino]-6-{4- nitrophenyl}[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; 7-(1 -azepanyl)-δ-chloro-6-{4-nitrophenyl}[1 ,2,4]triazolo[1 ,δ-ajpyrimidine; N-bicyclo[2.2.1jhept-2-yl-δ-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidin-7-amine; δ-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoroethyl)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidin-7-amine; δ-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoroethyl)[1 ,2,4]triazolo[1 ,δ- aJpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorobenzyl)-7-tetrahydro-2-furanyl[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; 7-(allylsulfanyl)-δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-N-ethyl-6-mesityl-N-(2-methyl-2-prόpenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-ethyl-6-(2-methoxyphenyl)-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-ajpyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1 ,2,4jtriazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-7-(4-methyl-1-piperidinyl)-6-[4- (methylsulfanyl)phenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-[4- (methylsulfanyl)phenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; N-(sec-butyl)-δ-chloro-6-[4-(methylsulfanyl)phenyl][1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chioro-6-[4-(methylsu!fanyl)phenySj-7-(4-thiomorpholinyi)[1 ,2,4jtriazolo[1 ,δ- ajpyrimidine; δ-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenylj-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(1-azepanyl)-δ-chloro-6-[2,6-dichloro-4- (trifluoromethyl)phenylj[1 ,2,4]triazoIo[1 ,δ-ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2,2,2- trifluoroethyl)sulfanyl][1 ,2,4jtriazolo[1 ,δ-a]pyrimidine; δ-chIoro-6-(2-chloro-6-fluorophenyl)-7-(4,4-dimethyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-7-(4- thiomorpholinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(3,δ-difluorophenyl)-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(isopropylsu!fanyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-tetrahydro-2-furanyl[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 4-[δ-chloro-7-(4-methyl-1 -piperidinyi)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-6-yl]aniline; N-{4-[5-chloro-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-6- yijphenyljacetamide; [δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazoio[1 ,δ-a]pyrimidin-7-yl]methyl acetate; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(chloromethyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; diethyl 2-[6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1 - piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-δ-yl]malonate; 7-(1-azepanylmethyl)-δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; N-allyl-5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-7-(4-methyl-1-piperidinyl)-6-[4- (trifluoromethoxy)phenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-7-(4-methyl-1 -piperidinyl)-6-(4-phenoxyphenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(cyclopropylmethyl)-N- propyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-7-(2-methyl-1 -piperidinyl)-6-(4-phenoxyphenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-{2-chloro-4-nitrophenyl}-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(4-chloro-2,3,δ,6-tetrafluorophenyl)-N- cyclopentyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 4-[δ-chloro-2-methyl-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin- 6-yl]-N,N-dimethylaniline; 6-(2-chloro-6-fluorophenyl)-δ-methyl-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1 -pyrrolidinyl )-1 -cyclohexen-1 - yl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(methoxymethyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-{2-chloro-4-nitrophenyl}-7-[ethyl(2-methyl-2- propenyl)amino][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-bromo-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-N-cyclopentyl-6-(4-ethoxy-2,3,δ,6- tetrafluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-methyl-N-(2-methyl-2-propenyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 4-bromo-1 -[5-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin- 7-yl]butyl acetate; diethyl 2-allyl-2-{[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-yl]oxy}ma!onate; 6-(2-chloro-6-fluorophenyl)-N-ethyl-δ-methyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin- 7- amine; N-butyl-δ-chloro-N-ethyl-6-(2,3,4,δ,6-pentafluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; 6-(2-chloro-6-fluorophenyl)-δ-(difluoromethoxy)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[(4- chlorophenyl)sulfanyl][1 ,2,4]triazolo[1 ,5-ajpyrimidine; 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2- methoxyphenyl)sulfanyl][1 ,2,4]triazolo[1 ,5-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; δ-chloro-6-(2,3,4,δ,6-pentafluorophenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4]triazolo[1 ,5-a3pyrimidin-7-amine; δ-chloro-6-(2,4,6-trifluorophenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; δ-chloro-6-(4-fluorophenyl)-N-(1 ,2,2- trirηethylpropyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ,7-bis(4-methyl-1 -piperidinyl )-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazoio[1 ,δ- a]pyrimidine; δ-chloro-6-(2-methylphenyi)-N-(1 ,2,2-trimethyipropyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2,4,δ-trifluorophenyl)-N-(1 ,2,2-trimethylpropyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; 6-(2-bromophenyl)-δ-chloro-N-(1 ,2,2-trimethyipropyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-isobutyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazoIo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-isobutyl-6-(2-methylphenyl)-N-(2,2,2- trifluoroethyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-(2,2,2-trifluoro-1-methylethyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; N-allyl-5-chloro-N-isobutyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; δ-chloro-N-(1 ,2-dimethylpropyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-isopropyl-N-methyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-isopropyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6- trifiuorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 7-butyl-δ-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-(1 -phenylethyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoro-1 -methylethyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-ethyl-N-isobutyl-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-hexyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-methylphenyl)-N,N-bis(2,2,2-trifluoroethyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-cyclopentyl-N-methyl-6-(2,3,4,δ ) 6- pentafluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 7-butyl-δ-chloro-6-(2,6-difluorophenyi)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-(1 ,2-dimethyIpropyi)-N-methyl-6-(2,3,4,δ,6- pentafluorophenyi)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-phenyl[1 ,2,4]triazoio[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methylpropanyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-pentyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-(1 ,2-dimethylpropyl)-N-methyl-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-bromo-δ-chlorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(3,3,3-trifluoropropyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(3-methylphenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; [δ-chloro-6-(2,4,6-trifluorophenyl)-[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]-(1 -p- tolyl-ethyl)-amine; δ-chloro-6-(2,4,6-trifluoro-phenyl)-7-cyclohexyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-7-cyclohexyl-6-(2,3,4,δ,6-pentafluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-difluoro-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(bicyclo[2.2.1]hept-2-ylamino)-δ-chloro-6-{2-fluoro-4- nitrophenyl}[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-{2-fluoro-4-nitrophenyl}-7-(4-methyl-1 -piperidinyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-(methylsulfanyl)-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4]triazolo[1 ,5- a]pyrimidine; [δ-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl] (2,2,2- trifluoro-1 -phenylethyl)-amine; δ-chloro-N-[1-(trifluoromethyl)propyl]-6-(2,4,6- trifluorophenyI)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-bromo-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; 6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-δ- amine; [δ-chloro-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]-(2- methy!-1-trifluoromethyl-propyl)amine; δ-chloro-7-(3-cyclohexen-1 -yl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-7-(1 -cyclohexen-1 -yi)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-N-[(1 R)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-[(1 R)-2,2,2-trifluoro-1 -methylethyl]-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 6-(2,4-difluorophenyl)-δ-chloro-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-[(1S)-2,2,2-trifluoro-1- methylethyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)-δ-methoxy[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chioro-7-(4-fluorocyclohexyl)-6-(2,4,6-trifluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2,6-dichloro-4-fluorophenyl)-7-(3,3,3- trifiuoropropyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; N-(sec-butyl)-δ-chloro-6-(2,6-dichloro-4-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; 4-{δ-chloro-7-[(2,2,2-trifluoro-1 -methylethyl)amino][1 ,2,4]triazolo[1 ,5- a]pyrimidin-6-yl}-3,6-difluorophenol; δ-chloro-7-(3-cyclohexen-1-yl)-6-(2,6-difluoro-4- methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3,6-dihydro-1(2H)- pyridinyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4- thiomorpholinyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; 7-(1 -azepanyl)-5-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1 ,2,4]triazoio[1 ,δ- ajpyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 5-ch!oro-6-(2,6-difluoro-4-methoxyphenyi)-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-amine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4- fluorocyclohexyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 6-(4-{δ-chloro-7-[(2,2,2-trifluoro-1 -methylethyl)amino][1 ,2,4]triazolo[1 ,δ- a]pyrimidin-6-yl}-3,δ-difluorophenoxy)hexanoic acid; 2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-isopropyl-6-{2-[(trifluoromethyl)sulfanyl]phenyl}[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-N-[4-(trifluoromethyl)phenyl]-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-(4,4,4-trifluoro-2-methylbutyl)-6-(2,4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3-methyl-3- butenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; δ-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-isobutyl[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; 7-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)-δ-methoxy[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(2-thienyl)-N-[(1 R)-2,2,2-trifluoro-1 -methylethyl[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; 4-(5-chloro-7-(2,2,2-trifluoro-1 -methyl-ethylamino)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-6-yl]-3,δ-difluoro-phenol; {δ-chloro-6-[2,6-difluoro-4-(2,2,2-trifluoro-ethoxy)-phenyl]-[1 ,2,4]triazolo[1 ,δ- a3pyrimidin-7-yl}-(2,2,2-trifluoro-1 -methyl-ethyl)amine; δ-chloro-6-{2,6-difluoro-4-(methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; (δ-chloro-6-{4-[2-(2-ethoxyethoxy]-ethoxy]-2,6-difluoro- phenyl}[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1 - methylethyl)amine; (δ-chloro-6-{2,6-difluoro-4-[2-(2-methoxy-ethoxy)ethoxy]-phenyl}- [1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1-methylethyl)amine; δ-chioro-6-[2,6-difluoro-4-(3-furan-3-ylmethoxy)phenyl[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-yl}-N-(2,2,2-trifluoro-1-methylethyl)amine; δ-chloro-6-(2,δ-difluoro-4-methoxyphenyl)-N-(1 ,2,2- trimethylpropyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenyi]-δ- methoxy[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-fluoro-4-methoxy-6-chlorophenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-[2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-ethyl-N-(2-methyl-2- propenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 2-[2-(4-{δ-chloro-7-[(2,2,2-trifluoro-1 -methylethyl)amino][1 ,2,4]triazolo[1 ,6- a]pyrimidin-6-yl}-3,δ-difluorophenoxy)ethoxy]ethanol; δ-chloro-6-(2,3-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-{4-(2-fluoroethoxy)-2,6-difluorphenyl}-N-(2,2,2-trifluoro-1- methylethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-N-(4-chlorobenzyl)-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-pyridinyl)-1- piperazinyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(1-ethylpentyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-chlorophenyl)-1- piperazinyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(4-methoxyphenyl)-3-methyl-1- piperazinyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-cyclopentyl-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,5- a]pyrimidin-7-amine; 5-chloro-7-phenoxy-6-(4-methoxy-pheny!)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-cyclopentyl-6-(4-methylphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ,7-diphenoxy-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-N-cyclopentyl-6-(2-chlorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N,N-diethyl-6-[4-methoxyphenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N,N-diethyl-6-[2,4-dichlorophenyl][1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; N-bicyclo[2.2.1]hept-2-yl-δ-chloro-6-(2,4-dichlorophenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; δ-chloro-6-(2-chloro-6-fiuorophenyl)-7-(1 ,4-dioxa-8-azaspiro[4.δ]dec-8- yl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-cyano-7-(4-methyl-1-piperidinyl)-6-(2-chloro-δ- fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; δ-(methylsulfanyl)-7-(4-methyl-1-piperidinyl)-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrimidine; δ-(methylsulfanyl)-7-(4-methyl-1-piperidinyl)-6-(2-chloro-δ- (methylsulfanyl)phenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chIoro-7-(1 ,4-dioxa-8-azaspiro[4,δ]dec-8-yl)-6-(4- methoxypheny!)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chioro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4- (methylsuifanyl)phenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 2-methyl-6,7-di-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 2-methyl-6-phenyl-7-(4-chlorophenyl)[1,2,4]triazolo[1 ,δ-a]pyrimidine; 2-trifluoromethyl-6-phenyl-7-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ,7-diphenoxy-6-(2-methylpropyl)[1,2,4]triazolo[1 ,δ-a]pyrimidine; δ-chloro-6-(3,4-difluorophenyl)-N-(isopropyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-bromo-6-(4-bromophenyl)-7-dimethylamino[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; δ-bromo-6-(4-trifluoromethylphenyl)-7-dimethylamino[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chioro-6-(3,4-difluorophenyl)-7-dimethylamino[1 ,2,4]triazolo[1 ,δ- a]pyrimidine; δ-chloro-6-(4-trifluoromethylphenyl)-N-(ethyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; 7-(1 -azepanyl)-δ-chloro-6-(4-tert-butylphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; ethyl {[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yl]amino}acetate; diethyl δ-chloro-6-(2,6-difluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- malonate; δ-chloro-6-(2,δ-difluorophenyl)-N-(3-methyl-2-butenyl)[1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; [δ-chloro-6-(2-chloro-6-fluorophenyl)-[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]acetic acid methyl ester; ' δ-chloro-6-(2,6-difluorophenyl)-7-(2-ethyl-1 H-imidazol-1-yl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-N,N-diethyl-6-[4-(methylsulfanyl)phenyl][1 ,2,4]triazolo[1 ,δ- a]pyrimidin-7-amine; ethyl [6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1 -piperidinyl)- [1 ,2,4]triazolo[1 ,δ- a]pyrimidin-δ-yl]acetate; δ-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4- phenoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; dimethyl 2-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin- 7-yl]malonate; diethyl 2-{[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yl]oxy}-2-isobutylmalonate; 2-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-yl]-1 ,3- cyclohexanedione; 2-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- yljcyclohexanone; δ-chloro-7-(3-nitro-4-methyianilino)-6-(2, 4, 6-trifluorophenyl) [1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-c ' yclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenyl]δ-(2- methoxyethoxy)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(3-bromophenyl)-2-ethyl-6-(4-methoxyphenyl)[1 ,2,4]triazoIo[1 ,δ- ajpyrimidine; 7-(3-bromophenyl)-6-(3-chlorophenyl)-2-ethyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; 7-(4-bromophenyl)-2-ethyl-6-[4-(trifluoromethyl)phenyl][1 ,2,4]triazolo[1 ,δ- ajpyrimidine; δ-chloro-6-(2-chloro-6-fluorophenyl)-N-(3,4,δ- trimethoxybenzyl)[1 ,2,4]triazoio[1 ,δ-a]pyrimidin-7-amine; 7-(2-benzyl-4,δ-dihydro-1 H-imidazol-1-yl)-δ-chloro-6-(2-chloro-6- fluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidine; N-4-[δ-chloro-6-(2-chloro-6-fluorophenyl)[1 ,2,43triazolo[1 ,δ-a]pyrimidin-7-yl- N,N-1-diethyl-1 ,4-pentanediamine; δ-chloro-N-(3-methyl-2-butenyl)-6-phenyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-dimethylamino-6-phenyl-N-cyclopentyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-7-[(2-furylmethyl)sulfanyi]-6-(4-methoxyphenyl)[1 ,2,4]triazolo[1 ,δ- ajpyrimidine; 6-[1 ,1'-biphenyl]-4-yi-δ-chloro-N-cyclopenty![1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; 6-[4-(benzyloxy)phenyl]-δ-chloro-N-isopropyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N-[(2,2-dichlorocyciopropyl)methyl]-6-(3,4,δ- trimethoxyphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; N-cyclopentyl-6-(2-fluorophenyl)-δ-hydrazino[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-N-ethyl-6-(2-methylphenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 6-(4-tert-butylphenyl)-δ-chloro-N-isopropyl[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7- amine; δ-chloro-6-[2,6-difluoro-4-[(3-methyl-2-butenyl)oxy]phenyl]-N-(2,2,2-trifluoro-1- methylethyl)-l[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-chloro-6-[2,6-difluoro-4-(1-propenyloxy)phenyl]-N-(2,2,2-trifluoro-1- methylethyl)-l[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; 5-chloro-N-(3-tricyclo[2.2.1.0 2,β lhept-1-yl)-6-(2 f 4,6- trifluorophenyl)[1 ,2,4]triazolo[1 ,δ-a]pyrimidin-7-amine; δ-azido-7-cyclohexyl-6-(2-fluoro-6-chlorophenyl) [1 ,2,4]triazolo[1 ,5- ajpyrimidine; 5-azido-6-[2-chloro-6-fluorophenyl]-7-(4-methyl-1- piperidinyl)[1 ,2,4]triazo!o[1 ,δ-a]pyrimidine; 2,δ-dichloro-7-(4-methyl-1-piperidinyl)-6-[2-chloro-6- fluorophenyljπ .δ-alpyrimidine or a pharmaceutically acceptable salt thereof is administered. 96. Use of a substituted triazolopyrimidine derivative to make a medicament for treating or inhibiting the growth of cancerous tumour cells and associated diseases or for the treatment or prevention of multiple drug resistance (MDR). 97. A substituted triazolopyrimidine derivative for use as a pharmaceutical.

Inventors: ALBERT GUIDO, BEYER CARL F, CARTER PAUL, HARRIS JANE E, KIRSCH DONALD R, PEES KLAUS-JUERGEN, PFRENGLE WALDEMAR, SCHMITT MARK R, ALBERT, GUIDO, BEYER, CARL, F., CARTER, PAUL, HARRIS, JANE, E., KIRSCH, DONALD, R., PEES, KLAUS-JUERGEN, PFRENGLE, WALDEMAR, SCHMITT, MARK, R.
Applicants: AMERICAN HOME PROD, AMERICAN HOME PRODUCTS CORPORATION
Application year: 2001
Main classification: C07D487
IPC codes: A61K31, A61P35, A61P43, C07D487, C07D519